
--- Fim da P√°gina 1 ---


--- Fim da P√°gina 2 ---

P O C K E T
NOTEBOOK
Pocket
MEDICINE
Fourth Edition
Edited by
MARC S. SABATINE, M.D., M.P.H.
ASSOCIATE PROFESSOR OF MEDICINE
HARVARD MEDICAL SCHOOL
The Massachusetts General Hospital
Handbook of Internal Medicine

--- Fim da P√°gina 3 ---

Acquisitions Editor: Sonya Seigafuse
Product Manager: Kerry Barrett
Production Manager: Bridgett Dougherty
Senior Manufacturing Manager: Benjamin Rivera
Marketing Manager: Kim Schonberger
Design Coordinator: Doug Smock
Production Service: Aptara
¬© 2011 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER
business
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103 USA
LWW.com
All rights reserved.This book is protected by copyright. No part of this book may 
be reproduced in any form by any means, including photocopying, or utilized by any
information storage and retrieval system without written permission from the copyright
owner, except for brief quotations embodied in critical articles and reviews. Materials
appearing in this book prepared by individuals as part of their official duties as U.S.
government employees are not covered by the above-mentioned copyright.
Printed in China
Library of Congress Cataloging-in-Publication Data
Pocket medicine / edited by Marc S. Sabatine.‚Äì4th ed.
p. ; cm.
‚ÄúThe Massachusetts General Hospital Handbook of Internal Medicine.‚Äù
Includes bibliographical references and index.
ISBN-13: 978-1-60831-905-3 (domestic : alk. paper)
ISBN-10: 1-60831-905-9 (domestic : alk. paper)
ISBN-13: 978-1-4511-0335-9 (international : alk. paper)
ISBN-10: 1-4511-0335-2 (international : alk. paper)
1. Internal medicine‚ÄìHandbooks, manuals, etc. I. Sabatine, Marc S.
II. Massachusetts General Hospital.
[DNLM: 1. Internal Medicine‚ÄìHandbooks. 2. Clinical
Medicine‚ÄìHandbooks.
WB 39 P7394 2011]
RC55.P63 2011
616‚Äìdc22
2010024523
DISCLAIMER Care has been taken to confirm the accuracy of the information presented
and to describe generally accepted practices. However, the authors, editors, and publisher
are not responsible for errors or omissions or for any consequences from application of the
information in this book and make no warranty, expressed or implied, with respect to
the currency, completeness, or accuracy of the contents of the publication. Application
of the information in a particular situation remains the professional responsibility of the
practitioner.
The authors, editors, and publisher have exerted every effort to ensure that drug
selection and dosage set forth in this text are in accordance with current recommenda-
tions and practice at the time of publication.However,in view of ongoing research,changes
in government regulations, and the constant flow of information relating to drug therapy
and drug reactions, the reader is urged to check the package insert for each drug for any
change in indications and dosage and for added warnings and precautions.This is particu-
larly important when the recommended agent is a new or infrequently employed drug.
Some drugs and medical devices presented in the publication have Food and Drug
Administration (FDA) clearance for limited use in restricted research settings. It is the
responsibility of the health care provider to ascertain the FDA status of each drug or
device planned for use in their clinical practice.
To purchase additional copies of this book, call our customer service department at
(800) 638-3030 or fax orders to (301) 223-2320. International customers should call
(301) 223-2300.
Visit Lippincott Williams & Wilkins on the Internet: at LWW.com. Lippincott Williams
& Wilkins customer service representatives are available from 8:30 am to 6 pm, EST.
10 9 8 7 6 5 4 3 2 1

--- Fim da P√°gina 4 ---

CONTENTS
Contributing Authors
vi
Foreword
ix
Preface
x
CARDIOLOGY
Rajat Gupta,Viviany R.Taqueti, David M. Dudzinski, Rory B.Weiner,
Michelle O‚ÄôDonoghue, Marc S. Sabatine
Electrocardiography
1-1
Chest Pain
1-3
Noninvasive Evaluation of CAD
1-4
Coronary Angiography and Revascularization
1-5
Acute Coronary Syndromes
1-6
PA Catheter and Tailored Therapy
1-12
Heart Failure
1-14
Cardiomyopathies
1-17
Valvular Heart Disease
1-20
Pericardial Disease
1-25
Hypertension
1-28
Aortic Aneurysm
1-30
Acute Aortic Syndromes
1-31
Arrhythmias
1-32
Atrial Fibrillation
1-35
Syncope
1-37
Intracardiac Devices
1-39
Cardiac Risk Assessment for Noncardiac Surgery
1-40
PULMONARY
Mary Berlik Rice, Kathryn A. Hibbert,Atul Malhotra
Dyspnea
2-1
Pulmonary Function Tests (PFTs)
2-1
Asthma
2-2
Chronic Obstructive Pulmonary Disease
2-5
Hemoptysis
2-7
Solitary Pulmonary Nodule
2-7
Obstructive Sleep Apnea (OSA)
2-8
Interstitial Lung Disease
2-9
Pleural Effusion
2-11
Venous Thromboembolism (VTE)
2-13
Pulmonary Hypertension (PHT)
2-16
Respiratory Failure
2-18
Mechanical Ventilation
2-19
Acute Respiratory Distress Syndrome
2-22
Sepsis
2-23
GASTROENTEROLOGY
Louis J. Cohen,Andrew S. de Lemos, Lawrence S. Friedman
Esophageal and Gastric Disorders
3-1
Gastrointestinal Bleeding
3-3
Diarrhea, Constipation, and Ileus
3-5
Diverticular Disease
3-9
Inflammatory Bowel Disease
3-10

--- Fim da P√°gina 5 ---

Intestinal Ischemia
3-12
Pancreatitis
3-13
Abnormal Liver Tests
3-15
Hepatitis
3-17
Acute Liver Failure
3-20
Cirrhosis
3-21
Hepatic Vascular Disease
3-25
Ascites
3-26
Biliary Tract Disease
3-27
NEPHROLOGY
Andrew L. Lundquist, Eugene P. Rhee, Hasan Bazari
Acid-Base Disturbances
4-1
Sodium and Water Homeostasis
4-6
Potassium Homeostasis
4-10
Renal Failure
4-12
Glomerular Disease
4-16
Urinalysis
4-18
Nephrolithiasis
4-19
HEMATOLOGY-ONCOLOGY
Andrew J. Aguirre, Franklin W. Huang, David B. Sykes, David T. Ting,
Daniel J. DeAngelo, David P. Ryan
Anemia
5-1
Disorders of Hemostasis
5-6
Platelet Disorders
5-7
Coagulopathies
5-10
Hypercoagulable States
5-11
Disorders of Leukocytes
5-12
Transfusion Therapy
5-13
Myelodysplastic Syndromes (MDS)
5-14
Myeloproliferative Neoplasms (MPN)
5-15
Leukemia
5-17
Lymphoma
5-21
Plasma Cell Dyscrasias
5-24
Hematopoietic Stem Cell Transplantation (HSCT)
5-26
Lung Cancer
5-28
Breast Cancer
5-30
Prostate Cancer
5-32
Colorectal Cancer (CRC)
5-33
Pancreatic Tumors
5-35
Oncologic Emergencies
5-36
Cancer of Unknown Primary Site
5-37
INFECTIOUS DISEASES
Roby P. Bhattacharyya, Rachel P. Simmons, Nesli Basgoz
Pneumonia
6-1
Fungal Infections
6-3
Infections in Susceptible Hosts
6-4
Urinary Tract Infections (UTI)
6-5
Soft Tissue and Bone Infections
6-6
Infections of the Nervous System
6-9
Bacterial Endocarditis
6-12
Tuberculosis
6-15

--- Fim da P√°gina 6 ---

HIV/AIDS
6-17
Tick-Borne Diseases
6-21
Fever of Unknown Origin (FUO)
6-23
ENDOCRINOLOGY
Alaka Ray, Geoffrey A.Walford, Michael Mannstadt
Pituitary Disorders
7-1
Disorders of Multiple Endocrine Systems
7-2
Thyroid Disorders
7-3
Adrenal Disorders
7-7
Calcium Disorders
7-11
Diabetes Mellitus
7-13
Lipid Disorders
7-16
RHEUMATOLOGY
Gwen C. Crevensten, Katherine P. Liao, Robert P. Friday
Arthritis‚ÄîOverview
8-1
Rheumatoid Arthritis (RA)
8-3
Relapsing Polychondritis
8-4
Crystal Deposition Arthritides
8-5
Seronegative Spondyloarthritis
8-7
Infectious Arthritis & Bursitis
8-9
Connective Tissue Diseases
8-11
Systemic Lupus Erythematosus (SLE)
8-15
Vasculitis
8-17
Cryoglobulinemia
8-21
Amyloidosis
8-22
NEUROLOGY
David Y. Hwang,Atul Maheshwari, Mikael L. Rinne, David M. Greer
Change in Mental Status
9-1
Seizures
9-3
Alcohol Withdrawal
9-5
Stroke
9-6
Weakness & Neuromuscular Dysfunction
9-8
Headache
9-10
Back and Spinal Cord Disease
9-11
APPENDIX
ACLS Algorithms
10-1
ICU Medications
10-4
Antibiotics
10-6
Formulae and Quick Reference
10-7
ABBREVIATIONS
11-1
INDEX
I-1
PHOTO INSERTS
Radiology
P-1
Echocardiography
P-9
Coronary Angiography
P-13
Peripheral Blood Smears
P-13
Leukemias
P-14
Urinalysis
P-15

--- Fim da P√°gina 7 ---

CONTRIBUTING AUTHORS
Andrew J. Aguirre, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
Nesli Basgoz, MD
Associate Chief and Clinical Director, Infectious Disease Division,
Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
Hasan Bazari, MD
Attending Physician, Nephrology Unit, Massachusetts General Hospital
Program Director, Internal Medicine Residency, Massachusetts 
General Hospital
Associate Professor of Medicine, Harvard Medical School
Roby P. Bhattacharyya, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
Louis J. Cohen, MD
Internal Medicine Resident, Massachusetts General Hospital
Gwen C. Crevensten, MD
Internal Medicine Resident, Massachusetts General Hospital
Andrew S. de Lemos, MD
Gastroenterology Fellow, Massachusetts General Hospital
Daniel J. DeAngelo, MD, PhD
Clinical Director, Adult Leukemia Program, Dana-Farber Cancer
Institute & Brigham and Women‚Äôs Hospital
Associate Professor of Medicine, Harvard Medical School
David M. Dudzinski, MD, JD
Cardiology Fellow, Massachusetts General Hospital
Robert P. Friday, MD, PhD
Attending Physician, Rheumatology Unit, Massachusetts General Hospital
Associate Director, Rheumatology Fellowship Program, Massachusetts
General Hospital
Instructor in Medicine, Harvard Medical School
Lawrence S. Friedman, MD
Chair, Department of Medicine, Newton-Wellesley Hospital
Assistant Chief of Medicine, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
Professor of Medicine,Tufts University School of Medicine
David M. Greer, MD, MA
Director, Neurological Consultation Service, Massachusetts General
Hospital
Program Director, Partners Neurology Residency Program
Associate Professor of Neurology, Harvard Medical School

--- Fim da P√°gina 8 ---

Rajat Gupta, MD
Internal Medicine Resident, Massachusetts General Hospital
Kathryn A. Hibbert, MD
Pulmonary and Critical Care Fellow, Harvard Medical School
Franklin W. Huang, MD, PhD
Internal Medicine Resident, Massachusetts General Hospital
David Y. Hwang, MD
Neurology Resident, Partners Neurology Residency
Katherine P. Liao, MD, MPH
Rheumatology Fellow, Brigham and Women‚Äôs Hospital
Andrew L. Lundquist, MD
Internal Medicine Resident, Massachusetts General Hospital
Atul Maheshwari, MD
Neurology Resident, Partners Neurology Residency
Atul Malhotra, MD
Associate Physician, Divisions of Pulmonary & Critical Care and Sleep
Medicine, Brigham and Women‚Äôs Hospital
Medical Director of the Brigham Sleep Disorders Program
Associate Professor of Medicine, Harvard Medical School
Michael Mannstadt, MD
Assistant Physician, Endocrine Unit, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Michelle O‚ÄôDonoghue, MD, MPH
Investigator,TIMI Study Group and Associate Physician, Cardiovascular
Division, Brigham and Women‚Äôs Hospital
Affiliate Physician, Cardiology Division, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School
Alaka Ray, MD
Internal Medicine Resident, Massachusetts General Hospital
Eugene P. Rhee, MD
Nephrology Fellow, BWH/MGH Joint Nephrology Fellowship Program
Mary Berlik Rice, MD
Internal Medicine Resident, Massachusetts General Hospital
Mikael L. Rinne, MD, PhD
Neurology Resident, Partners Neurology Residency
David P. Ryan, MD
Clinical Director, Massachusetts General Hospital Cancer Center
Associate Chief of Hematology/Oncology, Massachusetts General
Hospital
Associate Professor of Medicine, Harvard Medical School

--- Fim da P√°gina 9 ---

Marc S. Sabatine, MD, MPH
Vice Chair,TIMI Study Group and Associate Physician, Cardiovascular
Division, Brigham and Women‚Äôs Hospital
Affiliate Physician, Cardiology Division, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School
Rachel P. Simmons, MD
Infectious Disease Fellow, Massachusetts General Hospital and Brigham
and Women‚Äôs Hospital
David B. Sykes, MD, PhD
Hematology-Oncology Fellow, Dana-Farber/Partners CancerCare
Hematology/Oncology Program
Viviany R.Taqueti, MD
Internal Medicine Resident, Massachusetts General Hospital
David T.Ting, MD
Hematology-Oncology Fellow, Dana-Farber/Partners CancerCare
Hematology/Oncology Program
Geoffrey A.Walford, MD
Endocrinology Fellow, Massachusetts General Hospital
Rory B.Weiner, MD
Cardiology Fellow, Massachusetts General Hospital

--- Fim da P√°gina 10 ---

FOREWORD
To the 1st Edition
It is with the greatest enthusiasm that I introduce Pocket Medicine. In an
era of information glut, it will logically be asked,‚ÄúWhy another manual
for medical house officers?‚Äù Yet, despite enormous information readily
available in any number of textbooks, or at the push of a key on a com-
puter, it is often that the harried house officer is less helped by the
description of differential diagnosis and therapies than one would wish.
Pocket Medicine is the joint venture between house staff and faculty
expert in a number of medical specialties.This collaboration is designed
to provide a rapid but thoughtful initial approach to medical problems
seen by house officers with great frequency. Questions that frequently
come from faculty to the house staff on rounds, many hours after the
initial interaction between patient and doctor, have been anticipated and
important pathways for arriving at diagnoses and initiating therapies are
presented.This approach will facilitate the evidence-based medicine dis-
cussion that will follow the workup of the patient.This well-conceived
handbook should enhance the ability of every medical house officer to
properly evaluate a patient in a timely fashion and to be stimulated to
think of the evidence supporting the diagnosis and the likely outcome of
therapeutic intervention. Pocket Medicine will prove to be a worthy addi-
tion to medical education and to the care of our patients.
DENNIS A. AUSIELLO, MD
Physician-in-Chief, Massachusetts General Hospital
Jackson Professor of Clinical Medicine, Harvard Medical School

--- Fim da P√°gina 11 ---

PREFACE
For Jenny, Matteo, and Natalie with love
Written by residents, fellows, and attendings, the mandate for Pocket
Medicine was to provide,in a concise a manner as possible,the key infor-
mation a clinician needs for the initial approach to and management of
the most common inpatient medical problems.
The tremendous response to the previous editions suggests we
were able to help fill an important need for clinicians.With this fourth
edition come several major improvements including: a thorough updat-
ing of every topic; the addition of several new topics (including acute
aortic syndromes, sepsis, obstructive sleep apnea, hepatic vascular dis-
ease, optimal use of diuretics, viral respiratory infections, infections in
susceptible hosts, intensive glycemic control, approach to the patient
with joint pain, and alcohol withdrawal); incorporation of references to
the most recent reviews and important studies published through the
middle of 2010; and the addition of high-resolution chest radiographs,
chest and abdominal CTs, and echocardiograms, and photomicrographs
of peripheral blood smears and urinalyses.We welcome any suggestions
for further improvement.
Of course medicine is far too vast a field to ever summarize in a
textbook of any size. Long monographs have been devoted to many of
the topics discussed herein. Pocket Medicine is meant only as a starting
point to guide one during the initial phases of diagnosis and management
until one has time to consult more definitive resources. Although the
recommendations herein are as evidence-based as possible, medicine is
both a science and an art.As always, sound clinical judgement must be
applied to every scenario.
I am grateful for the support of the house officers, fellows, and
attendings at the Massachusetts General Hospital.It is a privilege to work
with such a knowledgeable,dedicated,and compassionate group of physi-
cians. I always look back on my time there as Chief Resident as one of
the best experiences I have ever had. I am grateful to several outstanding
clinical mentors, including Hasan Bazari, Denny Ausiello, Larry Friedman,
Nesli Basgoz, Mort Swartz, Eric Isselbacher, Bill Dec, Mike Fifer, and
Roman DeSanctis, as well as the late Charlie McCabe and Peter Yurchak.
Special thanks to my parents for their perpetual encouragement and love
and, of course, to my wife, Jennifer Tseng, who, despite being a surgeon, is
my closest advisor, my best friend, and the love of my life.
I hope that you find Pocket Medicine useful throughout the arduous
but incredibly rewarding journey of practicing medicine.
MARC S. SABATINE, MD, MPH

--- Fim da P√°gina 12 ---

ELECTROCARDIOGRAPHY
Approach (a systematic approach is vital) 
‚Ä¢ Rate (? tachy, brady) and rhythm (? relationship between P and QRS)
‚Ä¢ Intervals (PR, QRS, QT) and axis (? LAD or RAD)
‚Ä¢ Chamber abnormality (? LAA and/or RAA, ? LVH and/or RVH)
‚Ä¢ QRST changes (? Q waves, poor R-wave progression V1‚ÄìV6, ST c/T, or T-wave s)
Left axis deviation (LAD)
‚Ä¢ Definition: axis beyond ‚Äì30 (S  R in lead II)
‚Ä¢ Etiologies: LVH, LBBB, inferior MI,WPW
‚Ä¢ Left anterior fascicular block: LAD (‚Äì45 to
‚Äì90) and qR in aVL and QRS 120 msec and
no other cause of LAD (eg, IMI)
Right axis deviation (RAD)
‚Ä¢ Definition: axis beyond 90 (S  R in lead I)
‚Ä¢ Etiologies: RVH, PE, COPD (usually not 110),
septal defects, lateral MI,WPW
‚Ä¢ Left posterior fascicular block: RAD (90‚Äì180)
and rS in I & aVL and qR in III & aVF and
QRS 120 msec and no other cause of RAD
Bundle Branch Blocks (Circ 2009;119:e235)
Initial depol. is left-to-right across septum (r in V1 & q in V6;
Normal
nb, absent in LBBB) followed by LV & RV free wall, with LV
dominating (nb, RV depol. later and visible in RBBB).
RBBB
1. QRS 120 msec (110‚Äì119  incomplete)
2. rSR‚Äô in R precordial leads (V1,V2)
3. Wide S wave in I and V6
4.
	 STT or TWI in R precordial leads
LBBB
1. QRS 120 msec (110‚Äì119  incomplete)
2. Broad, slurred, monophasic R in I, aVL,V5‚ÄìV6 (	 RS in 
V5‚ÄìV6 if cardiomegaly)
3. Absence of Q in I,V5, and V6 (may have narrow q in aVL)
4. Displacement of ST & Tw opposite major QRS deflection
5.
	 PRWP, LAD, Qw‚Äôs in inferior leads
Bifascicular block: RBBB  LAFB/LPFB
Prolonged QT interval (JAMA 2003;289:2120; NEJM 2004;350:1013; www.torsades.org)
‚Ä¢ QT measured from beginning of QRS complex to end of T wave (measure longest QT)
‚Ä¢ QT varies w/ HR S correct w/ Bazett formula: QTc  QT/
(in sec),
formula inaccurate at very high and low HR (nl QTc 450 msec  and 460 msec )
‚Ä¢ Etiologies:
Antiarrhythmics: class Ia (procainamide, disopyramide), class III (amiodarone, sotalol)
Psych drugs: antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI,TCA
Antimicrobials: macrolides, quinolones, voriconazole, pentamidine, atovaquone,
chloroquine, amantadine, foscarnet, atazanavir, ? TMP-SMX
Other: antiemetics (droperidol, 5-HT3 antagonists), alfuzosin, methadone, ranolazine
Electrolyte disturbances: hypoCa, ? hypoK, ? hypoMg
Autonomic dysfxn: ICH (deep TWI), stroke, carotid endarterectomy, neck dissection
Congenital (long QT syndrome): K, Na, Ca channelopathies (Lancet 2008;372:750)
Misc: CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia
Left Atrial Abnormality (LAA)
Right Atrial Abnormality (RAA)
ECG
P wave
Criteria
Left ventricular hypertrophy (LVH) (Circ 2009;119:e251)
‚Ä¢ Etiologies: HTN,AS/AI, HCMP, coarctation of aorta
‚Ä¢ Criteria (all w/ Se 50%, Sp 85%)
Romhilt-Estes point-score system: 4 points  probable, 5 points  definite
cAmplitude (any of the following):largest R or S in limb leads 20 mm or S in V1 or V2
30 mm or R in V5 or V6 30 mm (3 points)
1RR
V
V
I  0¬∞
II
+60¬∞
III
+120¬∞
aVL
‚àí30¬∞
aVF
+90¬∞
aVR
‚àí150¬∞
‚àí90¬∞
¬±180¬∞
LAD
RAD
normal
axis
Figure 1-1 QRS axis
>120 msec
>40 msec
II
V
or
>1 mm
II
V1
or
>1.5 mm
>2.5 mm
ECG
1-1

--- Fim da P√°gina 13 ---

ST displacement opposite to QRS deflection: w/o dig (3 points); w/ dig (1 point)
LAA (3 points); LAD (2 points); QRS duration 90 msec (1 point)
Intrinsicoid deflection (QRS onset to peak of R) in V5 or V6 50 msec (1 point)
Sokolow-Lyon: S in V1  R in V5 or V6 35 mm
Cornell: R in aVL  S in V3 28 mm in men or 20 mm in women
Other: R in aVL 11 mm (or, if LAD/LAFB, 13 mm and S in III 15 mm)
Right ventricular hypertrophy (RVH) (Circ 2009;119:e251)
‚Ä¢ Etiologies: cor pulmonale, congenital (tetralogy,TGA, PS,ASD,VSD), MS,TR
‚Ä¢ Criteria (all tend to be insensitive, but highly specific, except in COPD)
R  S in V1 or R in V1 7 mm, S in V5 or V6 7 mm, drop in R/S ratio across precordium
RAD 110 (LVH  RAD or prominent S in V5 or V6 S biventricular hypertrophy)
Ddx of dominant R wave in V1 or V2
‚Ä¢ Ventricular enlargement: RVH (RAD, RAA, deep S waves in I,V5,V6); HCMP
‚Ä¢ Myocardial injury: true posterior MI (often IMI); Duchenne muscular dystrophy
‚Ä¢ Abnormal depolarization: RBBB (QRS 120 msec, rSR‚Äô);WPW (T PR, 
 wave, c QRS)
‚Ä¢ Other: dextroversion; lead misplacement; normal variant
Poor R-wave progression (PRWP) (Archives 1982;142:1145)
‚Ä¢ Definition: loss of anterior forces w/o frank Q waves (V1‚ÄìV3); R wave in V3 3 mm
‚Ä¢ Etiologies:
old anteroseptal MI (usually R wave V3 1.5 mm, 	 persistent ST c or TWI V2 & V3)
cardiomyopathy 
LVH (delayed RWP with prominent left precordial voltage)
RVH/COPD (small R wave and prominent S wave in lead I)
LBBB;WPW; clockwise rotation of the heart; lead misplacement
Pathologic Q waves
‚Ä¢ Definition: 30 msec or 25% height of the R wave in that complex
‚Ä¢ Small (septal) q waves in I, aVL,V5 & V6 are normal, as can be isolated Qw in III, aVR,V1
‚Ä¢ ‚ÄúPseudoinfarct‚Äù pattern may be seen in LBBB, infiltrative disease, HCMP, COPD, PTX,WPW
ST elevation (STE) (NEJM 2003;349:2128; Circ 2009;119:e241, e262)
‚Ä¢ Acute MI (upward convexity 	 TWI) or prior MI with persistent STE
‚Ä¢ Coronary spasm (Prinzmetal‚Äôs angina; transient STE in a coronary distribution)
‚Ä¢ Myopericarditis (diffuse, upward concavity STE; a/w PR T;Tw usually upright)
‚Ä¢ HCMP, Takotsubo CMP, ventricular aneurysm, cardiac contusion 
‚Ä¢ Pulmonary embolism (occ. STE V1‚ÄìV3; typically associated TWI V1‚ÄìV4, RAD, RBBB)
‚Ä¢ Repolarization abnormalities
LBBB (c QRS duration, STE discordant from QRS complex)
dx of STEMI in setting of LBBB: 1 mm STE concordant w/ QRS (Se 73%, Sp 92%)
or 5 mm discordant (Se 31%, Sp 92%) (‚ÄúSgarbossa criteria,‚Äù NEJM 1996;334:481)
LVH (c QRS amplitude); Brugada syndrome (rSR‚Äô, downsloping STE V1‚ÄìV2)
Hyperkalemia (c QRS duration, tall Ts, no Ps)
‚Ä¢ Early repolarization: most often seen in leads V2‚ÄìV5 and in young adults 
J point c 1‚Äì4 mm; notch in downstroke of R wave; upward concavity of ST; large Tw;
ratio of STE / T wave amplitude 25%; pattern may disappear with exercise
early repol in inf leads may be a/w c risk of VF, but absolute risk low (NEJM 2009;361:2529)
ST depression (STD)
‚Ä¢ Myocardial ischemia (	 Tw abnl) or acute true posterior MI (V1‚ÄìV3)
‚Ä¢ Digitalis effect (downsloping ST 	 Tw abnl, does not correlate w/ dig levels)
‚Ä¢ Hypokalemia (	 U wave)
‚Ä¢ Repolarization abnl in a/w LBBB or LVH (usually in leads V5,V6, I, aVL)
T wave inversion (TWI; generally 1 mm; deep if 5 mm) (Circ 2009;119:e241)
‚Ä¢ Ischemia or infarct;Wellens‚Äô sign (deep early precordial TWI) S proximal LCA lesion
‚Ä¢ Myopericarditis; CMP (incl Takotsubo & ARVD); MVP; PE (especially if TWI V1‚ÄìV4)
‚Ä¢ Repolarization abnl in a/w LVH/RVH (‚Äústrain pattern‚Äù), BBB
‚Ä¢ Post-tachycardia or post-pacing
‚Ä¢ Electrolyte, digoxin, PaO2, PaCO2, pH, or core temperature disturbances
‚Ä¢ Intracranial bleed (‚Äúcerebral T waves,‚Äù usually w/ c QT)
‚Ä¢ Normal variant in children (V1‚ÄìV4) and leads in which QRS complex predominantly ;
profound TWI in young athletes may predict future risk of CMP (NEJM 2008;358:152)
Low voltage
‚Ä¢ QRS amplitude (R  S) 5 mm in all limb leads & 10 mm in all precordial leads
‚Ä¢ Etiologies: COPD (precordial leads only), pericardial effusion, myxedema, obesity,
pleural effusion, restrictive or infiltrative CMP, diffuse CAD
ECG
1-2

--- Fim da P√°gina 14 ---

CHEST PAIN
1-3
CHEST PAIN
Cardiac Causes
Disorder
Typical Characteristics & Diagnostic Studies
Unstable 
Substernal pressure S neck, jaw, L arm; 30. 	 Dyspnea, diaphoresis,
angina
N/V. c w/ exertion; T w/ NTG or rest; however, relief by NTG in ED not 
reliable indicator of angina (Annals EM 2005;45:581). 	 ECG s (ST T/c,TWI).
MI
Same as angina but c intensity & duration.  troponin or CK-MB.
Pericarditis
Sharp pain S trapezius, c w/ respiration, T w/ sitting forward. 	 Pericardial
& Myo-
friction rub. ECG s (diffuse STE & PR T). 	 Pericardial effusion.
pericarditis
If myocarditis, same as above  c Tn and 	 s/s CHF and T EF.
Aortic
Abrupt onset severe tearing, knifelike pain (absence LR 0.3), ant or post 
dissection
mid-scapular. HTN or HoTN. 	 Asymmetric (20 mmHg) BP or pulse 
deficit (LR 5.7), focal neuro deficit (LR 6), AI, widened mediastinum 
on CXR (absence LR 0.3); false lumen on imaging. (JAMA 2002;287:2262)
Pulmonary Causes
Disorder
Typical Characteristics & Diagnostic Studies
Pneumonia
Pleuritic; dyspnea, fever, cough, sputum. c RR, crackles. CXR infiltrate.
Pleuritis
Sharp, pleuritic pain. 	 Pleuritic friction rub.
PTX
Sudden onset, sharp pleuritic pain. Hyperresonance, T BS. PTX on CXR.
PE
Sudden onset pleuritic pain. c RR & HR, T SaO2, ECG s (RAD, RBBB,
TWI V1‚ÄìV4, occ STE V1‚ÄìV3).  CTA.
PHT
Exertional pressure, dyspnea. T SaO2, loud P2, right-sided S3 and/or S4.
GI Causes
Disorder
Typical Characteristics & Diagnostic Studies
Esophageal
Substernal burning, acid taste in mouth, water brash. c by meals,
reflux
recumbency; T by antacids. EGD, manometry, pH monitoring.
Esoph spasm
Intense substernal pain. c by swallowing, T by NTG/CCB. Manometry.
Mallory-Weiss
Precipitated by vomiting. EGD.
Boerhaave
Precipitated by vomiting. Severe pain, c w/ swallowing. Palpable SC
syndrome
emphysema; mediastinal air on chest CT.
PUD
Epigastric pain, relieved by antacids. 	 GIB. EGD, 	 H. pylori test.
Biliary dis.
RUQ pain, nausea/vomiting. c by fatty foods. RUQ U/S, LFTs.
Pancreatitis
Epigastric/back discomfort. c amylase & lipase; abd CT.
Musculoskeletal and Miscellaneous Causes
Disorder
Typical Characteristics & Diagnostic Studies
Chostochondritis
Localized sharp pain. c w/ movement. Reproduced by palpation.
Herpes zoster
Intense unilateral pain. Dermatomal rash & sensory findings.
Anxiety
‚ÄúTightness‚Äù
Initial approach
‚Ä¢ Focused history: quality & severity of pain; location & radiation; provoking & palliating 
factors; duration, frequency & pattern; setting in which it occurred; associated sx
‚Ä¢ Targeted exam: VS (including BP in both arms), cardiac gallops, murmurs, or rubs;
signs of vascular disease (carotid or femoral bruits, T pulses), signs of heart failure;
lung & abdominal exam; chest wall exam for reproducibility of pain
‚Ä¢ 12-lead ECG: obtain w/in 10 min; c/w priors & obtain serial ECGs; consider posterior
leads (V7‚ÄìV9) to reveal isolated posterior MI if hx c/w ACS but ECG unrevealing
‚Ä¢ Cardiac biomarkers (Tn, CK-MB): serial testing at presentation, 6‚Äì12 h after sx onset
troponin (I/T): most Se & Sp marker; level 99th %ile in approp. clinical setting is dx of MI
detectable 3‚Äì6 h after injury, peaks 24 h, may remain elevated for 7‚Äì10 d in STEMI
high-sens. assays: 90‚Äì95% Se & Sp; 85% Se w/in 3 h of sx onset (NEJM 2009;361:858, 868)
‚Äúfalse ‚Äù (non-ACS myonecrosis): myocarditis/toxic CMP, severe CHF, HTN crisis, PE
or severe resp. distress, cardiac trauma/cardioversion, sepsis, SAH, demand ischemia;
? renal failure (T clearance, skeletal myopathy vs. true microinfarctions)
CK-MB: less Se & Sp (skel. muscle, tongue, diaphragm, intestine, uterus, prostate)
‚Ä¢ CXR; other imaging (echo, PE CTA, etc.) as indicated based on H&P and initial testing
‚Ä¢ Coronary CT angiography: 1‚ÅÑ2 free of CAD S 0% w/ ACS; 1‚ÅÑ2 w/ plaque S 17% w/ ACS;
even with signif stenosis, only 35% w/ ACS (JACC 2009;53:1642). ‚à¥good for r/o not r/i.

--- Fim da P√°gina 15 ---

STRESS TEST
1-4
NONINVASIVE EVALUATION OF CAD
Test
Sens
Spec
Pros
Cons
ETT
60%
75%
Exercise capacity; no 
Limited Sens (50% for 1VD,
(w/ ECG only)
radiation; low cost
but 85% for 3VD/LM)
SPECT/PET
85%
90%
Localizes ischemia; LV fxn Radiation; cost
Echo
85%
95%
Localizes ischemia; LV fxn Operator dependent; cost
& valve data, no radiation
CT Angio
90%
88%
High NPV to r/o CAD
Radiation; contrast; cost 
Exercise tolerance test (stress test) (NEJM 2001;344:1840)
‚Ä¢ Indications: dx CAD, evaluate if known CAD &  in clinical status, risk stratify s/p
ACS, evaluate exercise tolerance, localize ischemia (imaging required)
‚Ä¢ Contraindications
Absolute: AMI w/in 48 h, high-risk UA, acute PE, severe AS, uncontrolled CHF,
uncontrolled arrhythmias, myopericarditis, acute aortic dissection
Relative: left main CAD, mod valvular stenosis, severe HTN, HCMP, high-degree
AVB, severe electrolyte abnl, inability to exercise
‚Ä¢ Exercise: standard Bruce (c speed/incline q3min), modified Bruce (begins w/o tread-
mill incline), submax (if 3 wk post-MI), or sx-limited; hold antianginals if trying to
dx CAD, give if assessing if Pt ischemic on meds
‚Ä¢ Pharmacologic: if unable to exer., low exer. tol or recent MI. Se & Sp  exercise;
Preferred if LBBB. Requires imaging since ECG not specific in this setting. Coronary
vasodilators (will reveal CAD, but not tell you if Pt ischemic): regadenoson, dipyri-
damole, or adenosine (may precipitate bradycardia and bronchospasm).
Chronotropes/inotropes (physiologic): dobutamine (may precipitate tachyarrhythmias).
‚Ä¢ Imaging: used if uninterpretable ECG (paced, LBBB, resting STT 1 mm, dig., LVH,
WPW), after indeterminate ECG test, pharmacologic tests, or localization of ischemia
SPECT (eg, 99mTc-sestamibi), PET (rubidium-82; usually w/ pharm test), echo, MRI
Test results
‚Ä¢ HR (must achieve 85% of max predicted HR [220-age] for exercise test to be dx), BP
response, peak double product (HR  BP), HR recovery (HRpeak‚Äì HR1 min later; nl 12)
‚Ä¢ Max exercise capacity achieved (METS or min)
‚Ä¢ Occurrence of symptoms (at what level of exertion and similarity to presenting sx)
‚Ä¢ ECG changes: downsloping or horizontal ST T (1 mm) predictive of CAD (but dis-
tribution of ST T do not localize ischemic territory); STE highly predictive
‚Ä¢ Duke treadmill score  exercise min ‚Äì (5  max ST dev) ‚Äì (4  angina index) [0 none, 1
nonlimiting, 2 limiting]; score 5 S 1% 1-y mort; ‚Äì10 to 4 S 2‚Äì3%;  ‚Äì11 S 5%
‚Ä¢ Imaging: radionuclide defects or echocardiographic regional wall motion abnormalities
reversible defect  ischemia; fixed defect  infarct
false : breast S ant ‚Äúdefect‚Äù and diaphragm S inf ‚Äúdefect‚Äù
false  may be seen if balanced (eg, 3VD) ischemia (global T perfusion w/o regional s)
ECG-gating allows assessment of LV systolic function
High-risk test results (PPV 50% for LM or 3VD, ‚à¥consider coronary angiography)
‚Ä¢ ECG: ST T 2 mm or 1 mm in stage 1 or in 5 leads or 5 min in recovery; ST c; VT
‚Ä¢ Physiologic: T BP, exercise 4 METS, angina during exercise, Duke score  ‚Äì11; EF 35%
‚Ä¢ Radionuclide: 1 lg or 2 mod. reversible defects, transient LV cavity dilation, c lung uptake
Myocardial viability
‚Ä¢ Goal: identify hibernating myocardium that could regain fxn after revascularization
‚Ä¢ Options: MRI (Se 95%, Sp 70%), PET (Se 90%, Sp 75%), dobutamine stress
echo (Se 70%, Sp 85%); rest-redistribution thallium (Se 90%, Sp 55%)
CT & MR coronary angiography (NEJM 2008;369:2324; Circ 2010;121:2509)
‚Ä¢ Image quality best at slower & regular HR (give B if possible, goal HR 55‚Äì60)
‚Ä¢ Calcium generates artifact for CT angiography
‚Ä¢ MRI being studied: angiography, perfusion, LV fxn, hyperenhancement (Circ 2009;119:1671)
Coronary artery calcium score (CACS, NEJM 2008;358:1336; JAMA 2010;303:1610)
‚Ä¢ Quantitative evaluation of extent of calcium and thus estimate of plaque burden
‚Ä¢ Not able to assess % stenosis of coronary arteries (no IV contrast)
‚Ä¢ ? value in asx Pts w/ intermediate Framingham risk score (10‚Äì20% 10-y risk) w/ CACS of
0, 1‚Äì100, 101‚Äì300, and 300 corresponding to low, average, moderate, and high risk
‚Ä¢ May be of value as screening text to r/o CAD in sx Pt (CACS 100 S 3% probability
of signif CAD; but high scores have poor specificity)

--- Fim da P√°gina 16 ---

ANGIO/PCI
1-5
CORONARY ANGIOGRAPHY AND REVASCULARIZATION
Indications for coronary angiography in stable CAD or asx Pts
‚Ä¢ CCS class III-IV angina despite medical Rx or angina  systolic dysfxn
‚Ä¢ High-risk stress test findings (see prior topic)
‚Ä¢ Uncertain dx after noninvasive testing (& compelling need to determine dx), occupational
need for definitive dx (eg, pilot), or inability to undergo noninvasive testing
‚Ä¢ Systolic dysfxn with unexplained cause
‚Ä¢ Survivor of SCD, polymorphic VT, sustained monomorphic VT
‚Ä¢ Suspected spasm or nonatherosclerotic cause of ischemia (eg, anomalous coronary)
Pre-cath checklist
‚Ä¢ Document peripheral arterial exam (femoral, DP, PT pulses; femoral bruits); NPO 6 h
‚Ä¢ ‚úìCBC, PT, & Cr; give IVF (	 bicarb, acetylcysteine; see ‚ÄúCIAKI‚Äù); blood bank sample
‚Ä¢ ASA 325 mg; consider clopidogrel preRx (300‚Äì600 mg 2‚Äì6 h before) vs. prasugrel
at time of PCI (if ACS)
Coronary revascularization in stable CAD (JACC 2004;44:e213 & 2006;47:e1)
‚Ä¢ CABG: T mortality c/w med Rx (albeit pre statins & ACEI/ARB) in Pts w/ 3VD, LM,
or 2VD w/ critical prox LAD, and espec. if T EF (but viable myocardium); T repeat
revasc and trend toward T D/MI but c stroke c/w PCI in LM/3VD (NEJM 2009;360:961);
CABG vs. PCI being studied in DM (FREEDOM trial)
‚Ä¢ PCI: T angina c/w med Rx; does not T D/MI (COURAGE, NEJM 2007;356:1503); prompt
revasc (PCI or CABG) did not T mortality vs. med Rx in DM (NEJM 2009;360:2503)
‚Ä¢ PCI comparable to CABG in Pts w/o 3VD, w/o DM, and nl EF (Lancet 2009;373:1190)
‚Ä¢ For stable CAD w/o critical anatomy and w/o T EF, initial focus on optimal med Rx
‚Ä¢ If revasc deemed necessary, PCI if limited # of discrete lesions, nl EF, no DM, poor oper-
ative candidate; CABG if extensive or diffuse disease, T EF, DM, or valvular disease
‚Ä¢ Fractional flow reserve [ratio of maximal flow (induced by IV or IC adenosine) distal vs.
proximal to a stenosis]: PCI only if 0.8 S T # stents & T D/MI/revasc (NEJM 2009;360:213)
PCI
‚Ä¢ Balloon angioplasty (POBA): effective, but c/b dissection & elastic recoil & neointimal
hyperplasia S restenosis; now reserved for small lesions & ? some SVG lesions
‚Ä¢ Bare metal stents (BMS): T elastic recoil S 33‚Äì50% T restenosis & repeat revasc (to 
10% by 12 mos) c/w POBA; requires ASA lifelong & clopidogrel  4 wks
‚Ä¢ Drug-eluting stents (DES): T neointimal hyperplasia S 75% T restenosis, 50% T repeat
revasc (to 5% by 1 y), no c D/MI c/w BMS (NEJM 2008;359:1330); 2nd gen. everolimus DES
promising (NEJM 2010;362:1728); require ASA lifelong & clopidogrel  1 y (Circ 2007;115:813)
‚Ä¢ Anticoagulant: UFH (short-acting, rapidly reversible, but need to ‚úìPTT/ACT), LMWH (no
need for monitoring, but t1/2 8‚Äì12 h), bivalirudin (T bleeding, but 	c MI; NEJM 2009;359:688)
Post-PCI complications
‚Ä¢ Postprocedure ‚úìvascular access site, distal pulses, ECG, CBC, Cr, CK-MB
‚Ä¢ Bleeding
hematoma/overt bleeding: manual compression, reverse/stop anticoag
retroperitoneal bleed: may present with T Hct 	 back pain; c HR & T BP late;
Dx: abd/pelvic CT (I‚Äì); Rx: reverse/stop anticoag, IVF/PRBC as required
if bleeding uncontrolled, consult performing interventionalist or surgery
‚Ä¢ Vascular damage
pseudoaneurysm: triad of pain, expansile mass, systolic bruit; Dx: U/S; Rx: manual
compression, U/S-directed compression or thrombin injection, or surgical repair
AV fistula: continuous bruit; Dx: U/S; Rx: surgical repair
T perfusion to LE (embolization, dissection, thrombus): loss of distal pulse; Dx: angio;
Rx: percutaneous or surgical repair
‚Ä¢ Peri-procedural MI: 3 ULN of CK-MB occurs in 5‚Äì10%; Qw MI in 1%
‚Ä¢ Renal failure: contrast-induced manifests w/in 24 h, peaks 3‚Äì5 d (see ‚ÄúCIAKI‚Äù)
‚Ä¢ Cholesterol emboli syndrome (typically in middle-aged & elderly and w/ Ao atheroma)
renal failure (late and progressive, eos in urine); mesenteric ischemia (abd pain,
LGIB, pancreatitis); intact distal pulses but livedo pattern and toe necrosis
‚Ä¢ Stent thrombosis: mins to yrs after PCI, typically p/w AMI. Often due to mechanical
prob. (stent underexpansion or unrecognized dissection, typically presents early) or
d/c of antiplt Rx (espec if d/c both ASA & ADP blocker; JAMA 2005;293: 2126). Risk of
late stent thrombosis may be higher with DES than BMS (JACC 2006;48:2584).
‚Ä¢ In-stent restenosis: mos after PCI, typically p/w gradual c angina (10% p/w ACS).
Due to combination of elastic recoil and neointimal hyperplasia; T w/ DES vs. BMS.

--- Fim da P√°gina 17 ---

ACS
1-6
ACUTE CORONARY SYNDROMES
Myocardial ischemia typically due to atherosclerotic plaque rupture S coronary thrombosis
Spectrum of Acute Coronary Syndromes
Dx
UA
NSTEMI
STEMI
Coronary thrombosis
Subtotal
Total
History
angina that is new-onset, crescendo, or
angina at rest
at rest; usually 30 min
usually 30 min
ECG
	 ST depression and/or TWI
ST elevations
Troponin/CK-MB


 
Ddx (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)
‚Ä¢ Nonatherosclerotic coronary artery disease
Spasm: Prinzmetal‚Äôs variant, cocaine-induced (6% of CP  cocaine use r/i for MI)
Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde
extension (usually involving RCA S IMI), or mechanical (catheter, surgery, trauma)
Embolism: endocarditis, prosthetic valve, mural thrombus, myxoma; thrombosis
Vasculitis: Kawasaki syndrome,Takayasu arteritis, PAN, Churg-Strauss, SLE, RA
Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)
‚Ä¢ Fixed CAD but c myocardial O2 demand (eg, c HR, anemia,AS) S ‚Äúdemand‚Äù ischemia
‚Ä¢ Myocarditis (myocardial necrosis, but not caused by CAD); toxic CMP; cardiac contusion
Clinical manifestations (JAMA 2005;294:2623)
‚Ä¢ Typical angina: retrosternal pressure/pain/tightness 	 radiation to neck, jaw, or arms
precip. by exertion, relieved by rest or NTG; in ACS, new-onset, crescendo, or at rest
‚Ä¢ Associated symptoms: dyspnea, diaphoresis, N/V, palpitations, or lightheadedness
‚Ä¢ Many MIs (20% in older series) are initially unrecognized b/c silent or atypical sx
Physical exam
‚Ä¢ Signs of ischemia: S4, new MR murmur 2 papillary muscle dysfxn, paradoxical S2
‚Ä¢ Signs of heart failure: c JVP, crackles in lung fields,  S3, HoTN, cool extremities
‚Ä¢ Signs of other areas of atherosclerotic disease: carotid or femoral bruits, T distal pulses
Diagnostic studies
‚Ä¢ ECG: ST deviation (depression or elevation),TWI, LBBB not known to be old
Qw or PRWP suggest prior MI and ‚à¥CAD
‚úìECG w/in 10 min of presentation, with any  in sx, and at 6‚Äì12 h; c/w baseline
dx of STEMI in setting of LBBB: 1 mm STE concordant w/ QRS (Se 73%, Sp 92%)
or 5 mm discordant (Se 31%, Sp 92%) in any lead (NEJM 1996;334:481)
Localization of MI
Anatomic Area
ECG Leads w/ STE
Coronary Artery
Septal
V1‚ÄìV2
Proximal LAD
Anterior
V3‚ÄìV4
LAD
Apical
V5‚ÄìV6
Distal LAD, LCx, or RCA
Lateral
I, aVL
LCx
Inferior
II, III, aVF
RCA (85%), LCx (15%)
RV
V1‚ÄìV2 & V4R (most Se)
Proximal RCA
Posterior
ST depressionV1‚ÄìV3
RCA or LCx
If ECG non-dx and suspicion high, consider addt‚Äôl lateral (posterior) leads (V7‚ÄìV9) to further assess LCx territory.
Check right-sided precordial leads in patients with IMI to help detect RV involvement (STE in V4R most Se).
STE in III  STE in II and lack of STE in I or aVL suggest RCA rather than LCx culprit in IMI.
‚Ä¢ Cardiac biomarkers (Tn or CK-MB): serial testing at presentation, 6‚Äì12 h after sx onset;
rise to 99th %ile of reference limit in approp. clinical setting dx of MI (see ‚ÄúChest Pain‚Äù);
nb, in Pts w/ ACS & T CrCl, c Tn S poor prognosis (NEJM 2002;346:2047)
‚Ä¢ CT angiography: ‚àÖsignif stenosis 98% NPV;  only 35% PPV (JACC 2009;53:1642)
‚Ä¢ Echocardiogram: new wall motion abnormality (operator & reader dependent)
Prinzmetal‚Äôs (variant) angina
‚Ä¢ Coronary spasm S transient STE usually w/o MI (but MI,AVB,VT can occur)
‚Ä¢ Pts usually young, smokers, 	 other vasospastic disorders (eg, migraines, Raynaud‚Äôs)
‚Ä¢ Angiography S nonobstructive CAD, focal spasm w/ hyperventilation, acetylcholine
‚Ä¢ Treatment: high-dose CCB, nitrates (SL NTG prn), ? -blockers; d/c smoking
‚Ä¢ Cocaine-induced vasospasm: avoid B as unopposed -stimulation can worsen spasm

--- Fim da P√°gina 18 ---

Likelihood of ACS
Feature
High
Intermediate
Low
(any of below)
(no high features,
(no high/inter. features,
any of below)
may have below)
History
chest or L arm pain
chest or L arm pain
atypical sx (eg, pleuritic,
like prior angina
age 70 y
sharp, or positional pain)
h/o CAD (incl MI)
male, diabetes
Exam
HoTN, diaphoresis,
PAD or CVD
pain reproduced on palp.
CHF, transient MR
ECG
new STD (1 mm)
old Qw, STD (0.5‚Äì0.9 
TWF/TWI (1 mm) in 
TWI in mult leads
mm),TWI (1 mm)
leads w/ dominant R wave
Biomarkers
 Tn or CK-MB
Normal
Normal
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
Approach to triage
‚Ä¢ If hx and initial ECG & biomarkers non-dx, repeat ECG & biomarkers 12 h later
‚Ä¢ If remain nl and low likelihood of ACS, search for alternative causes of chest pain
‚Ä¢ If remain nl & Pt pain-free, have r/o MI, but if suspicion for ACS based on hx, then still
need to r/o UA w/ stress test to assess for inducible ischemia (or CTA to r/o CAD);
if low risk (age 70; √ò prior CAD, CVD, PAD; √ò rest angina) can do as outPt w/in 72 h
(0% mortality, 0.5% MI, Ann Emerg Med 2006;47:427);
if not low risk, admit and evaluate for ischemia (stress test or cath)
‚Ä¢ If ECG or biomarker abnl or high likelihood of ACS, then admit and Rx as per below
UA/NSTEMI (NSTE ACS)
Anti-Ischemic and Other Treatment
Nitrates (SL, PO, topical, or IV)
T anginal sx, no T in mortality
-blockers: PO; IV if ongoing pain,
13% T in progression to MI (JAMA 1988;260:2259)
HTN or c HR (w/o s/s CHF)
Contraindicated if HR 50, SBP 90,
eg, metoprolol 5 mg IV q5 min  3
moderate or severe CHF, 2/3 AVB, severe 
then 25‚Äì50 mg PO q6h
bronchospasm
titrate to HR 50‚Äì60
CCB (nondihydropyridines)
If cannot tolerate B b/c bronchospasm
ACEI or ARB
Especially if CHF or EF 0.40 and if SBP 100
Morphine
Consider if persistent sx or pulmonary edema
Should not be used to mask persistent CP
Oxygen
Use if necessary to keep SaO2 90%
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
Antiplatelet Therapy
Aspirin
50‚Äì70% T D/MI (NEJM 1988;319:1105)
162‚Äì325 mg  1 (1st dose crushed/chewed) If ASA allergy, use clopidogrel instead
then 75‚Äì325 mg/d
(and desensitize to ASA)
Clopidogrel (ADP receptor blocker)
Give in addition to ASA. 20% T CVD/MI/stroke
300 mg  1 S 75 mg/d 
c benefit if given upstream prior to PCI 
(requires 6 h to steady-state)
but need to wait 5 d after d/c clopi prior
600 mg  1 S 150 mg/d  7d may T
to CABG (NEJM 2001;345:494; Lancet 2001;358:257)
D/MI/stroke by 15% in PCI Pts
30% pop have T fxn CYP2C19 allele S T plt 
(CURRENT/OASIS-7, ESC 2009)
inhib & c ischemic events (NEJM 2009;360:354)
Prasugrel (ADP receptor blocker)
More rapid (30 min) and potent plt inhib c/w clopi.
60 mg  1 S 10 mg/d
19% T CVD/MI/stroke in ACS w/ planned PCI vs 
(? 5 mg/d if 60 kg)
clopi, but c bleeding (NEJM 2007;359:2001).
Particularly efficacious in DM (Circ 2008;118:1626).
Avoid if 75 y; contraindic. if h/o TIA/CVA.
Ticagrelor (ADP receptor blocker)
More rapid (30 min) and potent plt inhib c/w clopi.
180 mg  1 S 90 mg bid
16% T CVD/MI/stroke & 22% T death c/w clopi, but 
reversible (nl plt fxn after 72 h)
with c non-CABG bleeding (NEJM 2009;361;1045).
under review at FDA
c frequency of dyspnea.
GP IIb/IIIa inhibitors (GPI)
May be given in addition to oral antiplt Rx(s)
abciximab; eptifibatide; tirofiban
No clear benefit for starting GPI prior to PCI and c
infusions given 2‚Äì24 h post-PCI
risk of bleeding (NEJM 2009;360:2176)
(Adapted from ACC/AHA 2007 Guideline Update for UA/NSTEMI, Circ 2007;116:e148)
ACS
1-7

--- Fim da P√°gina 19 ---

Anticoagulant Therapy
UFH
24% T D/MI (JAMA 1996;276:811)
60 U/kg IVB (max 4000 U)
titrate to aPTT 1.5‚Äì2x cntl (50‚Äì70 sec)
12 U/kg/h (max 1000 U/h)
Enoxaparin (low-molecular-weight heparin)
Consider instead of UFH. 10% T D/MI (JAMA
1 mg/kg SC bid  2‚Äì8 d ( 	 30 mg IVB)
2004;292:89). Benefit greatest if conservative 
(qd if CrCl 30)
strategy. Can perform PCI on enoxaparin.
Bivalirudin (direct thrombin inhibitor)
Use instead of heparin for Pts w/ HIT.
0.75mg/kg IVB at time of PCI S 1.75 
With invasive strategy, bival alone noninferior to
mg/kg/h
heparin  GPI (non-signif 8% c D/MI/UR) w/
47% T bleeding (NEJM 2006;355:2203).
Fondaparinux (Xa inhibitor)
C/w enox, 17% T mortality & 38% T bleeding by
2.5 mg SC qd
30 d (NEJM 2006;354:1464). However, c risk of
cath thromb.; ‚à¥must supplement w/ UFH if PCI.
Coronary angiography (Circ 2007;116:e148 & 2009;120:2271)
‚Ä¢ Conservative approach  selective angiography
medical Rx with pre-d/c stress test; angio only if recurrent ischemia or strongly  ETT
‚Ä¢ Early invasive approach  routine angiography w/in 24‚Äì48 h
Indicated if high risk: recurrent ischemia,  Tn, ST,TRS 3, CHF, T EF, recent PCI 6
mos, sustained VT, prior CABG, hemodynamic instability
32% T rehosp for ACS, nonsignif 16% T MI, no  in mortality c/w cons. (JAMA 2008;300:71)
c peri-PCI MI counterbalanced by TT in spont. MI
Long-term mortality benefit likely only if c/w cons. strategy with low rate of angio/PCI
T D/MI/refractory ischemia if cath w/in 24 h c/w 36 h (NEJM 2009;360:2165);
‚à¥reasonable to cath high-risk Pts (GRACE score 140) w/ 12‚Äì24 of admission
TIMI Risk Score for UA/NSTEMI (JAMA 2000;284:825)
Calculation of Risk Score
Application of Risk Score
Characteristic
Point
Score
D/MI/UR by 14 d
Historical
0‚Äì1
5%
Age 65 y
1
2
8%
3 Risk factors for CAD
1
3
13%
Known CAD (stenosis 50%)
1
4
20%
ASA use in past 7 d
1
5
26%
Presentation
6‚Äì7
41%
Severe angina (2 episodes w/in 24 h)
1
Higher risk Pts (TRS 3) derive c
ST deviation 0.5 mm
1
benefit from LMWH, GP IIb/IIIa 
 cardiac marker (troponin, CK-MB)
1
inhibitors, and early angiography
RISK SCORE  Total points
(0‚Äì7)
(JACC 2003;41:89S)
Figure 1-2 Approach to UA/NSTEMI
ACS
1-8
CONS strategy
LOW RISK
HIGH RISK
‚äïTn, ST ‚Üì ‚â•0.5 mm, TRS ‚â•3, s/s CHF
ASA; clopidogrel (upstream or at time of PCI)
UFH, ENOX, or bival (depending on pref of cath lab)
¬± GP IIb/IIIa inhibitor
Angiography
‚Üì 
Stress test
once stabilized and before d/c
recurrent
ischemia
Med Rx
PCI (w/ GPI unless bival;
consider prasugrel vs. dopi) CABG
add
GPI
Long-term medical Rx
Med Rx
high risk
treadmill score    ‚Äì11
large perfusion defect (espec. ant)
multiple perfusion defects
low risk
w/in ~24 h
ASA & clopidogrel
ENOX, fonda, or UFH
INV strategy
EF
recent PCI
prior CABG
 Tn, no ST ‚Üì, and TRS 0‚Äì2,    CHF

--- Fim da P√°gina 20 ---

STEMI
Reperfusion
‚Ä¢ Immediate reperfusion (ie, opening occluded culprit coronary artery) is critical
‚Ä¢ In PCI-capable hospital, goal should be primary PCI w/in 90 min of 1st medical contact
‚Ä¢ In non-PCI-capable hospital, consider transfer to PCI-capable hospital (see below), o/w
fibrinolytic therapy w/in 30 min of hospital presentation
‚Ä¢ Do not let decision regarding method of reperfusion delay time to reperfusion
Primary PCI (NEJM 2007;356:47)
‚Ä¢ Superior to lysis: 27% T death, 65% T reMI, 54% T stroke, 95% T ICH (Lancet 2003;361:13)
‚Ä¢ Thrombus aspiration during angio prior to stenting T mortality (Lancet 2008;371:1915)
‚Ä¢ Transfer to center for 1 PCI may also be superior to lysis (NEJM 2003;349:733), see below
Fibrinolysis vs. Hospital Transfer for Primary PCI
Assess Time and Risk
1. Time required for transport to skilled PCI lab: door-to-balloon 90 min &
[door-to-balloon]-[door-to-needle] 1 h favors transfer for PCI
2. Risk from STEMI: high-risk Pts (eg, shock) fare better with mechanical reperfusion
3. Time to presentation: efficacy of lytics T w/ c time from sx onset, espec. 3 h
4. Risk of fibrinolysis: if high risk of ICH or bleeding, PCI safer option
Adapted from ACC/AHA 2004 STEMI Guidelines (Circ 2004;110:e82)
Fibrinolysis
‚Ä¢ Indications: sx 12 h and either STE 0.1 mV (1 mm) in 2 contig. leads or LBBB not
known to be old; benefit if sx 12 h less clear; reasonable if persistent sx & STE
‚Ä¢ Mortality T 20% in anterior MI or LBBB and 10% in IMI c/w ‚àÖreperfusion Rx
‚Ä¢ Prehospital lysis (ie, ambulance): further 17% T in mortality (JAMA 2000;283:2686)
‚Ä¢ 1% risk of ICH; high-risk groups include elderly (2% if 75 y), women, low wt
‚Ä¢ Although age not contraindic., c risk of ICH in elderly (75 y) makes PCI more attractive
Contraindications to Fibrinolysis
Absolute Contraindications
Relative Contraindications
‚Ä¢ Any prior ICH
‚Ä¢ Hx of severe HTN or SBP 180 or DBP 110 on
‚Ä¢ Intracranial neoplasm, aneurysm,
presentation (? absolute contra. if low-risk MI)
AVM
‚Ä¢ Ischemic stroke 3 mos prior
‚Ä¢ Nonhemorrhagic stroke or closed
‚Ä¢ Prolonged CPR (10 min)
head trauma w/in 3 mo
‚Ä¢ Trauma or major surgery w/in 3 wk
‚Ä¢ Active internal bleeding or known
‚Ä¢ Recent internal bleed (w/in 2‚Äì4 wk); active PUD
bleeding diathesis
‚Ä¢ Noncompressible vascular punctures
‚Ä¢ Suspected aortic dissection
‚Ä¢ Prior SK exposure (if considering SK)
‚Ä¢ Pregnancy
‚Ä¢ Current use of anticoagulants
Nonprimary PCI
‚Ä¢ Facilitated PCI: upstream lytic, GPI, or GPI  1‚ÅÑ2 dose lytic before PCI of no benefit
‚Ä¢ Rescue PCI if shock, unstable, failed reperfusion or persistent sx (NEJM 2005;353:2758)
‚Ä¢ Routine angio 	 PCI w/in 24 h of successful lysis: T D/MI/Revasc (Lancet 2004;364:1045) and
w/in 6 h T reMI, recurrent ischemia & CHF c/w w/in 2 wk (NEJM 2009;360:2705);
‚à¥if lysed at non-PCI capable hospital, consider transfer to PCI-capable hospital ASAP
espec if high-risk presentation (eg, anterior MI, inferior MI w/ low EF or RV infarct,
extensive STE or LBBB, HF, T BP or c HR)
‚Ä¢ Late PCI (median day 8) of occluded infarct-related artery: no benefit (NEJM 2006;355:2395)
Antiplatelet Therapy
Aspirin 162‚Äì325 mg (crushed/chewed)
23% T in death (Lancet 1988;ii:349)
ADP receptor blocker
Lysis: clopidogrel 41% c in patency, 7% T mort., no 
Clopidogrel: 600 mg pre-PCI, 300 mg
 in major bleed or ICH (NEJM 2005;352:1179; Lancet
if lysis (not if 75 y) S 75 mg/d
2005;366:1607); no data for prasugrel or ticagrelor
Prasugrel & ticagrelor as above
PCI: prasugrel and ticagrelor T CV events c/w clopi 
GP IIb/IIIa inhibitors
Lysis: no indication (Lancet 2001;357:1905)
abciximab, eptifibatide, tirofiban
Peri-PCI: 60% T D/MI/UR (NEJM 2001;344:1895)
Adapted from ACC/AHA 2009 STEMI Guidelines Focused Update (Circ 2009;120:2271)
ACS
1-9

--- Fim da P√°gina 21 ---

Anticoagulant Therapy
UFH
No demonstrated mortality benefit
60 U/kg IVB (max 4000 U)
c patency with fibrin-specific lytics
12 U/kg/h (max 1000 U/h)
Titrate to aPTT 1.5‚Äì2x cntl (50‚Äì70 sec)
Enoxaparin
Lysis: 17% T D/MI w/ ENOX  7 d vs. UFH  2 d
30 mg IVB  1 S 1 mg/kg SC bid
(NEJM 2006;354;1477)
(75 y: no bolus, 0.75 mg/kg SC bid)
PCI: acceptable alternative to UFH (age & CrCl
(CrCl  30 mL/min: 1 mg/kg SC qd)
adjustments untested in 1 PCI)
Bivalirudin
PCI: T death & T bleeding but c acute stent 
0.75 mg/kg IVB S 1.75 mg/kg/hr IV
thrombosis c/w heparin  GPI (NEJM 2008;358:2218)
Fondaparinux
Lysis: superior to placebo & to UFH, with less
2.5 mg SC QD
bleeding (JAMA 2006;295;1519)
PCI: risk of cath thromb.; should not be used
Immediate Adjunctive Therapy
-blockers
20% T arrhythmic death or reMI, 30% c cardiogenic
eg, metoprolol 25 mg PO q6h
shock, & no  overall mortality when given to Pts
titrate to HR 55‚Äì60
incl. those w/ mod CHF (Lancet 2005;366:1622)
IV only if HTN & no s/s CHF
Contraindic. if HR 60 or 110, SBP 120, mod/severe 
CHF, late present., 2/3 AVB, severe bronchospasm
Nitrates
? 5% T mortality (Lancet 1994;343:1115;1995;345:669)
SL or IV
Use for relief of sx, control of BP, or Rx of CHF
Contraindic. in hypovolemia, sx RV infarcts, sildenafil
Oxygen
Use if necessary to keep SaO2 90%.
Morphine
Relieves pain, T anxiety, venodilation S T preload
ACE inhibitors
10% T mortality (Lancet 1994;343:1115 & 1995;345:669)
eg, captopril 6.25 mg tid,
Greatest benefit in ant. MI, EF 40%, or prior MI
titrate up as tolerated
Contraindicated in severe hypotension or renal failure
ARBs
Appear  ACEI (VALIANT, NEJM 2003;349:20)
Insulin
Treat hyperglycemia 180 mg/dL while avoiding 
hypoglycemia, no clear benefit for intensive control
Adapted from ACC/AHA 2007 STEMI Guidelines Focused Update (Circ 2008;117:296)
LV failure (25%)
‚Ä¢ Diurese to achieve PCWP 15‚Äì20 S T pulmonary edema, T myocardial O2 demand
‚Ä¢ T Afterload S c stroke volume & CO, T myocardial O2 demand
can use IV NTG or nitroprusside (risk of coronary steal) S short-acting ACEI
‚Ä¢ Inotropes if CHF despite diuresis & T afterload; use dopamine, dobutamine, or milrinone
‚Ä¢ Cardiogenic shock (7%)  MAP 60 mmHg, CI 2 L/min/m2, PCWP 18 mmHg
inotropes, IABP, percutaneous VAD to keep CI  2; pressors (eg, norepinephrine) to keep
MAP 60; if not done already, coronary revascularization ASAP (NEJM 1999;341:625)
IMI complications (Circ 1990;81:401; Annals 1995;123:509)
‚Ä¢ Heart block (20%, occurs because RCA typically supplies AV node)
40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly
Rx: atropine, epi, aminophylline (100 mg/min  2.5 min), temp wire
‚Ä¢ Precordial ST T (15‚Äì30%): anterior ischemia vs. true posterior STEMI vs. reciprocal s
‚Ä¢ RV infarct (30‚Äì50%, but only 1‚ÅÑ2 of those clinically significant)
hypotension; c JVP,  Kussmaul‚Äôs; 1 mm STE in V4R; RA/PCWP 0.8; prox RCA occl.
Rx: optimize preload (RA goal 10‚Äì14, BHJ 1990;63:98); c contractility (dobutamine);
maintain AV synchrony (pacing as necessary); reperfusion (NEJM 1998;338:933);
mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)
Mechanical complications (incid.1% for each; typically occur a few days post-MI)
‚Ä¢ Free wall rupture: c risk w/ fibrinolysis, size of MI, age; p/w PEA or hypoTN, peri-
cardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, surgery
‚Ä¢ VSD: large MI in elderly;AMI S apical VSD, IMI S basal septum; 90% w/ harsh murmur 	
thrill (NEJM 2002;347:1426); Rx: diuretics, vasodil., inotropes, IABP, surgery, perc. closure
‚Ä¢ Papillary muscle rupture: small MI; more likely in IMI S PM pap. muscle (supplied by
PDA) than AMI S AL pap. muscle (supplied by diags & OMs); 50% w/ new murmur,
rarely a thrill, c v wave in PCWP tracing; asymmetric pulmonary edema. Rx: diuretics,
vasodilators, IABP, surgery.
Arrhythmias post-MI
‚Ä¢ Treat as per ACLS for unstable or symptomatic bradycardias & tachycardias
‚Ä¢ AF (10‚Äì16% incidence): -blocker, amiodarone, digoxin (particularly if CHF), heparin
ACS
1-10

--- Fim da P√°gina 22 ---

ACS
1-11
‚Ä¢ VT/VF: lido or amio  6‚Äì24 h, then reassess; c B as tol., replete K & Mg, r/o ischemia;
early monomorphic (48 h post-MI) does not carry bad prognosis
‚Ä¢ Accelerated idioventricular rhythm (AIVR): slow VT (100 bpm), often seen after
successful reperfusion; typically self-terminates and does not require treatment
‚Ä¢ Consider backup transcutaneous pacing (TP) if: 2 AVB type I, BBB
‚Ä¢ Backup TP or initiate transvenous pacing if: 2 AVB type II; BBB  AVB
‚Ä¢ Transvenous pacing (TV) if: 3 AVB; new BBB  2 AVB type II; alternating LBBB/RBBB
(can bridge w/ TP until TV, which is best accomplished under fluoro guidance)
Other Post-MI Complications
Complication
Clinical features
Treatment
LV thrombus
30% incid. (esp. lg antero-apical MI)
Anticoagulate  3‚Äì6 mo
Ventricular
Noncontractile outpouching of LV;
Surgery if recurrent CHF,
aneurysm
8‚Äì15% incid.; persistent STE.
thromboemboli, arrhythmia
Ventricular
Rupture S sealed by thrombus and
Surgery
pseudoaneurysm
pericardium
Pericarditis
10‚Äì20% incid.; 1‚Äì4 d post-MI
High-dose aspirin, NSAIDs
 pericardial rub; ECG s rare
Minimize anticoagulation
Dressler‚Äôs
4% incid.; 2‚Äì10 wk post-MI
High-dose aspirin, NSAIDs
syndrome
Fever, pericarditis, pleuritis
Prognosis
‚Ä¢ In registries, in-hospital mortality is 6% w/ reperfusion Rx (lytic or PCI) and 20% w/o
‚Ä¢ Predictors of mortality: age, time to Rx, anterior MI or LBBB, heart failure (Circ 2000;102:2031)
Killip Class
Class
Definition
Mort.
I
no CHF
6%
II
 S3 and/or basilar rales
17%
III
pulmonary edema
30‚Äì40%
IV
cardiogenic shock
60‚Äì80%
(Am J Cardiol 1967;20:457)
Forrester Class Mortality
PCWP (mmHg)
18
18
CI
2.2
3%
9%
2.2
23%
51%
(NEJM 1976;295:1356)
PREDISCHARGE CHECKLIST AND LONG-TERM POST-ACS MANAGEMENT
Risk stratification
‚Ä¢ Stress test if anatomy undefined or significant residual CAD after PCI of culprit vessel
‚Ä¢ Echocardiogram to assess EF; EF c 6% in STEMI over 6 mos (JACC 2007;50:149)
Medications (barring contraindications)
‚Ä¢ Aspirin: 162‚Äì325 mg/d for 1 mo (BMS) or 3‚Äì6 mos (DES); 75‚Äì162 mg/d thereafter
‚Ä¢ ADP receptor blocker (eg, clopidogrel): 12 mos (? longer if DES); some PPIs may
interfere with biotransformation of clopidogrel and ‚à¥plt inhibition, but no convincing
evidence to date of impact on clinical outcomes (Lancet 2009;374:989; COGENT, TCT 2009) 
‚Ä¢ -blocker: 23% T mortality after acute MI
‚Ä¢ Statin: high-intensity lipid-lowering (eg, atorvastatin 80 mg, NEJM 2004;350:1495)
‚Ä¢ ACEI: life-long if CHF, T EF, HTN, DM; 4‚Äì6 wks or at least until hosp. d/c in all STEMI
? long-term benefit in CAD w/o CHF (NEJM 2000;342:145 & 2004;351:2058; Lancet 2003;362:782)
‚Ä¢ Aldosterone antagonist: if EF 40% & signs of HF (see ‚ÄúHeart Failure‚Äù)
‚Ä¢ Nitrates: standing if symptomatic; SL NTG prn for all
‚Ä¢ Oral anticoagulants: beyond indic. for AF and LV thrombus, comb. of warfarin (goal
INR 2‚Äì2.5)  ASA T D/MI/CVA c/w ASA alone, but c bleeding (NEJM 2002;347:969);
addition of oral Xa or IIa inhibitors post-ACS under study (Lancet 2009;374:29)
ICD (NEJM 2008;359:2245)
‚Ä¢ If sust.VT/VF 2 d post-MI not due to reversible ischemia
‚Ä¢ Indicated in 1 prevention of SCD if post-MI w/ EF 30‚Äì40% (NYHA II‚ÄìIII) or
30‚Äì35% (NYHA I); need to wait 40 d after MI (NEJM 2004;351:2481 & 2009; 361;1427)
Risk factors and lifestyle modifications
‚Ä¢ Low chol. (200 mg/d) & low fat (7% saturated) diet; LDL goal 70 mg/dL; ? fish oil
(BMJ 2008;337:a2931)
‚Ä¢ BP 140/90 mmHg, 130/80 if diabetes or chronic kidney disease, consider 120/80
‚Ä¢ Smoking cessation
‚Ä¢ If diabetic, HbA1c 7% (avoid TZDs if CHF)
‚Ä¢ Exercise (30 mins 3‚Äì4  per wk);Weight loss with BMI goal 18.5‚Äì24.9 kg/m2
‚Ä¢ Influenza vaccination (Circ 2006;114:1549)

--- Fim da P√°gina 23 ---

PAC
1-12
PA CATHETER AND TAILORED THERAPY 
Rationale
‚Ä¢ Cardiac output (CO)  SV  HR; SV depends on LV end-diastolic volume (LVEDV)
‚à¥manipulate LVEDV to optimize CO while minimizing pulmonary edema
‚Ä¢ Balloon at tip of catheter inflated S floats into ‚Äúwedge‚Äù position. Column of blood extends
from tip of catheter, through pulmonary circulation, to a point just proximal to LA. Under
conditions of no flow, PCWP  LA pressure  LVEDP, which is proportional to LVEDV.
‚Ä¢ Situations in which these basic assumptions fail:
1) Catheter tip not in West lung zone 3 (and ‚à¥PCWP  alveolar pressure Z LA
pressure); clues include lack of a & v waves and if PA diastolic pressure  PCWP
2) PCWP  LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)
3) Mean LA pressure  LVEDP (eg, MR, MS)
4)  LVEDP-LVEDV relationship (ie, abnl compliance, ‚à¥‚Äúnl‚Äù LVEDP may not be optimal)
Indications (JACC 1998;32:840 & Circ 2009;119:e391)
‚Ä¢ Diagnosis and evaluation
Ddx of shock (cardiogenic vs. distributive; espec. if trial of IVF failed / high-risk) and
of pulmonary edema (cardiogenic vs. not; espec. if trial of diuretic failed / high-risk)
Evaluation of CO, intracardiac shunt, pulmonary HTN, MR, tamponade
‚Ä¢ Therapeutics
Tailored therapy to optimize PCWP, SV, SvO2 in heart failure/shock
Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in pulmonary HTN
Guide to perioperative management in some high-risk Pts, pre-transplantation
‚Ä¢ Contraindications
Absolute: right-sided endocarditis, thrombus, or mechanical R-sided valve
Relative: coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB
(5% risk of RBBB S CHB, place under fluoro), bioprosthetic R-sided valve
Efficacy concerns
‚Ä¢ No benefit to routine PAC in high-risk surgery or ARDS (NEJM 2006;354:2213)
‚Ä¢ No benefit in decompensated CHF (JAMA 2005;294:1625); untested in cardiogenic shock
‚Ä¢ But: 1‚ÅÑ2 of CO & PCWP clinical estimates incorrect; CVP & PCWP not well correl.; ‚à¥use
PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock
Placement
‚Ä¢ Insertion site: R internal jugular or L subclavian veins for ‚Äúanatomic‚Äù flotation into PA 
‚Ä¢ Inflate balloon (max 1.5 mL) when advancing and to measure PCWP
‚Ä¢ Use resistance to inflation and pressure tracing to avoid overinflation
‚Ä¢ Deflate the balloon when withdrawing and at all other times
‚Ä¢ CXR should be obtained after bedside placement to assess for catheter position and PTX
‚Ä¢ If catheter cannot be successfully floated (typically if severe TR or RV dilatation) or if
another relative contraindication exists, consider fluoroscopic guidance
Complications
‚Ä¢ Central venous access: pneumo/hemothorax (1‚Äì3%), arterial puncture, air embolism
‚Ä¢ Advancement: atrial or ventricular arrhythmias (3% VT), RBBB (5%), catheter knot-
ting, cardiac perforation/tamponade, PA rupture
‚Ä¢ Maintenance: infection (especially if catheter 3 d old), thrombus, pulmonary
infarction (1%), PA rupture/pseudoaneurysm (esp. w/ PHT), balloon rupture
Intracardiac pressures
‚Ä¢ Transmural pressure ( preload)  measured intracardiac pressure-intrathoracic pressure
‚Ä¢ Intrathoracic pressure (usually slightly ) is transmitted to vessels and heart
‚Ä¢ Always measure intracardiac pressure at end-expiration, when intrathoracic pressure
closest to 0; (‚Äúhigh point‚Äù in spont. breathing Pts;‚Äúlow point‚Äù in Pts on  pressure vent.)
‚Ä¢ If c intrathoracic pressure (eg, PEEP), measured PCWP overestimates true transmural
pressures. Can approx by subtracting 1‚ÅÑ2 PEEP (convert cmH2O to mmHg by  3‚ÅÑ4).
‚Ä¢ PCWP: LV preload best estimated at a wave; risk of pulmonary edema from avg PCWP 
Cardiac output
‚Ä¢ Thermodilution: saline injected in RA.  in temp over time measured at thermis-
tor (in PA) is integrated  1/CO. Inaccurate if T CO, sev TR, or shunt.
‚Ä¢ Fick method: O2 consumption (L/min)  CO (L/min)  arteriovenous O2 difference.
CO derived by dividing O2 consumption by observed AV O2 difference [10  1.34 ml
O2/g Hb  Hb g/dl  (SaO2 ‚Äì SvO2)].
Can estimate O2 consumption using wt-based formula, but best to measure (espec
if c metabolism, eg, sepsis).
If SVO2 80%, consider wedged (ie, pulm vein) sat, LSR shunt, impaired O2 utiliza-
tion (severe sepsis, cyanide, carbon monoxide), cc O2 delivery.

--- Fim da P√°gina 24 ---

PA Catheter Waveforms
Location
RA
RV
PA
PCWP
Distance
20 cm
30 cm
40 cm
50 cm
Pressure
mean 6
syst 15‚Äì30
syst 15‚Äì30
mean 12
(mmHg)
diast 1‚Äì8
mean 9‚Äì18
diast 6‚Äì12
Waves
a  atrial contraction,
RVEDP occurs
Waveform should
Similar to RA except
occurs in PR interval
right before
contain notch (closure dampened and delayed.
c  bulging of TV back into
upstroke and 
of pulmonic valve).
a wave after QRS,
RA at start of systole
 mean RA
Peak during T wave
	 distinct c wave,
x  atrial relaxation and
pressure unless
PA systolic  RV
v wave after T
Comment
descent of base of heart
there is TS or TR
systolic unless there
(helps distinguish
v  blood entering RA, occurs
is a gradient (eg, PS).
PCWP w/ large v
mid T wave
waves 2 MR from 
y  blood exiting RA after TV
PA).
opens at start of diastole
PCWP waveform abnormalities: large a wave S ? mitral stenosis; large v wave S ? mitral regurgitation;
blunted y descent S ? tamponade; steep x & y descents S ? constriction.
Hemodynamic Profiles of Various Forms of Shock
RA
PCWP
CO
SVR
Type of shock
(JVP)
(CXR)
(UOP)
(Cap refill)
Hypovolemic
T
T
T
c
Cardiogenic
nl or c
c
T
c
Distributive
variable
variable
usually c
T
(but can be T in sepsis)
RV Infarct / Massive PE
c
nl or T
T
c
Tamponade
c
c
T
c
(Surrogates for hemodynamic parameters shown below parameter in parentheses.)
Tailored therapy in cardiogenic shock (Circ 2009;119:e391)
‚Ä¢ Goals: optimize both MAP and CO while T risk of pulmonary edema
MAP  CO  SVR; CO  HR  SV (which depends on preload, afterload, and contractility)
pulmonary edema when PCWP 20‚Äì25 (higher levels may be tolerated in chronic HF)
‚Ä¢ Optimize preload  LVEDV  LVEDP  LAP  PCWP (NEJM 1973;289:1263)
goal PCWP 14‚Äì18 in acute MI, 10‚Äì14 in chronic heart failure
optimize in individual Pt by measuring SV w/ different PCWP to create Starling curve
c by giving NS (albumin w/o clinical benefit over NS; PRBC if significant anemia)
T by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics 
‚Ä¢ Optimize afterload ‚âàwall stress during LV ejection  [(SBP  radius) / (2  wall thick.)]
and ‚à¥‚àùMAP and ‚àùSVR  (MAP ‚Äì CVP / CO); goals: MAP 60, SVR 800‚Äì1200
MAP 60 & SVR c: vasodilators (eg, nitroprusside, NTG,ACEI, hydral.) or wean pressors
MAP 60 & SVR c (& ‚à¥CO T): temporize w/ pressors until can c CO (see below)
MAP 60 & SVR low/nl (& ‚à¥inappropriate vasoplegia): vasopressors (eg, norepineph-
rine [, ], dopamine [D, , ], phenylephrine [], or vasopressin [V1] if refractory)
‚Ä¢ Optimize contractility ‚àùCO for given preload & afterload; goal CI  (CO/ BSA) 2.2
if too low despite optimal preload & vasodilators (as MAP permits):  inotropes 
eg, dobutamine (moderate inotrope & mild vasodilator), milrinone (strong 
inotrope & vasodilator, incl pulmonary artery), both proarrhythmic, or epinephrine 
(strong inotrope and vasopressor); also consider mechanical assistance with 
IABP or percutaneous or surgical LVAD 	 RVAD
PAC
1-13
0
5
10
15
20
25
30
mm
Hg
simultaneous
ECG
a
c
x
y
v
a
x
y
v

--- Fim da P√°gina 25 ---

HF
1-14
HEART FAILURE
Definitions (Braunwald‚Äôs Heart Disease, 8th ed., 2008)
‚Ä¢ Failure of heart to pump blood forward at sufficient rate to meet metabolic demands of
peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures
‚Ä¢ Low output (T cardiac output) vs. high output (c stroke volume 	 c cardiac output)
‚Ä¢ Left-sided (pulmonary edema) vs. right-sided (c JVP, hepatomegaly, peripheral edema)
‚Ä¢ Backward (c filling pressures, congestion) vs. forward (impaired systemic perfusion)
‚Ä¢ Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)
Figure 1-3 Approach to left-sided heart failure
History
‚Ä¢ Low output: fatigue, weakness, exercise intolerance,  MS, anorexia
‚Ä¢ Congestive: left-sided S dyspnea, orthopnea, paroxysmal nocturnal dyspnea
right-sided S peripheral edema, RUQ discomfort, bloating, satiety
Functional classification (New York Heart Association class)
‚Ä¢ Class I: no sx w/ ordinary activity; class II: sx w/ ordinary activity;
Class III: sx w/ minimal activity; class IV: sx at rest
Physical exam (‚Äú2-minute‚Äù hemodynamic profile; JAMA 2002;287:628)
‚Ä¢ Congestion (‚Äúdry‚Äù vs. ‚Äúwet‚Äù)
c JVP (80% of the time JVP 10 S PCWP 22; J Heart Lung Trans 1999;18:1126)
 hepatojugular reflux: 1 cm c in JVP for 15 sec with abdominal pressure
73% Se & 87% Sp for RA 8 and 55% Se & 83% Sp for PCWP 15 (AJC 1990;66:1002)
Valsalva square wave (c SBP thru strain) (JAMA 1996;275:630)
S3 (in Pts w/ HF S 40% c risk of HF hosp. or pump failure death; NEJM 2001;1345:574)
rales, dullness at base 2 pleural effus. (often absent due to lymphatic compensation)
	 hepatomegaly, ascites and jaundice, peripheral edema
‚Ä¢ Perfusion (‚Äúwarm‚Äù vs. ‚Äúcold‚Äù)
narrow pulse pressure (25% of SBP) S CI 2.2 (91% Se, 83% Sp; JAMA 1989;261:884)
pulsus alternans, cool & pale extremities, T UOP, muscle atrophy
‚Ä¢ 	 Other: Cheyne-Stokes resp., abnl PMI (diffuse, sustained, or lifting depending on cause of
HF), S4 (diast. dysfxn), murmur (valvular dis., c MV annulus, displaced papillary muscles)
Evaluation for the presence of heart failure
‚Ä¢ CXR (see Radiology insert): pulm edema, pleural effusions 	 cardiomegaly, cephaliza-
tion, Kerley B-lines
‚Ä¢ BNP / NT-proBNP: can help exclude HF as cause of dyspnea if low; predicts risk of rehosp
‚Ä¢ Evidence of T perfusion to vital organs: c BUN, c Cr, T serum Na, abnormal LFTs
‚Ä¢ Echo (see inserts): T EF & c chamber size S systolic dysfxn; hypertrophy, abnl MV inflow,
abnl tissue Doppler S ? diastolic dysfxn; abnl valves or pericardium; estimate RVSP
‚Ä¢ PA catheterization: c PCWP, T CO and c SVR (low-output failure)
Left-sided Heart Failure
‚ÜëAfterload
AS, HCMP
HTN crisis
Coarctation
r/o mitral valve disease
consider myxoma, pulmonary VOD
‚ÜëLVEDP
‚ÜëLVEDV
‚ÜìContractility
Ischemia/MI
DCMP
Chronic AI/MR
High Output
AV fistula
Paget‚Äôs
Sepsis
Beriberi
Anemia
Thyrotoxicosis
or
‚ÜìForward Flow
MR, AI, VSD
Systolic
Dysfunction
High SV
Failure
LVH
1¬∞ HCMP
2¬∞ to HTN, AS
or
Ischemia
or
RCMP
Myocardial
Endomyocardial
Pericardial
Disease
(usually right-
sided failure)
Tamponade
Constriction
normal LVEDV
Diastolic
Dysfunction
‚ÜëSV
‚ÜëESV

--- Fim da P√°gina 26 ---

Evaluation of the causes of heart failure
‚Ä¢ ECG: evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCMP) 
‚Ä¢ Coronary angiography (or ? CT coronary angiography)
‚Ä¢ If no CAD, w/u for nonischemic DCMP, HCMP, or RCMP (see ‚ÄúCardiomyopathies‚Äù)
Precipitants of acute heart failure
‚Ä¢ Myocardial ischemia or infarction; myocarditis
‚Ä¢ Renal failure (acute, progression of CKD, or insufficient dialysis) S c preload
‚Ä¢ Hypertensive crisis (incl. from RAS), worsening AS S c left-sided afterload
‚Ä¢ Dietary indiscretion or medical nonadherence
‚Ä¢ Drugs (B, CCB, NSAIDs,TZDs) or toxins (EtOH, anthracyclines)
‚Ä¢ Arrhythmias; acute valvular dysfxn (eg, endocarditis), espec. mitral or aortic regurgitation 
‚Ä¢ COPD or PE S c right-sided afterload
‚Ä¢ Anemia, systemic infection, thyroid disease
Treatment of acute decompensated heart failure 
‚Ä¢ Assess degree of congestion & adequacy of perfusion
‚Ä¢ For congestion: ‚ÄúLMNOP‚Äù
Lasix w/ monitoring of UOP; high-dose
(IVB 2.5 PO dose) vs. low-dose (IVB  
1 PO dose) S c UOP but transient 
c in renal dysfxn; ‚àÖclear diff between
cont vs. intermittent (DOSE,ACC 2010) 
Morphine (T sx, venodilator, T afterload)
Nitrates (venodilator)
Oxygen 	 noninvasive ventilation (see ‚ÄúMechanical Ventilation‚Äù)
Position (sitting up & legs dangling over side of bed S T preload)
‚Ä¢ For low perfusion, see below 
Treatment of advanced heart failure (Circ 2009;119:e391)
‚Ä¢ Tailored Rx w/ PAC (qv); goals of MAP 60, CI 2.2 (MVO2 60%), SVR 800, PCWP 18
‚Ä¢ IV vasodilators: NTG, nitroprusside (risk of coronary steal in Pts w/ CAD;
prolonged use S cyanide/thiocyanate toxicity); nesiritide (rBNP) T PCWP & sx,
but may c Cr & mortality (JAMA 2002;287:1531 & 2005;293:1900)
‚Ä¢ Inotropes (properties in addition to c inotropy listed below)
dobutamine: vasodilation at doses 5 g/kg/min; mild T PVR; desensitization over time
dopamine: splanchnic vasodil. S c GFR & natriuresis; vasoconstrict. at 5 g/kg/min
milrinone: prominent systemic & pulmonary vasodilation; T dose by 50% in renal failure
‚Ä¢ Ultrafiltration: 1 L fluid loss at 48 h and 50% T in rehosp. (JACC 2007;49:675)
‚Ä¢ Mechanical circulatory support
intraaortic balloon pump (IABP): deflates in diastole & inflates in systole to T impe-
dence to LV ejection of blood & c coronary perfusion
ventricular assist device (LVAD 	 RVAD): as bridge to recovery (NEJM 2006;355:1873) or
transplant (some temporary types can be placed percutaneously  PVAD), or as
destination therapy (45‚Äì50% T mort. vs. med Rx; NEJM 2001;345:1435 & 2009;361:2241)
‚Ä¢ Cardiac transplantation: 15‚Äì20% mort. in 1st y, median survival 10 y
Recommended Chronic Therapy by CHF Stage (Circ 2009;119: e391)
Stage (Not NYHA Class)
Pt Characteristics
Therapy
High risk for HF
HTN, DM, CAD
Treat HTN, lipids, DM, SVT
 Structural heart dis.
Cardiotoxin exposure
Stop smoking, EtOH
A
Asx
FHx of CMP
Encourage exercise
ACEI if HTN, DM, CVD, PAD
B
 Structural heart dis.
Prior MI, T EF, LVH
All measures for stage A
Asx
or asx valvular dis.
ACEI & B if MI/CAD or T EF
 Structural heart dis.
All measures for stage A
 Symptoms of HF
ACEI, B, diuretics, Na restrict
C
(prior or current) 
Overt HF
Consider aldactone, ICD, CRT
Consider nitrate/hydral, digoxin
Refractory HF
Sx despite maximal 
All measures for stage A‚ÄìC
requiring specialized
medical Rx
IV inotropes,VAD, transplant
D
interventions
4 yr mortality 50%
End-of-life care
(Circ 2009;119:e391)
‚Ä¢ No clear evidence that BNP-guided Rx results in superior clinical outcomes outside
of encouraging intensification of established therapies (JAMA 2009;301:383)
‚Ä¢ Implantable PA pressure sensor may T risk of hosp (CHAMPION, HF Congress 2010)
HF
1-15
Congestion?
No
Yes
Warm & Dry Warm & Wet
OutPt Rx
Diuresis 	
vasodilator
Cold & Dry
Cold & Wet
	 Inotropes
Tailored Rx 
(CCU)
(CCU)
Low perfusion?
Yes
No

--- Fim da P√°gina 27 ---

Treatment of Chronic Heart Failure with Reduced Ejection Fraction
Diet, exercise
Na 2 g/d, fluid restriction, exercise training in ambulatory Pts
ACEI
T mortality: 40% in NYHA IV, 16% in NYHA II/III, 20% in asx,
post-MI, EF 40% (NEJM 1987;316:1429; 1991;325:293; 1992;327:669)
20% T reMI; 20‚Äì30% T rehosp for HF (c amt of benefit w/ T EF)
30% T HF in asx Pts w/ EF 35% (SOLVD-P, NEJM 1992;327:685)
High-dose ACEI more efficacious than low-dose 
Watch for azotemia, c K (can ameliorate by low-K diet, diuretics,
kayexalate), cough, angioedema
ATII receptor
Consider as alternative if cannot tolerate ACEI (eg, b/c cough)
blockers (ARBs)
Noninferior to ACEI (VALIANT, NEJM 2003;349:1893)
Good alternative if ACEI intol (CHARM-Alternative, Lancet 2003;362:772)
As with ACEI, higher doses more efficacious (Lancet 2009;374:1840)
? T HF (Val-HEFT, NEJM 2001;345:1667) and T mort. when added to 
ACEI (CHARM-Added, Lancet 2003;362:767), but c risk of c K and c Cr
Hydralazine  nitrates
Consider if cannot tolerate ACEI/ARB or in blacks w/ Class III/IV
25% T mort. (NEJM 1986;314:1547); infer. to ACEI (NEJM 1991;325:303)
40% T mort. in blacks on standard Rx (A-HEFT, NEJM 2004;351:2049)
-blocker
EF will transiently T, then c. Contraindic. in decompensated HF.
(data for carvedilol,
35% T mort. & 40% T rehosp. in NYHA II‚ÄìIV (JAMA 2002;287:883)
metoprolol, bisoprolol)
Carvedilol superior to low-dose metoprolol (Lancet 2003;362:7)
Aldosterone
Consider if HF severe or post-MI, adeq. renal fxn; watch for c K
antagonists
30% T mort. in NYHA III/IV & EF 35% (RALES, NEJM 1999;341:709)
15% T mort. in HF post-MI, EF 40% (EPHESUS, NEJM 2003;348:1309)
Cardiac
Consider if EF 35%, QRS 120 ms, and symptomatic
resynchronization
36% T mort. & c EF in NYHA III‚ÄìIV (CARE-HF, NEJM 2005;352:1539)
therapy (CRT)
T HF if EF30% & NYHA I/II, espec if QRS 150 ms, no  in 
mortality (NEJM 2009;361:1329)
No single measure of dyssynchrony on echo improves Pt 
selection for CRT (Circ 2008;117:2608)
ICD
Use for 1 prevention if sx & EF 35% or for 2 prevention
T mort. in Pts w/ MI & EF 30% (NEJM 2002;346:877); no  mort.
early post-MI (NEJM 2004;351:2481; 2009;361:1427), ‚à¥wait 40 d
23% T mort. in all DCMP, EF 35% (SCD-HeFT, NEJM 2005;352:225)
T arrhythmic death in nonisch DCMP (DEFINITE, NEJM 2004;350:2151)
Diuretics
Loop 	 thiazides diuretics (sx relief; no mortality benefit)
Digoxin
23% T HF hosp., no  mortality (NEJM 1997;336:525)
? c mort. in women, ? related to c levels (NEJM 2002;347:1403)
? optimal dig concentration 0.5‚Äì0.8 ng/mL (JAMA 2003;289:871)
-3 fatty acids
9% T mortality (Lancet 2008;372:1223)
Anticoagulation
Consider if AF, LV thrombus, large akinetic LV segment, EF 30%
Heart rhythm
Catheter ablation of AF S c in EF, T sx (NEJM 2004;351:2373)
No mortality benefit to AF rhythm vs. rate cntl (NEJM 2008;358:2667)
For sx AF, pulm vein isolation improves sx c/w AVN ablation & 
CRT (NEJM 2008;359:1778)
(Lancet 2009;373:941; Circ 2009;119:e391; NEJM 2010;362:228)
Heart failure with preserved EF (‚ÄúDiastolic HF‚Äù) (JACC 2009;53:905)
‚Ä¢ 40‚Äì60% of Pts w/ HF have normal or only min. impaired systolic fxn (EF 40%) (NEJM
2006;355:251, 260), w/ mortality rates similar to those w/ systolic dysfxn
‚Ä¢ 30% of population 45 y w/ diastolic dysfxn on echo, 20% mild, 10% mod/sev,
but only 50% of severe and 5% of moderate cases were symptomatic (JAMA 2003;289:194)
‚Ä¢ Etiologies (impaired relaxation and/or c passive stiffness): ischemia, prior MI, LVH,
HCMP, infiltrative CMP, RCMP, aging, hypothyroidism
‚Ä¢ Precipitants of pulmonary edema: volume overload (poor compliance of LV S sensitive
to even modest c in volume); ischemia (T relaxation); tachycardia (T filling time in
diastole),AF (loss of atrial boost to LV filling); HTN (T afterload S T stroke volume) 
‚Ä¢ Dx w/ clinical s/s of HF w/ preserved systolic and impaired diastolic fxn on echo:
abnormal MV inflow: E/A reversal and s in E wave deceleration time
T myocardial relax.: c isovol relax. time & T early diastole tissue Doppler vel
LVH, LAE
‚Ä¢ Treatment: diuresis for volume overload, BP control, prevention of tachycardia and
ischemia. No clear benefit of ACEI/ARB in Pts with isolated diastolic HF (Lancet
2003;362:777; NEJM 2008;359:2456). May underscore heterogeneity of Pt population.
HF
1-16

--- Fim da P√°gina 28 ---

CMP
1-17
CARDIOMYOPATHIES
Diseases with mechanical and/or electrical dysfunction of the myocardium
DILATED CARDIOMYOPATHY (DCMP)
Definition and epidemiology (Circ 2006;113:1807)
‚Ä¢ Ventricular dilatation and T contractility 	 T wall thickness,
‚Ä¢ Incidence: 5‚Äì8 cases/100,000 population per y; prevalence: 1 in 2500
Etiologies (NEJM 1994;331:1564 & 2000;342:1077)
‚Ä¢ Ischemia: systolic dysfxn & dilation out of proportion to CAD (poor remodeling post-MI)
‚Ä¢ Valvular disease: systolic dysfxn due to chronic volume overload in MR & AI
‚Ä¢ Familial (25%): mutations in cytoskeletal, nuclear, and filament proteins (NEJM 1992;362:77)
‚Ä¢ Idiopathic (25% of DCMP, ? undiagnosed infectious, alcoholic, or genetic cause)
‚Ä¢ Infectious myocarditis (10‚Äì15%, autoimmune response to infxn; NEJM 2009;360:1526)
Viruses (coxsackie, adeno, echovirus, CMV): ranging from subacute (dilated LV w/ mild-
mod dysfxn) to fulminant (nondilated, thickened, edematous LV w/ severe dysfxn)
Bacterial, fungal, rickettsial,TB, Lyme (mild myocarditis, often with AVB)
HIV: 8% of asx HIV ; due to HIV vs. other viruses vs. meds (NEJM 1998;339:1093)
Chagas: apical aneurysm 	 thrombus, RBBB, megaesophagus or colon (NEJM 1993;329:639)
‚Ä¢ Toxic
Alcohol (5%) typically 7‚Äì8 drinks/d  5 y, but much interindividual variability
Anthracyclines (risk c 550 mg/m2, may manifest late), cyclophosphamide, trastuzumab 
Cocaine, antiretrovirals, lead, carbon monoxide poisoning, radiation
‚Ä¢ Infiltrative (5%): often mix of DCMP  RCMP (qv) with thickened wall
amyloidosis, sarcoidosis, hemochromatosis, tumor
‚Ä¢ Autoimmune
Collagen vascular disease (3%): polymyositis, SLE, scleroderma, PAN, RA,Wegener‚Äôs
Peripartum (last month S 5 mo postpartum): 0.1% of preg.; c risk w/ multiparity &
c age; 50% will improve; ? c risk w/ next preg. (JAMA 2000;283:1183)
Idiopathic giant cell myocarditis (GCM): avg age 42 y, fulminant,VT (NEJM 1997;336:1860)
Eosinophilic (variable peripheral eosinophilia): hypersensitivity (mild CHF) or
acute necrotizing (ANEM; STE, effusion, severe CHF)
‚Ä¢ Stress-induced (Takotsubo apical ballooning): mimics MI (pain, 	 STE & c Tn; deep TWI
& c QT; mid/apical dyskinesis; ? Rx w/ ACEI; usually improves over wks (NEJM 2005;352:539)
‚Ä¢ Tachycardia-induced: likelihood proportional to rate and duration
‚Ä¢ Arrhythmogenic right ventricular cardiomyopathy (ARVC): fibrofatty replacement
of RV S dilation (dx w/ MRI); ECG: 	 RBBB,TWI V1‚ÄìV3,  wave; risk VT (Circ 2004;110:1879)
‚Ä¢ Metabolic & other: hypothyroidism, acromegaly, pheo, thiamine, sleep apnea
Clinical manifestations
‚Ä¢ Heart failure: both congestive & poor forward flow sx; signs of L- & R-sided HF
diffuse, lat.-displaced PMI, S3, 	 MR or TR (annular dilat., displaced pap. muscle)
‚Ä¢ Embolic events (10%), arrhythmias & palpitations
‚Ä¢ Chest pain can be seen w/ some etiologies (eg, myocarditis)
Diagnostic studies and workup
‚Ä¢ CXR: moderate to marked cardiomegaly, 	 pulmonary edema & pleural effusions
‚Ä¢ ECG: may see PRWP, Q waves, or BBB; low voltage; AF (20%)
‚Ä¢ Echocardiogram: LV dilatation, T EF, regional or global LV HK, 	 RV HK, 	 mural thrombi
‚Ä¢ Laboratory evaluation:TFTs, iron studies, HIV, SPEP, ANA; others per clinical suspicion
‚Ä¢ Family hx (20‚Äì35% w/ familial dis.), genetic counseling 	 genetic testing (JAMA 2009;302:2471)
‚Ä¢ Stress test: completely  test useful to r/o ischemic etiology (low false  rate), but
 test does not rule in ischemic etiology (high false  rate, even w/ imaging)
‚Ä¢ Coronary angiography to r/o CAD if risk factors, h/o angina, Qw MI on ECG,
equivocal ETT; consider CT angiography (JACC 2007;49:2044) 
‚Ä¢ ? Endomyocardial biopsy (JACC 2007;50:1914): yield 10% (of these, 75% myocarditis, 25% 
systemic disease); 40% false  rate (patchy dis.) & false  (necrosis S inflammation)
no proven Rx for myocarditis; ‚à¥biopsy if: acute & hemodyn compromise (r/o GCM,
ANEM); arrhythmia or RCMP features (r/o infiltrative); or suspect toxic, allergic, tumor
‚Ä¢ Cardiac MRI: detect myocarditis or infiltrative disease, but nonspecific (EHJ 2005;26:1461)
Treatment (see ‚ÄúHeart Failure‚Äù for standard HF Rx)
‚Ä¢ Implantation of devices may be tempered by possibility of reversibility of CMP
‚Ä¢ Immunosuppression: for giant cell myocarditis (prednisone  AZA), collagen vascular
disease, peripartum (? IVIg), & eosinophilic; no proven benefit for viral myocarditis
‚Ä¢ Prognosis differs by etiology (NEJM 2000;342:1077): postpartum (best), ischemic (worst)

--- Fim da P√°gina 29 ---

HYPERTROPHIC CARDIOMYOPATHY (HCMP)
Definition and epidemiology
‚Ä¢ LV (usually 15 mm) and/or RV hypertrophy disproportionate to hemodynamic load
‚Ä¢ Prevalence: 1 case/500 population; 50% sporadic, 50% familial
‚Ä¢ Differentiate from 2 LVH: hypertension (espec. elderly women; NEJM 1985;312:277),AS,
elite athletes (wall thickness usually 13 mm & symmetric and nl/c rates of tissue
Doppler diastolic relaxation; NEJM 1991;324:295), Fabry dis. (c Cr, skin findings)
Pathology
‚Ä¢ Autosomal dominant mutations in cardiac sarcomere genes (eg, -myosin heavy chain) 
‚Ä¢ Myocardial fiber disarray with hypertrophy
‚Ä¢ Morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical
Pathophysiology
‚Ä¢ Subaortic outflow obstruction: narrowed tract 2 hypertrophied septum  systolic
anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and
papillary muscle displacement. Gradient (‚àá) worse w/ c contractility
(digoxin, -agonists), T preload, or T afterload.
‚Ä¢ Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and abnormal
mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)
‚Ä¢ Diastolic dysfunction: c chamber stiffness  impaired relaxation
‚Ä¢ Ischemia: small vessel dis., perforating artery compression (bridging), T coronary perfusion
‚Ä¢ Syncope: s in load-dependent CO, arrhythmias
Clinical manifestations (70% are asymptomatic at dx)
‚Ä¢ Dyspnea (90%): due to c LVEDP, MR, and diastolic dysfunction
‚Ä¢ Angina (25%) even w/o epicardial CAD; microvasc. dysfxn (NEJM 2003;349:1027)
‚Ä¢ Arrhythmias (AF in 20‚Äì25%;VT/VF) S palpitations, syncope, sudden cardiac death
Physical exam
‚Ä¢ Sustained PMI, S2 paradox. split if severe outflow obstruction,  S4 (occ. palpable)
‚Ä¢ Systolic crescendo-decrescendo murmur at LLSB: c w/ Valsalva & standing
‚Ä¢ 	 mid-to-late or holosystolic murmur of MR at apex
‚Ä¢ Bisferiens carotid pulse (brisk rise, decline, then 2nd rise); JVP w/ prominent a wave
‚Ä¢ Contrast to AS, which has murmur that T w/ Valsalva and T carotid pulses
Diagnostic studies
‚Ä¢ CXR: cardiomegaly (LV and LA)
‚Ä¢ ECG: LVH, anterolateral and inferior pseudo-Qw, 	 apical giant TWI (apical variant)
‚Ä¢ Echo: no absolute cutoffs for degree of LVH but septum / post wall 1.3 suggestive,
as is septum 15 mm; other findings include dynamic outflow obstruction, SAM, MR
‚Ä¢ MRI: hypertrophy  patchy delayed enhancement (useful for dx & prognosis) 
‚Ä¢ Cardiac cath: subaortic pressure ‚àá; Brockenbrough sign  T pulse pressure post-
extrasystolic beat (in contrast to AS, in which pulse pressure c postextrasystole)
Treatment (NEJM 2004;350:1320)
‚Ä¢ Heart failure
 inotropes/chronotropes: -blockers, CCB (verapamil), disopyramide.
Careful use of diuretics.Vasodilators only if systolic dysfxn.Avoid digoxin.
If refractory to drug therapy and there is obstructive physiology (‚àá50 mmHg):
a) Alcohol septal ablation (NEJM 2002;347:1326)
triphasic ‚àáresponse: acute T S 	 partial c back to 50% of baseline S T over months
by 1 y resting ‚àá15 mmHg & stress-induced ‚àá31 mmHg (J Interv Card 2006;19:319)
complications: transient (& occ. delayed) 3 AVB w/ 10‚Äì20% req. PPM;VT
b) Surgical myectomy: long-term sx improvement in 90% (Circ 2005;112:482)
c) ? Dual-chamber pacing, but largely placebo effect (JACC 1997;29:435; Circ 1999;99:2927)
If refractory to drug therapy and there is nonobstructive pathophysiology: transplant
‚Ä¢ Acute HF: can be precip. by dehydration or tachycardia; Rx w/ fluids, B, phenylephrine 
‚Ä¢ AF: rate control with -blockers, maintain SR with disopyramide, amiodarone
‚Ä¢ Sudden cardiac death: ICD (JACC 2003;42:1687). Major risk factors include history of VT/VF,
 FHx SCD, unexplained syncope, NSVT, T SBP or relative HoTN (c SBP 20
mmHg) w/ exercise, LV wall 30 mm; risk 4%/y in high-risk Pts (JAMA 2007;298:405)
‚Ä¢ Counsel to avoid dehydration, extreme exertion
‚Ä¢ Endocarditis prophylaxis no longer recommended (Circ 2007;16:1736)
‚Ä¢ First-degree relatives: periodic screening w/ echo (as timing of HCMP onset variable)
CMP
1-18

--- Fim da P√°gina 30 ---

RESTRICTIVE CARDIOMYOPATHY (RCMP)
Definition
‚Ä¢ Impaired ventricular filling due to T compliance in absence of pericardial disease
Etiology (NEJM 1997;336:267; JACC 2010;55:1769)
‚Ä¢ Myocardial processes
autoimmune (scleroderma, polymyositis-dermatomyositis)
infiltrative diseases (see primary entries for extracardiac manifestations, Dx, Rx)
amyloidosis (JACC 2007;50:2101): age at presentation 60 y; male:female  3:2
AL (MM, light-chain, MGUS,WM); familial (transthyretin,TTR);AA/senile (TTR, ANP)
ECG: T QRS amplitude (50%), pseudoinfarction pattern (Qw),AVB (10‚Äì20%),
hemiblock (20%), BBB (5‚Äì20%)
Echo: biventricular wall thickening, granular sparkling texture (30%), biatrial
enlargement (40%), thickened atrial septum, valve thickening (65%), diastolic 
dysfxn, small effusion
normal voltage & normal septal thickness has NPV 90%
MRI: distinct late gadolinium enhancement pattern (JACC 2008;51:1022)
sarcoidosis: age at present. 30 y; more common in blacks, N. Europeans, women
5% of those with sarcoid w/ overt cardiac involvement; cardiac w/o systemic in 10%
ECG:AVB (75%), RBBB (20‚Äì60%),VT
Echo: regional WMA (particularly basal septum) with thinning or mild hypertrophy
nuclear imaging: gallium uptake in areas of sestaMIBI perfusion defects
hemochromatosis: presents in middle-aged men (particularly N. European)
storage diseases: Gaucher‚Äôs, Fabry, Hurler‚Äôs, glycogen storage diseases
diabetes mellitus
‚Ä¢ Endomyocardial processes
chronic eosinophilic: L√∂ffler‚Äôs endocarditis (temperate climates; c eos.; mural thrombi
that embolize); endomyocardial fibrosis (tropical climates; var. eos.; mural thrombi)
toxins: radiation, anthracyclines
serotonin: carcinoid, serotonin agonists, ergot alkaloids
metastatic cancer
Pathology & pathophysiology
‚Ä¢ Path: normal or c wall thickness 	 infiltration or abnormal deposition
‚Ä¢ T myocardial compliance S nl EDV but c EDP S c systemic & pulm. venous pressures
‚Ä¢ T ventricular cavity size S T SV and T CO
Clinical manifestations (Circ 2000;101:2490)
‚Ä¢ Right-sided  left-sided heart failure with peripheral edema  pulmonary edema
‚Ä¢ Diuretic ‚Äúrefractoriness‚Äù
‚Ä¢ Thromboembolic events
‚Ä¢ Poorly tolerated tachyarrhythmias;VT S syncope/sudden cardiac death
Physical exam
‚Ä¢ c JVP, 	 Kussmaul‚Äôs sign (classically seen in constrictive pericarditis)
‚Ä¢ Cardiac: 	 S3 and S4, 	 murmurs of MR and TR
‚Ä¢ Congestive hepatomegaly, 	 ascites and jaundice, peripheral edema
Diagnostic studies
‚Ä¢ CXR: normal ventricular chamber size, enlarged atria, 	 pulmonary congestion
‚Ä¢ ECG: low voltage, pseudoinfarction pattern (Qw), 	 arrhythmias
‚Ä¢ Echo: symmetric wall thickening, biatrial enlarge., 	 mural thrombi, 	 cavity oblit.
w/ diast dysfxn: c early diast (E) and T late atrial (A) filling, c E/A ratio, T decel. time
‚Ä¢ Cardiac MRI: may reveal inflammation or evidence of infiltration (although nonspecific)
‚Ä¢ Cardiac catheterization
atria: M‚Äôs or W‚Äôs (prominent x and y descents)
ventricles: dip & plateau (rapid T pressure at onset of diastole, rapid c to early plateau)
concordance of LV and RV pressure peaks during respiratory cycle (vs. discor-
dance in constrictive pericarditis; Circ 1996;93:2007)
‚Ä¢ Endomyocardial biopsy if suspect infiltrative process
‚Ä¢ Restrictive cardiomyopathy vs. constrictive pericarditis: see ‚ÄúPericardial Disease‚Äù
Treatment (in addition to Rx‚Äôing underlying disease)
‚Ä¢ Gentle diuresis. May not tolerate CCB or other vasodilators.
‚Ä¢ Control HR and maintain SR (important for diastolic filling). Dig proarrhythmic in amyloid.
‚Ä¢ Anticoagulation (particularly with AF or low CO)
‚Ä¢ Transplantation for refractory cases
CMP
1-19

--- Fim da P√°gina 31 ---

VALVES
1-20
VALVULAR HEART DISEASE
AORTIC STENOSIS (AS)
Etiology
‚Ä¢ Calcific: predominant cause in Pts 70 y; risk factors include HTN, c chol., ESRD
‚Ä¢ Congenital (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts 70 y
‚Ä¢ Rheumatic heart disease (AS usually accompanied by AI and MV disease)
‚Ä¢ AS mimickers: subvalvular (HCMP, subAo membrane), supravalvular
Clinical manifestations (usually indicates AVA 1 cm2 or concomitant CAD)
‚Ä¢ Angina: c O2 demand (hypertrophy)  T O2 supply (T cor perfusion pressure) 	 CAD
‚Ä¢ Syncope (exertional): peripheral vasodil. w/ fixed CO S T MAP S T cerebral perfusion
‚Ä¢ Heart failure: outflow obstruct  diastolic dysfxn S pulm. edema; precip. by AF (T LV filling)
‚Ä¢ Acquired von Willebrand disease (20% of sev.AS): destruction of vWF (NEJM 2003;349:343)
‚Ä¢ Natural hx: usually slowly progressive (AVA T 0.1 cm2 per y, but varies; Circ 1997;95:2262),
until sx develop; mean survival based on sx: angina  5 y; syncope  3 y; CHF  2 y 
Physical examination
‚Ä¢ Midsystolic crescendo-decrescendo murmur at
RUSB, harsh, high-pitched, radiates to carotids, apex
(holosystolic  Gallavardin effect) c w/ passive leg raise,
T w/ standing & Valsalva
‚Ä¢ In contrast, dynamic outflow obstruction (eg, HCMP) T
w/ passive leg raise & c w/ standing & Valsalva
‚Ä¢ Ejection click after S1 sometimes heard with bicuspid AoV
‚Ä¢ Signs of severity: late-peaking murmur, paradoxically split S2
or inaudible A2, small and delayed carotid pulse (‚Äúpulsus
parvus et tardus‚Äù), LV heave,  S4 (occasionally palpable)
Diagnostic studies
‚Ä¢ ECG: LVH, LAE, LBBB,AF (in late disease)
‚Ä¢ CXR: cardiomegaly,AoV calcification, poststenotic dilation of
ascending Ao, pulmonary congestion
‚Ä¢ Echo: valve morphology, estim pressure gradient & calculate AVA, EF 
‚Ä¢ Cardiac cath: pressure gradiant (‚àá) across AoV,AVA, r/o CAD (in 50% of calcific AS)
‚Ä¢ Dobutamine challenge during echo or cath if low EF and ‚àá30 to differentiate:
afterload mismatch: 20% c SV & c ‚àá, no  AVA (implies contractile reserve & c EF post-AVR) 
pseudostenosis: 20% c SV, no  in ‚àá, c AVA (implies low AVA artifact of LV dysfxn)
limited contractile reserve: no  SV, ‚àá, or AVA (implies EF prob. will not improve w/ AVR)
Classification of Aortic Stenosis
Stage
Mean Gradient (mmHg)
Jet Vel. (m‚ÅÑs)
AVA (cm2)
LVEF
Normal
0
1
3‚Äì4
normal
Mild
25
3
1.5
normal
Moderate
25‚Äì40
3‚Äì4
1.0‚Äì1.5
normal
Severe, compensated
40
4
1.0*
normal
Severe, decompensated
Variable
Variable
1.0*
T
*AVA index (AVA relative to BSA) 0.6 cm2/m2 also qualifies for severe AS.
Treatment (Circ 2008;118:e523 & Lancet 2009;373:956)
‚Ä¢ Management decisions are based on symptoms: once they develop surgery is needed.
If asx, HTN can be cautiously Rx‚Äôd; statins have not been proven to T progression.
‚Ä¢ AVR: only effective Rx for severe AS. Indicated in sx AS (almost invariably severe; if
not, look for another cause of sx) & asx sev. AS  EF 50%. Consider if asx
sev. AS and AVA 0.6 cm2, mean gradient 60 mmHg, aortic jet 5 m/s, T
BP w/ exercise (can carefully exercise asx AS to uncover sx, do not exercise sx
AS), high likelihood of rapid prog. or asx mod sev AS and undergoing CV surgery.
‚Ä¢ Medical therapy: used in sx Pts who are not operative candidates
careful diuresis, control HTN, maintain SR; digoxin if low EF or AF 
avoid venodilators (nitrates) and  inotropes (-blockers & CCB) in severe AS
avoid vigorous physical exertion once AS moderate-severe
? nitroprusside if p/w CHF w/ sev.AS, EF 35%, CI 2.2, & nl BP (NEJM 2003;348:1756)
‚Ä¢ IABP: stabilization, bridge to surgery
‚Ä¢ Balloon Ao valvotomy (BAV): 50% c AVA & T peak ‚àá, but 50% restenosis by 6‚Äì12 mo &
c risk of peri-PAV stroke/AI (NEJM 1988;319:125), ‚à¥bridge to AVR or palliation
‚Ä¢ Transcatheter AoV implantation (TAVI); bioprosthetic valve mounted on balloon-
expandable stent (JACC 2009;53:1829); AVA c 1 cm2 (JACC 2010;55:1080); RCTs ongoing
ECG 
50 
110 
130 
150 
30 
10 
Pathophysiology of Heart
Disease, 4th ed., 2006, for
this and subseq graphics.

--- Fim da P√°gina 32 ---

AORTIC INSUFFICIENCY (AI)
Etiology (Circ 2006;114:422)
‚Ä¢ Valve disease (43%)
rheumatic heart disease (usually mixed AS/AI and concomitant MV disease)
bicuspid AoV: natural hx: 1/3 S normal, 1/3 S AS, 1/6 S AI, 1/6 S endocarditis S AI
infective endocarditis
valvulitis: RA, SLE; anorectics (fen/phen) & other serotoninergics (NEJM 2007;356:29,39)
‚Ä¢ Root disease (57%)
HTN
aortic aneurysm or dissection, annuloaortic ectasia, Marfan syndrome
aortic inflammation: giant cell,Takayasu‚Äôs, ankylosing spond., reactive arthritis, syphilis
Clinical manifestations
‚Ä¢ Acute: sudden T forward SV and c LVEDP (noncompliant ventricle) S pulmonary edema
	 hypotension and cardiogenic shock
‚Ä¢ Chronic: clinically silent while LV dilates (to c compliance to keep LVEDP low) more
than it hypertrophies S chronic volume overload S LV decompensation S CHF
‚Ä¢ Natural hx: variable progression (unlike AS, can be fast or slow); once decompensation
begins, prognosis poor w/o AVR (mortality 10%/y)
Physical examination
‚Ä¢ Early diastolic decrescendo murmur at LUSB
(RUSB if dilated Ao root); c/ sitting forward, expir,
handgrip; severity of AI  duration of murmur (except in 
acute and severe late); Austin Flint murmur:mid-to-late diastolic 
rumble at apex (AI jet interfering w/ mitral inflow) 
‚Ä¢ Wide pulse pressure due to c stroke volume, hyperdy-
namic pulse S many of classic signs (see table); pulse
pressure narrows in late AI with T LV fxn; bisferiens
(twice-beating) arterial pulse
‚Ä¢ PMI diffuse and laterally displaced; soft S1 (early closure of
MV); 	 S3 (Z T EF but rather just volume overload in AI) 
Classic Eponymous Signs in Chronic AI (South Med J 1981;74:459)
Sign
Description
Corrigan‚Äôs pulse
‚Äúwater hammer‚Äù pulse (ie, rapid rise/fall or distention/collapse)
Hill‚Äôs sign
(popliteal SBP ‚Äì brachial SBP) 60 mmHg
Duroziez‚Äôs sign
to-and-fro murmur heard over femoral artery w/ light compression
Pistol shot sounds
pistol shot sound heard over femoral artery
Traube‚Äôs sound
double sound heard over femoral artery when compressed distally
de Musset‚Äôs sign
head-bobbing with each heartbeat (low Se)
M√ºller‚Äôs sign
systolic pulsations of the uvula
Quincke‚Äôs pulses
subungual capillary pulsations (low Sp)
Diagnostic studies
‚Ä¢ ECG: LVH, LAD, abnl repolarization; CXR: cardiomegaly 	 ascending Ao dilatation
‚Ä¢ Echo: severity of AI (severe  width of regurgitant jet 65% LVOT, vena contracta
0.6 cm, regurg fraction 50%, regurg orifice 0.3 cm2, flow reversal in descending
Ao); LV size & fxn
Treatment (Circ 2008;118:e523)
‚Ä¢ Acute decompensation (consider ischemia and endocarditis as possible precipitants)
surgery usually urgently needed for acute severe AI which is poorly tolerated by LV
IV afterload reduction (nitroprusside) and inotropic support (dobutamine)
	 chronotropic support (c HR S T diastole S T time for regurgitation)
pure vasoconstrictors and IABP contraindicated
‚Ä¢ In chronic AI, management decisions based on LV size and fxn (and before sx occur) 
‚Ä¢ Surgery (AVR, replacement or repair if possible)
sx (if equivocal, consider stress test) severe AI (if not severe, unlikely to be cause of sx)
asx severe AI and EF 50% or LV dilation (end syst. diam. 55 mm or end diast. diam.
75 mm, or 50 & 70, respectively, if progression) or undergoing cardiac surgery
‚Ä¢ Medical therapy: vasodilators (nifedipine,ACEI, hydralazine) if severe AI w/ sx or LV
dysfxn & Pt not operative candidate or to improve hemodynamics before AVR;
no clear benefit on clinical outcomes or LV fxn when used to try to prolong compen-
sation in asx severe AI w/ mild LV dilation & nl LV fxn (NEJM 2005;353:1342)
VALVES
1-21
ECG

--- Fim da P√°gina 33 ---

MITRAL REGURGITATION (MR)
Etiology (Lancet 2009;373:1382) 
‚Ä¢ Leaflet abnormalities: myxomatous degeneration (MVP), endocarditis, calcific
RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs
‚Ä¢ Functional: inferoapical papillary muscle displacement due to ischemic LV
remodeling or other causes of DCMP; LV annular dilation due to LV dilation 
‚Ä¢ Ruptured chordae tendinae: myxomatous, endocarditis, spontaneous, trauma
‚Ä¢ Acute papillary muscle dysfxn b/c of ischemia or rupture during MI [usu. posteromedial
papillary m. (supplied by PDA only) vs. anterolateral (suppl. by diags & OMs)]
‚Ä¢ HCMP: (see ‚ÄúCardiomyopathy‚Äù)
Clinical manifestations
‚Ä¢ Acute: pulmonary edema, hypotension, cardiogenic shock (NEJM 2004;351:1627)
‚Ä¢ Chronic: typically asx for yrs, then as LV fails S progressive DOE, fatigue,AF, PHT
‚Ä¢ Prognosis: 5-y survival w/ medical therapy is 80% if asx, but only 45% if sx
Physical examination
‚Ä¢ High-pitched, blowing, holosystolic murmur at apex;
radiates to axilla; 	 thrill; c w/ handgrip (Se 68%, Sp 92%),
T w/ Valsalva (Se 93%) (NEJM 1988;318:1572)
ant. leaflet abnl S post. jet heard at spine 
post. leaflet abnl S ant. jet heard at sternum
‚Ä¢ Lat. displ. hyperdynamic PMI, obscured S1, widely split S2
(A2 early b/c T LV afterload, P2 late if PHT); 	 S3
‚Ä¢ Carotid upstroke brisk (vs. diminished and delayed in AS)
Diagnostic studies
‚Ä¢ ECG: LAE, LVH, 	 atrial fibrillation
‚Ä¢ CXR: dilated LA, dilated LV, 	 pulmonary congestion
‚Ä¢ Echo: MV anatomy (ie, cause of MR); MR severity: jet area
(can underestimate eccentric jets), jet width at origin (‚Äúvena
contracta‚Äù), or effective regurgitant orifice (ERO; predicts survival,
NEJM 2005;352:875); LV fxn (EF should be supranormal if compensated, ‚à¥EF 60% w/ sev.
MR  LV dysfxn);TEE if TTE inconclusive or pre/intraop to guide repair vs. replace
‚Ä¢ Cardiac cath: prominent PCWP cv waves (not spec. for MR), LVgram for MR severity & EF
Classification of Mitral Regurgitation
Severity
Regurg.
Jet Area
Jet width
ERO
Angio
fraction
(% of LA)
(cm)
(cm2)
(see footnote)
Mild
30%
20
0.3
0.2
1
Moderate
30‚Äì49%
20‚Äì40
0.3‚Äì0.69
0.2‚Äì0.39
2
Severe
50%
40
0.70
0.40
3/4
1  LA clears w/ each beat; 2  LA does not clear, faintly opac. after several beats; 3  LA & LV opac. equal
Treatment (Circ 2008;118:e523; NEJM 2009;361:2261)
‚Ä¢ Acute decompensation (consider ischemia and endocarditis as precipitants)
IV afterload reduction (nitroprusside), 	 inotropes (dobuta), IABP, avoid vasoconstrictors 
surgery usually needed for acute severe MR as prognosis is poor w/o MVR
‚Ä¢ Surgery (repair [preferred if feasible] vs. replacement w/ preservation of mitral apparatus)
sx severe MR, asx severe MR and EF 30‚Äì60% or LV sys. diam.  40 mm
consider MV repair for asx severe MR w/ preserved EF, esp. if new AF or PHT
if in AF, Maze procedure or pulm vein isolation may S NSR and prevent future stroke
‚Ä¢ In Pts undergoing CABG w/ mod/sev fxnal ischemic MR, consider annuloplasty ring
‚Ä¢ Percutaneous MV repair: edge-to-edge clip may be noninferior to surgery (EVEREST II,
ACC 2010); annuloplasty band placed in coronary sinus (Circ 2006;113:851) under study 
‚Ä¢ Medical: ‚àÖbenefit (incl ACEI) in asx Pts; indicated if sx but not an operative candidate 
T preload (T CHF and MR by T MV orifice): diuretics, nitrates (espec if ischemic/fxnal MR)
if LV dysfxn:ACEI, B (carvedilol), 	 biV pacing; maintain SR
MITRAL STENOSIS (MS)
Etiology
‚Ä¢ Rheumatic heart disease (RHD): fusion of commissures S ‚Äúfish mouth‚Äù valve
from autoimmune rxn to  strep infxn; seen largely in developing world today
‚Ä¢ Mitral annular calcification (MAC): encroachment upon leaflets S functional MS
‚Ä¢ Congenital, infectious endocarditis w/ large lesion, myxoma, thrombus 
‚Ä¢ Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)
VALVES
1-22
Tall v
wave
ECG 

--- Fim da P√°gina 34 ---

Clinical manifestations (Lancet 2009;374:1271)
‚Ä¢ Dyspnea and pulmonary edema (if due to RHD, sx usually begin in 30s)
precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia,AF
‚Ä¢ Atrial fibrillation: onset often precipitates heart failure in Pts w/ MS
‚Ä¢ Embolic events: commonly cerebral, especially in AF or endocarditis
‚Ä¢ Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure
‚Ä¢ Ortner‚Äôs syndrome: hoarseness from LA compression of recurrent laryngeal nerve
Physical examination
‚Ä¢ Low-pitched mid-diastolic rumble at apex
w/ presystolic accentuation (if not in AF); best
heard in L lat decubitus position during expi-
ration, c w/ exercise; severity proportional to
duration (not intensity) of murmur 
‚Ä¢ Opening snap (high-pitched early diastolic
sound at apex) from fused leaflet tips;
MVA proportional to S2‚ÄìOS interval (tighter 
valve S c LA pressure S shorter interval)
‚Ä¢ Loud S1 (unless MV calcified)
Diagnostic studies
‚Ä¢ ECG: LAE (‚ÄúP mitrale‚Äù), 	 AF, 	 RVH
‚Ä¢ CXR: dilated LA (straightening of left heart border, double density on right, left
mainstem bronchus elevation)
‚Ä¢ Echo: estimate pressure gradient (‚àá), RVSP, valve area, valve echo score (0‚Äì16, based on
leaflet mobility & thickening, subvalvular thickening, Ca; exercise TTE if discrepancy
between sx and severity of MS at rest;TEE to assess for LA thrombus before PMV 
‚Ä¢ Cardiac cath: ‚àáfrom simultaneous PCWP & LV pressures, calculated MVA; LA
pressure tall a wave and blunted y descent; c PA pressures
Classification of Mitral Stenosis
Stage
Mean gradient (mmHg)
MV area (cm2)
PA Systolic (mmHg)
Normal
0
4‚Äì6
25
Mild
5
1.5‚Äì2
30
Moderate
5‚Äì10
1‚Äì1.5
30‚Äì50
Severe
10
1
50
Treatment (Circ 2008;118:e523)
‚Ä¢ Medical: Na restriction, cautious diuresis, -blockers, sx-limited physical stress
‚Ä¢ Anticoagulation if AF, prior embolism, LA thrombus, or large LA
‚Ä¢ Indications for mechanical intervention: heart failure sx w/ MVA 1.5 or
heart failure sx w/ MVA 1.5 but c PASP, PCWP, or MV ‚àáw/ exercise, or
asx Pts w/ MVA 1.5 and PHT (PASP 50 or 60 mmHg w/ exercise) or new-onset AF
‚Ä¢ Percutaneous mitral valvotomy (PMV): preferred Rx if RHD; MVA doubles, ‚àáT by 50%;
MVR if valve score 8,  mild MR, √ò AF or LA clot (NEJM 1994;331:961; Circ 2002;105:1465)
‚Ä¢ Surgical (MV repair if possible, o/w replacement): consider in sx Pts w/ MVA 1.5
if PMV unavailable or contraindicated (mod. MR, LA clot), or valve morphology unsuitable
‚Ä¢ Pregnancy: if NYHA class III/IV S PMV, o/w medical Rx w/ low-dose diuretic & B
MITRAL VALVE PROLAPSE (MVP)
Definition and Etiology
‚Ä¢ Billowing of MV leaflet 2 mm above mitral annulus in parasternal long axis echo view
‚Ä¢ Leaflet redundancy from myxomatous proliferation of spongiosa of MV apparatus 
‚Ä¢ Idiopathic, familial, and a/w connective tissue diseases (eg, Marfan‚Äôs, Ehlers-Danlos)
‚Ä¢ Prevalence 1‚Äì2.5% of gen. population,  (NEJM 1999;341:1), most common cause of MR
Clinical manifestations (usually asymptomatic)
‚Ä¢ MR (from leaflet prolapse or ruptured chordae); infective endocarditis; embolic events
‚Ä¢ Arrhythmias, rarely sudden cardiac death
Physical exam
‚Ä¢ High-pitched, midsystolic click 	 mid-to-late systolic murmur
T LV volume (standing) S click earlier; c LV volume or afterload S click later, softer
Treatment
‚Ä¢ Endocarditis prophylaxis no longer recommended (Circ 2007:116:1736)
‚Ä¢ Aspirin or anticoagulation if prior neurologic event or atrial fibrillation
VALVES
1-23
ECG 
OS

--- Fim da P√°gina 35 ---

PROSTHETIC HEART VALVES
Mechanical (60%)
‚Ä¢ Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball
‚Ä¢ Characteristics: very durable (20‚Äì30 y), but thrombogenic and ‚à¥require anticoagulation
consider if age 65 y or if anticoagulation already indicated (JACC 2010;55:2413)
Bioprosthetic (40%)
‚Ä¢ Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft 
‚Ä¢ Characteristics: less durable, but minimally thrombogenic
consider if age 65 y, lifespan 20 y, or contraindication to anticoagulation
Physical examination
‚Ä¢ Normal: crisp sounds, 	 soft murmur during forward flow (normal to have small ‚àá)
‚Ä¢ Abnormal: regurgitant murmurs, absent mechanical valve closure sounds
Anticoagulation (Circ 2008;118:e523)
‚Ä¢ Warfarin
low-risk mech AVR: INR 2‚Äì3 (consider 2.5‚Äì3.5 for 1st 3 mo)
mech MVR or high-risk (defined below) mech AVR: INR 2.5‚Äì3.5
high-risk bioprosthetic: INR 2‚Äì3 (and consider for 1st 3 mo in low-risk)
high-risk features: prior thromboembolism,AF, T EF, hypercoagulable 
‚Ä¢ ASA (75‚Äì100 mg) indicated for all Pts with prosthetic valves; avoid adding to 
warfarin if h/o GIB, uncontrolled HTN, erratic INR, or 80 y
Periprocedural ‚ÄúBridging‚Äù of Anticoagulation in Pts with Mechanical Valve(s)
AVR w/o risk factors
d/c warfarin 48‚Äì72 h before surg; restart 24 h after surg
MVR or AVR w/ risk factors
Preop: d/c warfarin, start UFH when INR 2
4‚Äì6 h preop: d/c UFH; postop: restart UFH & warfarin ASAP
Procedures include noncardiac surgery, invasive procedures, and major dental work (Circ 2008;118:e523)
Correction of overanticoagulation (Circ 2008;118:e626)
‚Ä¢ Risk from major bleeding must be weighed against risk of valve thrombosis
‚Ä¢ Not bleeding & INR 5: withhold warfarin, do not give vit K, ‚úìserial INRs
‚Ä¢ Not bleeding & INR 5‚Äì10: withhold warfarin, vit K 1‚Äì2.5 mg PO, ‚úìserial INRs
‚Ä¢ Bleeding or INR 10: FFP 	 low-dose (1 mg) vit K IV
Endocarditis prophylaxis (see ‚ÄúEndocarditis‚Äù)
‚Ä¢ Indicated for all prosthetic valves to T IE risk during transient bacteremia
Complications 
‚Ä¢ Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley;
bioprosthetic valves: up to 30% fail rate w/in 10‚Äì15 y, mitral  aortic
‚Ä¢ Paravalvular leak (r/o endocarditis); small central jet of regurg is normal in mech. valves
‚Ä¢ Obstruction from thrombosis or pannus ingrowth: ‚úìTTE,TEE and/or fluoroscopy if ? clot
significantly sx pannus ingrowth: remove w/ surgery
thrombosis: surgery if left-sided valve & either severe sx or lg (? 1 cm) clot burden;
fibrinolytic Rx often ineffective for left-sided thrombosis & 12‚Äì15% risk of stroke;
consider UFH 	 lytic if mild sx and small clot burden or poor surg candidate;
fibrinolytic therapy reasonable for right-sided thrombosis 
‚Ä¢ Infective endocarditis 	 valvular abscess and conduction system disruption
‚Ä¢ Embolization (r/o endocarditis); risk 1%/y w/ warfarin (vs. 2% w/ ASA, or 4% w/o meds)
mech MVR 2 risk of embolic events vs. mech AVR (Circ 1994:89:635)
‚Ä¢ Bleeding (from anticoag), hemolysis (especially w/ caged-ball valves or paravalvular leak)
HEART VALVES (superior view, JAMA 1976;235:1603)
AV  aortic valve
AVN  AV node
B His  bundle of His
CS  coronary sinus
Cx  circumflex artery
LAD  left anterior descending artery
LAF  left anterior fascicle
LCA  left coronary artery
LPF  left posterior fascicle
MV  mitral valve
RB  right bundle
RC/LC/NC  right/left/noncoronary cusp
RCA  right coronary artery
TV  tricuspid valve
VALVES
1-24

--- Fim da P√°gina 36 ---

PERICARDIAL
1-25
PERICARDIAL DISEASE
GENERAL PRINCIPLES
Anatomy
‚Ä¢ 2-layered (parietal & visceral) tissue sac surrounding heart & proximal great vessels
Disease states
‚Ä¢ Inflammation (w/ or w/o fluid accumulation) S pericarditis
‚Ä¢ Fluid accumulation (usually in setting of inflammation) S effusion 	 tamponade
‚Ä¢ Change in compliance (sequela of inflammation) S constriction
‚Ä¢ Tamponade and constriction characterized by increased ventricular interdependence
PERICARDITIS AND PERICARDIAL EFFUSION
Etiologies of Pericarditis (Lancet 2004;363:717)
Infectious
Viral: Coxsackie, echo, adeno, EBV,VZV, HIV, influenza
(50%)
Bacterial (from endocarditis, pneumonia, or s/p cardiac surgery):
S. pneumococcus, N. meningitidis, S. aureus, Borrelia (Lyme)
Tuberculous (extension from lung or hematogenous)
Fungal: Histo, Coccidio, Candida; Parasitic: Entamoeba, Echino
Neoplastic
Common: metastatic (lung, breast, lymphoma, leukemia, renal cell)
(35%)
Rare: primary cardiac & serosal tumors (mesothelioma)
Autoimmune
Connective tissue diseases: SLE, RA, scleroderma, Sj√∂gren‚Äôs
Vasculitides: PAN, Churg-Strauss,Wegener‚Äôs
Drug-induced: procainamide, hydralazine, INH, CsA
Uremia
Develops in 20% of Pts, especially if on HD. May be transudative.
Cardiovascular
Acute transmural MI (5‚Äì20%); late post-MI (Dressler‚Äôs syndrome)
Proximal aortic dissection (up to 45%)
Chest trauma or s/p cardiac procedure or surgery
Radiation
4,000 cGy to mediastinum; acute or delayed; may be transudative
Idiopathic
Most presumed to be undiagnosed viral
Effusions w/o
CHF, cirrhosis, nephrotic syndrome, hypothyroidism, amyloidosis.;
pericarditis
Transudative.
Clinical manifestations (NEJM 2004;351:2195)
‚Ä¢ Pericarditis: chest pain that is pleuritic, positional (T by sitting forward), radiates to
trapezius; may be absent in tuberculous, neoplastic, post-XRT, and uremic pericarditis;
	 fever; 	 s/s of systemic etiologies
‚Ä¢ Effusion: ranges from asx to tamponade (see below)
Physical exam
‚Ä¢ Pericarditis: multiphasic friction rub best heard at LLSB w/ diaphragm of stethoscope
(leathery sound w/ up to 3 components: atrial contraction, ventricular contraction,
ventricular relaxation) that is notoriously variable and evanescent
‚Ä¢ Effusion: distant heart sounds, dullness over left posterior lung field due to 
compressive atelectasis from pericardial effusion (Ewart‚Äôs sign)
Diagnostic studies (EHJ 2004;25:587; Circ 2006;113:1622)
‚Ä¢ ECG: may show diffuse STE (concave up) & PR depression (except in aVR: ST T & PR c),
TWI; classically and in contrast to STEMI,TWI do not occur until STs normalize
Stages: STE & PR T (I); ST & PR normalize (II); diffuse TWI (III);Tw normalize (IV).
May show evidence of large effusion w/ low voltage & electrical alternans (beat-to-
beat  in QRS amplitude and/or axis).
‚Ä¢ CXR: if large effusion (250 mL of fluid) S c cardiac silhouette w/ ‚Äúwater-bottle‚Äù
heart and epicardial halo
‚Ä¢ Echocardiogram: presence, size, & location of effusion; presence of tamponade
physiology; pericarditis itself w/o spec. abnl (‚à¥echo can be nl), although can see
pericardial stranding (fibrin or tumor); can also detect asx myocarditis
‚Ä¢ CT will reveal pericardial effusions, often appearing larger than on echocardiography
‚Ä¢ CK-MB or troponin ( in 30%, JACC 2003;42:2144) if myopericarditis
Workup for effusion
‚Ä¢ r/o infxn: usually apparent from Hx & CXR; ? ‚úìacute and convalescent serologies
‚Ä¢ r/o noninfectious etiologies: BUN, Cr, ANA, RF, screen for common malignancies

--- Fim da P√°gina 37 ---

‚Ä¢ Pericardiocentesis if suspect infxn or malignancy or if effusion large (2 cm)
‚úìcell counts,TP, LDH, glc, gram stain & Cx,AFB, cytology
ADA, PCR for MTb, and specific tumor markers as indicated by clinical suspicion
‚Äúexudate‚Äù criteria:TP 3 g/dL,TPeff/TPserum 0.5,LDHeff/LDHserum 0.6,or glc 60 mg/dL
high Se (90%) but very low Sp (20%); overall low utility (Chest 1997;111:1213)
‚Ä¢ Pericardial bx if suspicion remains for malignancy or tuberculosis
Treatment of pericarditis (EHJ 2004;25:587; Circ 2006;113:1622)
‚Ä¢ NSAIDs (eg, ibuprofen 600‚Äì800 mg tid) 	 colchicine 0.5 mg bid (Circ 2005;112:2012) 
sx usually subside in 1‚Äì3 d, continue Rx for 7‚Äì14 d (JAMA 2003;289:1150)
‚Ä¢ Steroids (usually systemic; occ. intrapericardial) for systemic rheum or autoimmune
disorder, uremic, preg., contraindication to NSAID, or refractory idiopathic dis.
Risks of steroids: ? c rate of relapse, and c osteoporosis, Cushing‚Äôs (Circ 2008;118:667).
‚Ä¢ Avoid anticoagulants
‚Ä¢ Infectious effusion S pericardial drainage (preferably surgically)  systemic antibiotics
‚Ä¢ Acute idiopathic effusion self-limited in 70‚Äì90% of cases
‚Ä¢ Recurrent effusion S consider pericardial window (percutaneous vs. surgical)
PERICARDIAL TAMPONADE
Etiology
‚Ä¢ Any cause of pericarditis but especially malignancy, uremia, idiopathic,
proximal aortic dissection with rupture, myocardial rupture
‚Ä¢ Rapidly accumulating effusions most likely to cause tamponade as no time for 
pericardium to stretch (c compliance) and accommodate fluid
Pathophysiology (NEJM 2003;349:684)
‚Ä¢ c intrapericardial pressure, compression of heart chambers, T venous return S T CO
‚Ä¢ Diastolic pressures c & equalize in all cardiac chambers S minimal flow of blood from
RA to RV when TV opens S blunted y descent
‚Ä¢ c ventricular interdependence S pulsus paradoxus (pathologic exaggeration of nl physio) 
Inspiration S T intrapericardial & RA pressures S c venous return S c RV size S
septal shift to left.Also, c pulmonary vascular compliance S T pulm venous return.
Result is T LV filling S T LV stroke volume & blood pressure.
Clinical manifestations
‚Ä¢ Cardiogenic shock (hypotension, fatigue) without pulmonary edema
‚Ä¢ Dyspnea (seen in 85%) may be due to c respiratory drive to augment venous return
Physical exam (JAMA 2007;297:1810)
‚Ä¢ Beck‚Äôs triad (present in minority): distant heart sounds, c JVP, hypotension
‚Ä¢ c JVP (76%) w/ blunted y descent
‚Ä¢ Reflex tachycardia (77%), hypotension (26%; occasionally hypertensive), cool extremities
‚Ä¢ Pulsus paradoxus (Se 82%, Sp 70%)  T SBP 10 mmHg during inspiration
LR 3.3 (5.9 if pulsus 12), LR 0.03
Ddx  PE, hypovolemia, severe obstructive lung disease, constriction (1/3), CHF
Can be absent if pre-existing c LVEDP, cardiac arrhythmia, or regional tamponade
‚Ä¢ Distant heart sounds (28%), 	 pericardial friction rub (30%)
‚Ä¢ Tachypnea but clear lungs
Diagnostic studies
‚Ä¢ ECG: T voltage (seen in 42%), electrical alternans, 	 signs of pericarditis
‚Ä¢ CXR: c cardiac silhouette (89%)
‚Ä¢ Echocardiogram:  effusion, IVC plethora, septal shift with inspiration,
diastolic collapse of RA (Se 85%, Sp 80%) and/or RV (Se 80%, Sp 90%)
respirophasic ‚Äôs in transvalvular velocities (c across TV & T across MV w/ inspir.)
postsurgical tamponade may be localized and not easily visible 
‚Ä¢ Cardiac cath (right heart and pericardial): elevation (15‚Äì30 mmHg) and equalization of
intrapericardial and diastolic pressures (RA, RV, PCWP), blunted y descent in RA
c in stroke volume postpericardiocentesis ultimate proof of tamponade
if RA pressure remains elevated after drainage, may have effusive-constrictive disease
(NEJM 2004;350:469) or myocardial dysfxn (eg, from concomitant myocarditis)
Treatment
‚Ä¢ Volume (but be careful as overfilling can worsen tamponade) and  inotropes (avoid B)
‚Ä¢ Pericardiocentesis (except if due to aortic or myocardial rupture, in which cases 
consider removing just enough fluid to reverse PEA while awaiting surgery)
PERICARDIAL
1-26

--- Fim da P√°gina 38 ---

PERICARDIAL
1-27
CONSTRICTIVE PERICARDITIS
Etiology
‚Ä¢ Any cause of pericarditis but especially postviral, radiation, uremia, TB, post-
cardiac surgery, and idiopathic
Pathophysiology
‚Ä¢ Rigid pericardium limits diastolic filling S c systemic venous pressures
‚Ä¢ Venous return is limited only after early rapid filling phase; ‚à¥rapid T in RA pressure with
atrial relaxation and opening of tricuspid valve and prominent x and y descents
‚Ä¢ Kussmaul‚Äôs sign: JVP does not decrease with inspiration (c venous return with inspi-
ration, but negative intrathoracic pressure not transmitted to heart because of
rigid pericardium)
Clinical manifestations
‚Ä¢ Right-sided  left-sided heart failure
Physical exam
‚Ä¢ c JVP with prominent y descent,  Kussmaul‚Äôs sign (Ddx:TS, acute cor pulmonale,
RV infarct, RCMP)
‚Ä¢ Hepatomegaly, ascites, peripheral edema
‚Ä¢ PMI usually not palpable, pericardial knock, usually no pulsus paradoxus
Diagnostic studies
‚Ä¢ ECG: nonspecific,AF common in advanced cases
‚Ä¢ CXR: calcification (MTb most common cause), especially in lateral view (although does
not necessarily  constriction)
‚Ä¢ Echocardiogram: 	 thickened pericardium, ‚Äúseptal bounce‚Äù  abrupt posterior dis-
placement of septum during rapid filling in early diastole
‚Ä¢ Cardiac catheterization
atria: Ms or Ws (prominent x and y descents)
ventricles: dip-and-plateau or square-root sign (rapid T pressure at onset of
diastole, rapid c to early plateau)
discordance between LV & RV pressure peaks during respiratory cycle (Circ 1996;93:2007)
‚Ä¢ CT or MRI: thickened pericardium (4 mm on CT) with tethering
Treatment
‚Ä¢ Diuresis for intravascular volume overload, surgical pericardiectomy
Constrictive Pericarditis vs. Restrictive Cardiomyopathy
Evaluation
Constrictive pericarditis
Restrictive cardiomyopathy
 Kussmaul‚Äôs sign
	 Kussmaul‚Äôs sign
Physical exam
Absent PMI
Powerful PMI, 	 S3 and S4
 Pericardial knock
	 Regurg murmurs of MR,TR
ECG
	 Low voltage
Low voltage
	 Conduction abnormalities
Normal wall thickness
	 c wall thickness
Septal bounce during
Biatrial enlargement
early diastole
Inspir. S T flow across TV & MV
Echocardiogram
Inspir. S c flow across
Slower peak filling rate
TV and T flow across MV
Longer time to peak filling rate
E (tissue velocity) nl/c
E T
Expir. hepatic vein flow reversal
Inspir. hepatic vein flow reversal
CT/MRI
Thickened pericardium
Normal pericardium
Prominent x and y descents
Dip-and-plateau sign
LVEDP  RVEDP
LVEDP  RVEDP (espec. w/ vol.)
RVSP 55 (Se 90%, Sp 29%)
RVSP 55 mmHg
Cardiac
RVEDP 1‚ÅÑ3 RVSP (Se 93%, Sp 46%)
RVEDP 1‚ÅÑ3 RVSP
catheterization
Discordance of LV & RV
Concordance of LV & RV pressure 
pressure peaks during 
peaks during respiratory cycle
respiratory cycle
Systolic area index (ratio of RV to Systolic area index 1.1
LV pressure‚Äìtime area in inspir
(JACC 2008;51:315)
vs. expir) 1.1 (Se 97%, Sp 100%)
Endomyocardial
Usually normal
 Specific etiology of RCMP
biopsy

--- Fim da P√°gina 39 ---

HYPERTENSION
1-28
HYPERTENSION
JNC VII Classification
Category
Systolic (mmHg)
Diastolic (mmHg)
Normal
120
80
Pre-HTN
120‚Äì139
80‚Äì89
Stage 1 HTN
140‚Äì159
90‚Äì99
Stage 2 HTN
160
100
Epidemiology (JAMA 2003;290:199)
‚Ä¢ Prevalence 30% in U.S. adults; 65 million affected (29% in whites, 33.5% in blacks)
‚Ä¢ 60% of those w/ HTN are on Rx, only half of whom are adequately controlled
Etiologies
‚Ä¢ Essential (95%): onset 25‚Äì55 y;  FHx. Unclear mechanism but ? additive microvasc 
renal injury over time w/ contribution of hyperactive sympathetics (NEJM 2002;346:913)
genetic loci under investigation (Nat Genet 2009;41:666 & 677)
‚Ä¢ Secondary: Consider if Pt 20 or 50 y or if sudden onset, severe, refractory or c HTN
Secondary Causes of Hypertension
Diseases
Suggestive Findings
Initial Workup
Renal parenchymal
h/o DM, polycystic kidney 
CrCl, albuminuria
(2‚Äì3%)
disease, glomerulonephritis
See ‚ÄúRenal Failure‚Äù
Renovascular (1‚Äì2%)
ARF induced by ACEI/ARB
MRA (90% Se & Sp),
Athero (90%)
Recurrent flash pulm edema
CTA, duplex U/S, angio,
FMD (10%, young women)
Renal bruit; hypokalemia
plasma renin (low Sp)
PAN, scleroderma
(NEJM 2009;361:1972)
Hyperaldo or
Hypokalemia
See ‚ÄúAdrenal Disorders‚Äù
Cushing‚Äôs (1‚Äì5%)
Metabolic alkalosis
Pheochromocytoma (1%)
Paroxysmal HTN, H/A, palp.
Myxedema (1%)
See Thyroid Disorders
TFTs
Hypercalcemia (1%)
Polyuria, dehydration,  MS
ICa
Obstructive sleep apnea (qv)
Medications: OCP, steroids, licorice; NSAIDs (espec. COX-2); Epo; cyclosporine
Coarctation of aorta: T LE pulses, systolic murmur, radiofemoral delay; abnl TTE, CXR
Polycythemia vera: c Hct
Standard workup
‚Ä¢ Goals: (1) identify CV risk factors or other diseases that would modify prognosis or Rx;
(2) reveal 2 causes of hypertension; (3) assess for target-organ damage
‚Ä¢ History: CAD, CHF,TIA/CVA, PAD, DM, renal insufficiency, sleep apnea;  FHx for HTN
diet, Na intake, smoking, alcohol, prescription and OTC medications, OCP
‚Ä¢ Physical exam: ‚úìBP in both arms; funduscopic, cardiac (LVH, murmurs), vascular,
abdominal (masses or bruits), neurologic
‚Ä¢ Laboratory tests: K, BUN, Cr, Ca, glc, Hct, U/A, lipids,TSH, ECG (for LVH), CXR,
urinary albumin:creatinine (if appropriate) 
Complications of HTN
‚Ä¢ Each c 20 mmHg SBP or 10 mmHg DBP S 2 c CV complications (Lancet 2002;360:1903)
‚Ä¢ Neurologic: TIA/CVA, ruptured aneurysms
‚Ä¢ Retinopathy: I  arteriolar narrowing, II  copper-wiring,AV nicking, III  hemorrhages
and exudates, IV  papilledema
‚Ä¢ Cardiac: CAD, LVH, CHF
‚Ä¢ Vascular: aortic dissection, aortic aneurysm
‚Ä¢ Renal: proteinuria, renal failure
Treatment (NEJM 2003;348:610)
‚Ä¢ Goal: 140/90 mmHg; if DM or renal disease goal is 130/80 mmHg
‚Ä¢ Treatment results in 50% T CHF, 40% T stroke, 20‚Äì25% T MI (Lancet 2000;356:1955);
benefits of Rx‚Äôing stage II HTN extend to Pts 80 y (NEJM 2008;358:1887)
‚Ä¢ Lifestyle modifications (each T SBP 5 mmHg)
weight loss: goal BMI 18.5‚Äì24.9; aerobic exercise: 30 min exercise/d, 5 d/wk
diet: rich in fruits & vegetables, low in saturated & total fat (DASH, NEJM 2001;344:3)
sodium restriction: 2.4 g/d and ideally 1.5 g/d (NEJM 2010;362:2102)
limit alcohol consumption: 2 drinks/d in men; 1 drink/d in women & lighter-wt Pts
BP should be determined by
making 2 measurements
separated by 2 min.
Confirm stage 1 w/in 2 mo;
can Rx stage 2 immediately.
(JAMA 2003;289:2560;
JNC VIII forthcoming)
OTHER
ENDO
RENAL

--- Fim da P√°gina 40 ---

‚Ä¢ Pharmacologic options (if HTN or pre-HTN  diabetes or renal disease)
Pre-HTN: ARB prevents onset of HTN, no T in clinical events (NEJM 2006;354:1685)
HTN: choice of therapy controversial, concomitant disease may help guide
uncomplicated: ? thiazide better than ACEI or CCB in preventing CVD (JAMA
2002;288:2981; NEJM 2009;361:2153); -blockers not first line (Lancet 2005;366:1545)
 high-risk CAD:ACEI (NEJM 2000;342;145) or ARB (NEJM 2008;358:1547);ACEI  CCB
superior to ACEI  thiazide (NEJM 2008;359:2417) or B  diuretic (Lancet 2005;366:895)
 angina: -blockers, CCB 
 post-MI: B (JAMA 1982;247:1707),ACEI (NEJM 1992;327:669), 	 aldosterone antagonist
 HF:ACEI/ARB, -blockers, diuretics, aldosterone antagonist (see ‚ÄúHeart Failure‚Äù)
 recurrent stroke prevention:ACEI (Lancet 2001;358:1033); benefit of ARB unclear
(Lancet 2002;359:995; NEJM 2008;359:1225).
 diabetes mellitus: ACEI or ARB; can also consider diuretic, BB, or CCB
 chronic kidney disease:ACEI/ARB (NEJM 1993;329:1456 & 2001;345:851, 861)
most will require 2 drugs; if not at goal S optimize doses or add drug 
‚Ä¢ Secondary causes
Renovasc: control BP w/ diuretic  ACEI/ARB (watch for c Cr w/ bilat. RAS) or CCB
Atherosclerosis risk-factor modification: quit smoking, T chol.
If refractory HTN, recurrent HF, UA, or worse CKD, revasc. indicated (JACC 2006;47:1)
For atherosclerosis: stenting T restenosis vs. PTA alone, but no clear improvement in
BP or renal function vs. med Rx alone (NEJM 2009;361:1953; Annals 2009;150:840)
For FMD (usually more distal lesions): PTA 	 bailout stenting
Surgery for complex lesions or aortic involvement
Renal parenchymal: salt and fluid restriction, 	 diuretics
Endocrine etiologies: see ‚ÄúAdrenal Disorders‚Äù
‚Ä¢ Pregnancy: methyldopa, labetalol; other B and CCB probably safe
HYPERTENSIVE CRISES
‚Ä¢ Hypertensive emergency: c BP S acute target-organ ischemia and damage
neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema
cardiac damage:ACS, HF/pulmonary edema, aortic dissection
renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis
microangiopathic hemolytic anemia; preeclampsia-eclampsia
‚Ä¢ Hypertensive urgency: SBP 180 or DBP 120 (?110) w/ min./no target-organ damage
Precipitants
‚Ä¢ Progression of essential HTN 	 medical noncompliance (especially clonidine)
‚Ä¢ Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia
‚Ä¢ Endocrine: pheochromocytoma, Cushing‚Äôs
‚Ä¢ Sympathomimetics: cocaine, amphetamines, MAO inhibitors  foods rich in tyramine
‚Ä¢ Cerebral injury (do not treat HTN in acute ischemic stroke unless Pt getting lysed, extreme,
BP, ie, 220/120, or Ao dissection, active ischemia, or CHF; Stroke 2003;34:1056)
Treatment (Chest 2007;131:1949)
‚Ä¢ Tailor goals to clinical context (eg, more rapid lowering for Ao dissection)
‚Ä¢ Emergency: T MAP by 25% in mins to 2 h w/ IV agents (may need arterial line for
monitoring); goal DBP 110 w/in 2‚Äì6 h, as tolerated
‚Ä¢ Urgency: T BP in hours using PO agents; goal normal BP in 1‚Äì2 d
‚Ä¢ Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated
Drugs for Hypertensive Crises
Intravenous agents
Oral agents
Agent
Dose
Agent
Dose
Nitroprusside*
0.25‚Äì10 g/kg/min
Captopril
12.5‚Äì100 mg tid
Nitroglycerin
17‚Äì1000 g/min
Labetalol
200‚Äì800 mg tid
Labetalol
20 mg load S 20‚Äì80 mg IVB
Clonidine
0.2 mg load S
q10min or 0.5‚Äì2 mg/min
0.1 mg qh
Hydralazine
10‚Äì20 mg q20‚Äì30min
Hydralazine
10‚Äì75 mg qid
Esmolol
500 g/kg load S 25‚Äì300 g/kg/min
Fenoldopam
0.1‚Äì1.6 g/kg/min
Nicardipine
5‚Äì15 mg/h
Phentolamine
5‚Äì15 mg bolus q5‚Äì15min
*Metabolized to cyanide S  MS, lactic acidosis, death. Limit use of very high doses (8‚Äì10 g/kg/min) to 10 min.
Monitor thiocyanate levels. Hydroxocobalamin or sodium thiosulfate infusion for treatment of cyanide toxicity.
HYPERTENSION
1-29

--- Fim da P√°gina 41 ---

AORTA
1-30
AORTIC ANEURYSM
Definitions
‚Ä¢ True aneurysm (involves all 3 layers of aorta) vs. false (rupture contained in adventitia)
‚Ä¢ Location: root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoab-
dominal aortic aneurysm, abdominal aortic aneurysm (AAA)
‚Ä¢ Type: fusiform (circumferential dilation) vs. saccular (localized dilation)
Epidemiology (Circ 2005;111:816 & 2008;117:242)
‚Ä¢ Aortic aneurysms 13th leading cause of death in U.S. (15,000 deaths/y from ruptures)
‚Ä¢ TAA: : 1.7:1; usually involves root/asc Ao or descending Ao (arch & thoracoabd rare)
Risk factors: HTN; atherosclerosis; aortitis (Takayasu‚Äôs, GCA, spondyloarthritis,
syphilis); congenital (bicuspid AoV,Turner‚Äôs); connective tissue diseases
(Marfan, Ehlers-Danlos type IV); familial; chronic Ao dissection; trauma
‚Ä¢ AAA: 5% prev. in individuals 65 y; 5‚Äì10 more common in  than ; most infrarenal
Risk factors  risk factors for atherosclerosis: smoking, HTN, hyperlipidemia, age, FHx
Pathophysiology (NEJM 2009;361:1114; Nat Med 2009;15:649)
‚Ä¢ LaPlace‚Äôs law: tension across a cylinder ‚àù[(P  r) / (wall thickness)]
‚Ä¢ TAA: cystic medial necrosis (medial degeneration, mucoid infiltration, apoptosis) 
‚Ä¢ AAA: atherosclerosis & inflammation S matrix degeneration S medial weakening
‚Ä¢ Inflammatory and infectious (‚Äúmycotic‚Äù) aneurysms rare
Screening (JAMA 2009;302:2015)
‚Ä¢ TAA: no established population screening guidelines
‚Ä¢ AAA: ‚úìfor pulsatile abdominal mass in all Pts; U/S for all men 60 y w/ FHx of AAA
and all men 65‚Äì75 y w/ prior tobacco use ( J Vasc Surg 2004;39:267; Annals 2005;142:203;)
Diagnostic studies (Circ 2005;111:816)
‚Ä¢ Contrast CT: quick, noninvasive, good Se & Sp for all aortic aneurysms
‚Ä¢ CXR: often abnormal, but not definitive in TAA
‚Ä¢ Abdominal ultrasound: screening and surveillance test of choice for AAA
‚Ä¢ TTE/TEE: useful for root and rest of TAA
‚Ä¢ MRI: preferred for aortic root imaging for TAA, but also useful in AAA
Treatment (Circ 2006;113;e463; 2008;177:1883; 2010;121:1544)
‚Ä¢ Risk factor modification: smoking cessation, LDL-C 70 mg/dL; ? macrolides or
tetracyclines (inhibit MMPs, anti-Chlamydia)
‚Ä¢ BP control: -blockers (T dP/dt) T aneurysm growth (NEJM 1994;330:1335); ACEI a/w T
risk of rupture (Lancet 2006;368:659),ARB may T rate of aortic root growth in Marfan (NEJM
2008;358:2787);no burst activity/exercise requiring Valsalva maneuvers (eg,heavy lifting)
‚Ä¢ Surgery
TAA: symptomatic, ascending 5.5 cm; descending 6 cm; Marfan Pt 4.0‚Äì4.5 cm;
growing 0.5 cm/y; aneurysm 4.5 cm and planned AoV surgery
AAA: 5 cm; rapidly growing; infrarenal/juxtarenal 5.5 cm (NEJM 2002;346:1437)
‚Ä¢ Endovascular aneurysm repair (EVAR) (NEJM 2008;358:494)
T short-term mortality, bleeding, and length of stay, but, long-term graft complica-
tions (2‚Äì5%/y; leak, rupture) necessitating periodic surveillance and no  in
overall mortality (JAMA 2009;302:1535; NEJM 2010;362:1863 & 1881). Consider for high-
risk operative Pts or in descending thoracic aneurysms 5.5 cm (JACC 2010;55:986).
In Pts unfit for surgery: T aneurysm mortality but no  in overall mortality over
medical Rx (NEJM 2010;362:1872). EVAR noninferior (? superior) to open repair in
ruptured AAA w/ favorable anatomy (Ann Surg 2009;250:818).
Complications
‚Ä¢ Pain: gnawing chest, back, or abdominal pain
‚Ä¢ Rupture: risk c w/ diameter, female sex, current smoking, HTN
TAA: 2.5%/y if 6 cm vs. 7% if 6 cm; AAA: 1%/y if 5 cm vs. 6.5% if 5‚Äì5.9 cm
may be heralded by c pain; once occurs, usually fatal or Pt may p/w severe constant
pain and in hemorrhagic shock; 90% mortality
‚Ä¢ Aortic Dissection (see following section)
‚Ä¢ Thromboembolic ischemic events
‚Ä¢ Compression of adjacent structures (eg, SVC, trachea, esophagus)
Follow-up
‚Ä¢ Expansion rate 0.1 cm/y for TAA, 0.4 cm/y for AAA
‚Ä¢ Serial imaging first 3, 6, 9, & 12 mo, then annually
‚Ä¢ Screening for CAD, PAD, and aneurysms elsewhere, espec. popliteal. 25% of Pts w/
TAA will also have AAA.

--- Fim da P√°gina 42 ---

AORTA
1-31
ACUTE AORTIC SYNDROMES
Definitions (Circ 2003;108:628)
‚Ä¢ Classic dissection: intimal tear S extravasation of blood into aortic media
‚Ä¢ Incomplete dissection: intimomedial tear without significant intramural extravasation
‚Ä¢ Intramural hematoma (IMH): vasa vasorum rupture S medial hemorrhage
‚Ä¢ Penetrating ulcer: ulceration of plaque penetrating intima S medial hemorrhage
Classification
‚Ä¢ Proximal: involves ascending Ao, regardless of origin (  Stanford A, DeBakey I & II)
‚Ä¢ Distal: involves descending Ao only, distal to subclavian art. (  Stanford B, DeBakey III)
Risk factors 
‚Ä¢ Hypertension (h/o HTN in 70% of dissections); male sex (70% male)
‚Ä¢ Connective tissue disease: Marfan (fibrillin): arachnodactyly, joint disloc., pectus,
ectopia lentis, MVP; Ehlers-Danlos type IV (type III procollagen): translucent skin; bowel
or uterine rupture; Loeys-Dietz; annuloaortic ectasia, familial AoD; PCKD
‚Ä¢ Congenital aortic anomaly: bicuspid aortic valve or coarctation (eg, in Turner‚Äôs)
‚Ä¢ Aortitis:Takayasu‚Äôs, giant cell arteritis, Beh√ßet‚Äôs, syphilis
‚Ä¢ Pregnancy: typically in 3rd trimester; can also see spont. coronary artery dissections
‚Ä¢ Trauma: blunt, IABP, cardiac or aortic surgery, cardiac catheterization
Clinical Manifestations and Physical Examination (JAMA 2000;283:897)
Feature
Proximal
Distal
‚ÄúAortic‚Äù pain (often severe, tearing or ripping 
94%
98%
pain, maximal at onset [vs. crescendo for ACS])
(chest, back)
(back, chest, abd)
Syncope (often due to tamponade)
13%
4%
CHF (usually AI)
9%
3%
CVA
6%
2%
Hypertension
35%
70%
Hypotension/shock (tamponade,AI, MI, rupture)
25%
4%
Pulse deficit
19%
9%
AI murmur
44%
12%
Diagnostic studies (Circ 2005;112:3802)
‚Ä¢ Check bilateral BP and radial pulses for symmetry
‚Ä¢ CXR: abnormal in 60‚Äì90% (c mediastinum, effusion), but cannot be used to r/o dissection
‚Ä¢ CT: quick, noninvasive, good Se (80% for proximal; 90‚Äì95% for distal); multidetector CT
may improve Se; however, if  & high clin. suspicion S additional studies
‚Ä¢ TEE: Se 95% for proximal, 80% for distal; can assess coronaries, pericardium,AI
‚Ä¢ MRI: Se & Sp 98%, but time-consuming & not readily available
‚Ä¢ Aortography: Se 90%, time-consuming, cannot detect IMH; can assess branch vessels
‚Ä¢ D-dimer 500 ng/mL may help r/o dissection when sx 24 h (Circ 2009;119:2702)
Treatment (Lancet 2008;372:55; Circ 2010;121:1544)
‚Ä¢ Medical: T dP/dt targeting HR 60 and SBP 100‚Äì120
first with IV -blockers (eg, propranolol, esmolol, labetalol) to blunt reflex c HR &
inotropy that will occur in response to vasodilators
then T SBP with IV vasodilators (eg, nitroprusside)
control pain with MSO4 prn
‚Ä¢ Surgery
proximal (root replacement): all acute; chronic if c/b progression,AI or aneurysm
distal: if c/b progression, signif. branch artery involvement, uncontrolled HTN, aneurysm
‚Ä¢ Endovascular options: covered stent to seal entry; bare-metal stent to restore
flow down compromised branches; fenestration of false lumen
Complications
‚Ä¢ Rupture: pericardial sac S tamponade (avoid pericardiocentesis unless shock/PEA);
pleural space; mediastinum; retroperitoneum
‚Ä¢ Obstruction of branch artery
can be static (avulsed/thrombosed) or dynamic (s in pressure in true vs. false lumen)
coronary S MI (usually RCA S IMI, since dissection often occurs along outer curvature)
innominate/carotid S CVA, Horner; intercostal/lumbar S spinal cord ischemia/paraplegia
innominate/subclavian S upper extremity ischemia; iliac S lower extremity ischemia
celiac/mesenteric S bowel ischemia; renal S acute renal failure
‚Ä¢ AI: due to annular dilatation or disruption or displacement of leaflet by false lumen
‚Ä¢ Mortality: 1‚Äì2%/h  48 h for acute proximal; 10% at 30 d for acute distal 

--- Fim da P√°gina 43 ---

ARRHYTHMIAS
1-32
ARRHYTHMIAS
BRADYCARDIAS, AV BLOCK, AND AV DISSOCIATION
Sinus bradycardia (SB) (NEJM 2000;342:703)
‚Ä¢ Etiologies: meds (incl B, CCB, amio, Li, dig), c vagal tone (incl. athletes, sleep, IMI),
metabolic (hypoxia, sepsis, myxedema, hypothermia, T glc), OSA, c ICP
‚Ä¢ Treatment: usually none required; atropine or pacing if symptomatic
‚Ä¢ Most common cause of sinus pause is blocked premature atrial beat
Sick sinus syndrome (SSS) 
‚Ä¢ Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial
tachyarrhythmias (‚Äútachy-brady‚Äù syndrome), chronotropic incompetence w/ ETT
‚Ä¢ Treatment: meds alone usually fail (adeq. control tachy S unacceptable brady); usually
need combination of meds (B, CCB, dig) for tachy & PPM for brady
AV Block
Type
Features
1	
Prolonged PR (200 ms), all atrial impulses conducted (1:1).
2	 Mobitz I
Progressive c PR until impulse not conducted (S ‚Äúgrouped beating‚Äù).
(Wenckebach)
Abnl AV node due to ischemia (IMI), inflammation (myocarditis, MV 
surgery), high vagal tone (athletes), drug-induced.
Classically (50%), absolute c in PR decreases over time (S T RR
intervals, duration of pause 2 preceding RR interval).
AVB usually worsens w/ carotid sinus massage, improves w/ atropine.
Often paroxysmal/asx, no Rx required.
2	 Mobitz II
Occasional or repetitive blocked impulses w/ consistent PR interval.
Abnl His-Purkinje system due to ischemia (AMI), degeneration of
conduction system, infiltrative disease, inflammation/AoV surgery.
AVB usually improves w/ carotid sinus massage, worsens w/ atropine.
Often progresses to 3 AVB. Pacing wire or PPM often required.
3	 (complete)
No AV conduction. Escape, if present, narrow (jxnal) or wide (vent.)
Nb, if 2:1 block, cannot distinguish Type I vs. II 2 AVB (no chance to observe PR prolongation); usually catego-
rize based on other ECG & clinical data. High-grade AVB usually refers to block of 2 successive impulses.
AV dissociation 
‚Ä¢ Default: slowing of SA node allows subsidiary pacemaker (eg,AV junction) to take over
‚Ä¢ Usurpation: acceleration of subsidiary pacemaker (eg,AV junctional tach,VT)
‚Ä¢ 3 AV block: atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges
distinguish from isorhythmic dissociation (A V rate, ‚à¥some P‚Äôs non-conducting)
SUPRAVENTRICULAR TACHYCARDIAS (SVTS)
Arise above the ventricles, ‚à¥narrow QRS unless aberrant conduction or pre-excitation.
Etiologies of SVT (NEJM 1995;332:162; 2006;354:1039)
Type
Features
Sinus tachycardia (ST)
Caused by pain, fever, hypovolemia, hypoxia,
anemia, anxiety, -agonists, etc.
SA node reentrant tachycardia
Rare. Reentrant loop w/in SA node, discern
(SANRT)
from ST by rapid onset & termination.
Atrial tachycardia (AT)
Originate at site in atria other than SA node.
Seen w/ CAD, COPD, c catechols, EtOH, dig.
Multifocal atrial tachycardia (MAT)
c automaticity at multiple sites in the atria
Atrial flutter (AFL)
Macroreentry, usually w/in tricuspid annulus
Atrial fibrillation (AF)
Wavelets irregularly passing down AVN, often
originate from the pulmonary veins
AV nodal reentrant tach (AVNRT)
Reentrant circuit using dual pathways w/in AVN
Atrioventricular reciprocating
Reentrant circuit using AVN and accessory
tachycardia (AVRT)
pathway. Orthodromic (conducts down AVN;
usually narrow QRS) vs. antidromic (conducts 
down accessory path; wide QRS).
Nonparoxysmal junctional
c automaticity at AV junction
tachycardia (NPJT)
May see retrograde P waves or AV dissociation
Seen in myo/endocarditis, cardiac surg, IMI, dig.
AV Jxn
Atrial

--- Fim da P√°gina 44 ---

Treatment of SVT
Rhythm
Acute treatment
Long-term treatment
Unstable
Cardioversion per ACLS
n/a
ST
Treat underlying stressor(s)
n/a
AT
-blockers, CCB, or amiodarone
-blockers or CCB, 	 antiarrhythmics
? Radiofrequency ablation
AVNRT
Vagal maneuvers
For AVNRT (see next section for AVRT):
or AVRT
Adenosine (caution in AVRT*)
Radiofrequency ablation
CCB or -blockers
CCB or -blockers (chronic or prn)
	 Class IC antiarrhythmics (if nl heart)
NPJT
CCB, -blockers, amiodarone
Rx underlying dis. (eg, dig tox, ischemia)
AF
-blockers, CCB, digoxin, AAD
See ‚ÄúAtrial Fibrillation‚Äù
AFL
-blockers, CCB, digoxin, AAD
Radiofrequency ablation
-blockers or CCB 	 antiarrhythmics
MAT
CCB or -blockers if tolerated
Treat underlying disease process
? AVN ablation  PPM
*Avoid adenosine & nodal agents if accessory pathway  preexcited tachycardia, see below. (JACC 2003;42:1493)
‚Ä¢ Catheter ablation has high overall success rate (AFL/AVNRT 95%, AF 80%)
Complications: stroke, MI, bleeding, perforation, conduction block (JAMA 2007;290:2768)
ACCESSORY PATHWAYS (WOLFF-PARKINSON-WHITE)
Definitions
‚Ä¢ Accessory pathway (bypass tract) of conducting myocardium connect-
ing atria & ventricles, allowing impulses to bypass normal AVN delay
‚Ä¢ Preexcitation (WPW) pattern: T PR interval, c QRS width w/ 
wave (slurred onset, can be subtle), ST & Tw abnl (can mimic old IMI);
only seen w/ pathways that conduct antegrade (if pathway only conducts
retrograde then ECG will be normal during SR;‚Äúconcealed‚Äù bypass tract)
‚Ä¢ WPW syndrome: accessory pathway  paroxysmal tachycardia
Diagnosis of SVT Type (NEJM 2006;354:1039)
Onset
Abrupt onset/offset suggests reentry (AVNRT,AVRT, SANRT)
Rate
Not diagnostic as most SVTs can range from 140‚Äì250 bpm, but:
ST usually 150 bpm;AFL often conducts 2:1 S ventricular rate 150 bpm
AVNRT & AVRT are usually 150 bpm
Rhythm
Irregular S AF,AFL w/ variable block, or MAT
P wave
Before QRS S ST, AT (P different from sinus), MAT (3 morphologies)
morphology
After QRS & inverted in inf. leads S retrograde atrial activation via AVN
AVNRT: buried in or distort terminal portion of QRS (pseudo RSR‚Äô in V1)
AVRT: slightly after but usually distinct from QRS
Usually short RP interval (1/2 RR), but can be long RP 
Fibrillation or no P waves S AF
Saw-toothed ‚ÄúF‚Äù waves (best seen in inferior leads & V1) S AFL
Response to
c automaticity rhythms (ST,AT, MAT) S slow rate or c AV block
vagal stim.
AVN reentry (AVNRT,AVRT) S abruptly terminate (classically with a P
or adenosine
wave after last QRS) or no response
AFL S c AV block S unmasking of ‚ÄúF‚Äù waves
Figure 1-4 Approach to SVT
ARRHYTHMIAS
1-33
upright
  QRS
ST
SANRT
SVT
Regular
Irregular
P wave morphology
‚â† sinus
   QRS
a
ATAC
retrograde
p QRS
AVNRT
AVRT, NPJT
none or
distorts QRS
‚â•3 morph.
a QRS
AVNRT
F waves
@ 300 bpm
AFL
none or
fibrillation
AF
MAT
P wave morphology
a
Œ¥ wave

--- Fim da P√°gina 45 ---

Tachycardias
‚Ä¢ Orthodromic AVRT: narrow-complex SVT (typically), conducting T AVN & c accessory
pathway; requires retrograde conduction and ‚à¥can occur w/ concealed bypass tracts
‚Ä¢ Antidromic AVRT: wide-complex SVT, conducting T accessory pathway & c AVN;
requires antegrade conduction and ‚à¥should see WPW pattern during SR
‚Ä¢ AF with rapid conduction down accessory pathway, ‚à¥wide-complex irregular SVT;
requires antegrade conduction and ‚à¥should see WPW pattern during SR
Treatment
‚Ä¢ AVRT: vagal maneuvers, B, ? CCB; caution w/ adenosine (can precip. AF); have defib-
rillator ready
‚Ä¢ AF/AFL w/ conduction down accessory pathway: need to Rx arrhythmia and c pathway
refractoriness; use procainamide, ibutilide, flecainide or cardiovert; avoid CCB & B
(ineffective) and dig/adenosine (can T refractoriness of pathway S c vent. rate SVF)
‚Ä¢ Long term: Rx tachycardias w/ radiofrequency ablation or antiarrhythmics (IA, IC)
consider pathway ablation if asx but AVRT or AF inducible on EPS (NEJM 2003;349:1803)
risk of SCD related to how short R-R interval is in AF and if SVT inducible w/ exercise
WIDE-COMPLEX TACHYCARDIAS (WCTS)
Etiologies
‚Ä¢ Ventricular tachycardia (VT)
‚Ä¢ SVT conducted with aberrancy: either fixed BBB, rate-dependent BBB (usually
RBBB), conduction via an accessory pathway, or atrially-triggered ventricular pacing 
Monomorphic ventricular tachycardia (MMVT)
‚Ä¢ All beats look similar; predominantly upward in V1  RBBB-type vs. downward  LBBB-type
‚Ä¢ Etiologies in a structurally abnormal heart: prior MI (scar); CMP; myocarditis;
arrhythmogenic RV CMP (ARVC): incomplete RBBB,
 wave (terminal notch in QRS) & TWI in V1‚Äì3 on resting
ECG, LBBB-type VT, dx w/ MRI (Lancet 2009;373:1289)
‚Ä¢ Etiologies in a structurally normal heart:
RVOT VT: normal resting ECG, LBBB-type VT w/ inferior axis;
idiopathic LV VT (responds to verapamil)
Polymorphic ventricular tachycardia (PMVT)
‚Ä¢ QRS morphology changes from beat to beat
‚Ä¢ Etiologies: ischemia; CMP; catecholaminergic;
torsades de pointes (TdP, ‚Äútwisting of the points‚Äù, PMVT  c QT): c QT acquired
(eg, meds, lytes, see ‚ÄúECG‚Äù) or congenital (K/Na channelopathies; Tw abnl; TdP trig-
gered by sympathetic stim [exercise, emotion, sudden loud noises]; Lancet 2008;372:750) 
Brugada syndrome (Na channelopathy): pseudo-RBBB
w/ STE in V1‚Äì3 (provoked w/ IA or IC) on resting ECG
Diagnostic clues that favor VT (assume until proven o/w)
‚Ä¢ Prior MI, CHF, or LV dysfunction best predictors that WCT is VT (Am J Med 1998;84:53)
‚Ä¢ Hemodynamics and rate do not reliably distinguish VT from SVT
‚Ä¢ MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy;
grossly irregularly irregular rhythm suggests AF w/ aberrancy
‚Ä¢ ECG features that favor VT (Circ 1991;83:1649)
AV dissociation (independent P waves, capture or fusion beats) proves VT
very wide QRS (140 ms in RBBB-type or 160 in LBBB-type); extreme axis deviation
QRS morphology atypical for BBB
RBBB-type: absence of tall R‚Äô (or presence of monophasic R) in V1, r/S ratio 1 in V6
LBBB-type: onset to nadir 60‚Äì100 ms in V1, q wave in V6
concordance (QRS in all precordial leads w/ same pattern/direction)
Long-term management (JACC 2006;48:1064)
‚Ä¢ Workup: echo to ‚úìLV fxn, cath or stress test to r/o ischemia, ? MRI and/or RV bx to
look for infiltrative CMP or ARVC, ? EP study to assess inducibility
‚Ä¢ ICD: 2 prevention after documented VT/VF arrest (unless due to reversible cause)
1 prevention if high-risk, eg, EF 30‚Äì35% (see ‚ÄúHeart Failure‚Äù), ? ARVD, ? Brugada,
? certain long QT syndromes, severe HCMP
‚Ä¢ Medications: -blockers (espec for LQTS), antiarrhythmics (eg, amiodarone) to suppress
recurrent VT, triggering ICD firing, or if not ICD candidate, anti-tachycardic pacing
‚Ä¢ If med a/w TdP S QT 500 	VPBs: d/c med, replete K, give Mg, 	 pacing (JACC 2010;55:934)
‚Ä¢ Radiofrequency ablation if isolated VT focus, or if recurrent VT triggering ICD 
firing; ablation before ICD implantation T discharge rate by 40% (Lancet 2010;375:31)
ARRHYTHMIAS
1-34
Epsilon
V2

--- Fim da P√°gina 46 ---

AF
1-35
(Adapted from NEJM 2004;351:2408; & JACC 2006;48:e149)
Rate Control for AF (Goal HR 60‚Äì80, 90‚Äì115 with exertion)
Agent
Acute (IV)
Maint. (PO)
Comments
Verapamil
5‚Äì10 mg over 2
120‚Äì360 mg/d
T BP (Rx w/ Ca gluc)
may repeat in 30
in divided doses
Watch for CHF
0.25 mg/kg over 2
120‚Äì360 mg/d
Preferred if COPD
Diltiazem
may repeat after 15
in divided doses
Can c dig levels
5‚Äì15 mg/h infusion
Metoprolol
5 mg over 2
25‚Äì100 mg bid
T BP (Rx w/ glucagon)
may repeat q5  3
or tid
Watch for CHF &
Propranolol
1 mg q2
80‚Äì240 mg/d in
bronchospasm
divided doses
Preferred if CAD
Digoxin
0.25 mg q2h
0.125‚Äì0.375 mg
Consider in HF or low BP
(takes hrs)
up to 1.5 mg
qd (adj for CrCl)
Poor exertional HR ctrl
Amiodarone
150 mg over 10 S 0.5‚Äì1 mg/min
IV B, CCB, and digoxin contraindicated if evidence of WPW (.e., pre-excitation or WCT) since may
facilitate conduction down accessory pathway leading to VF; ‚à¥procainamide 1st line Rx
ATRIAL FIBRILLATION
Classification (JACC 2006;48:e149)
‚Ä¢ Paroxysmal (self-terminating) vs. persistent (sustained 7 d) vs. permanent (typically
1 y and when cardioversion has failed or is foregone)
‚Ä¢ Valvular (rheumatic MV disease, prosthetic valve, or valve repair) vs. nonvalvular
‚Ä¢ Lone AF  age 60 y and w/o clinical or echo evidence of cardiac disease (including HTN)
Epidemiology and Etiologies (Annals 2008;149:ITC5-2)
‚Ä¢ 1% of population has recurrent AF (8% of elderly); mean age at presentation 75 y 
‚Ä¢ Acute (up to 50% w/o identifiable cause)
Cardiac: CHF, myo/pericarditis, ischemia/MI, hypertensive crisis, cardiac surgery
Pulmonary: acute pulmonary disease or hypoxia (eg, COPD flare, pneumonia), PE
Metabolic: high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis
Drugs: alcohol (‚Äúholiday heart‚Äù), cocaine, amphetamines, theophylline, caffeine
Neurogenic: subarachnoid hemorrhage, ischemic stroke
‚Ä¢ Chronic: c age, HTN, ischemia, valve dis. (MV,TV,AoV), CMP, hyperthyroidism, obesity
Pathophysiology (NEJM 1998;339:659; & Circ 1995;92:1954)
‚Ä¢ Commonly originates from ectopic foci in atrial ‚Äúsleeves‚Äù in the pulmonary veins
‚Ä¢ Loss of atrial contraction S HF; LA stasis S thromboemboli; tachycardia S CMP
Evaluation
‚Ä¢ H&P, ECG, CXR, echo (LA size, ? thrombus, valves, LV fxn, pericardium), K, Mg, FOBT
before anticoag,TFTs, ? r/o ischemia (AF unlikely due to ischemia in absence of other sx)
Figure 1-5 Approach to acute AF
B
CCB
New or Recent-Onset AF
1. Rate Control
2. Anticoagulate
Œ≤B or CCB
(see Table)
AF <48 hrs &
low risk of stroke
unstable
Urgent
cardioversion
stable
IV UFH if admitting & cardioverting
o/w oral anticoag
Spont. cardioversion
(occurs w/in 24 hrs in 50-67% acute AF)
3. Cardiovert
Cardioversion
(electrical and/or pharmacologic)
Cardioversion
anticoag √ó ‚â•4‚Äì12 wks
oral
Empiric oral
anticoag √ó ‚â•3 wks
TEE
AF >48 hrs (or unknown)
or high risk of stroke 
  LA
thromb.
+
re
‚Üì
  LA
thromb.
‚àí

--- Fim da P√°gina 47 ---

Strategies for recurrent AF
‚Ä¢ Rate control: goal HR typically 60‚Äì80 at rest (although no clear benefit vs. goal
110, NEJM 2010;362:1363) and 90‚Äì115 w/ exertion (see above table for options) 
AV node ablation  PPM as a last resort (NEJM 2001;344:1043; NEJM 2002;346:2062)
‚Ä¢ Rhythm control: no clear survival benefit vs. rate ctrl (NEJM 2002;347:1825 & 2008;358:2667)
‚Ä¢ Anticoag (if indicated) to prevent thromboemboli, whether rate or rhythm strategy
Antiarrhythmic Drugs (AAD) for AF
Agent
Conversion
Maintenance
Comments
Amiodarone
5‚Äì7 mg/kg IV over
200‚Äì400 mg qd
c QT but TdP rare
30‚Äì60‚Äô S 1 mg/min
(most effective
Pulm, liver, thyroid toxicity
to achieve 10-g load drug)
‚úìPFTs, LFTs,TFTs
Dronedarone
n/a
400 mg bid
c QT, contraindic severe CHF
T side effects c/w amio
T efficacy but also T CV mort
Ibutilide
1 mg IV over 10‚Äô
n/a
Contraindic. if T K or c QT
may repeat  1
c QT, 3‚Äì8% risk of TdP
Mg 1‚Äì2 g IV to T risk TdP
Dofetilide
0.5 mg PO bid
0.5 mg bid
c QT, c risk of TdP
Renally adjust dose
Sotalol
n/a
90‚Äì160 mg bid
‚úìfor T HR, c QT
Renally adjust dose
Flecainide
300 mg PO  1
100‚Äì150 mg bid PreRx w/ AVN blocker
Propafenone
600 mg PO  1
150‚Äì300 mg tid Contraindic. if structural or
ischemic heart disease
Procainamide
10‚Äì15 mg/kg IV
1‚Äì2 g bid of
T BP; c QT
over 1 h
slow release
	 PreRx w/ AVN blocker
(JACC 2006;48:e149; NEJM 2007;357:987 & 2009;360:668; JACC 2009;54:1089)
‚Ä¢ Lone AF S class IC drugs or sotalol, ? statins
‚Ä¢ CAD S class III drugs
‚Ä¢ CHF S dofetilide or amiodarone (NEJM 2007;356:935)
Cardioversion
‚Ä¢ Consider pharm or DC cardioversion w/ 1st AF episode of if sx;
if AF 48 h, 2‚Äì5% risk stroke w/ cardioversion (pharm. or electric)
‚à¥either TEE to r/o thrombus or therapeutic anticoagulation for 3 wks prior
‚Ä¢ Likelihood of success dependent on AF duration (better 7 d) and atrial size
‚Ä¢ Consider pre-Rx w/ antiarrhythmic drugs (especially if 1st attempt fails)
‚Ä¢ For pharmacologic cardioversion, class III and IC drugs have best proven efficacy
‚Ä¢ Even if SR returns, atria mechanically stunned.Also, greatest likelihood of recurrent AF
in first 3 mos after return to SR, ‚à¥must anticoagulate postcardioversion 4‚Äì12 wks.
‚Ä¢ ‚ÄúPill-in-pocket‚Äù: if IC drugs have been safely tolerated in Pts w/o ischemic or
structural heart disease, can take as outPt prn if recurrent sx AF (NEJM 2004;351:2384)
Nonpharmacologic therapy
‚Ä¢ Radiofrequency ablation (circumferential pulm. vein isolation): 80% success; consider
if T EF or AADs failed/contraindic (NEJM 2006;354:934; JAMA 2005;293:2634 & 2010;303:333)
‚Ä¢ Surgical ‚Äúmaze‚Äù procedure (70‚Äì95% success rate) option if undergoing cardiac surgery
‚Ä¢ Left atrial appendage closure if undergoing cardiac surgery T risk of stroke; percuta-
neous closure may be comparable to warfarin and w/ T risk of ICH (Lancet 2009;374:534)
Anticoagulation (JACC 2006;48:e149; Chest 2008;133:546S)
‚Ä¢ Risk of stroke 4.5% per year in nonvalvular AF; risk factors include:
CHADS2: CHF (1 point), HTN (1), Age 75 y (1), DM (1), prior Stroke/TIA (2)
echo: EF 35%, dense spontaneous echo contrast in LAA, ? c LA size, ? Ao athero
‚Ä¢ Risk of stroke cc in valvular AF,  anticoagulate all
‚Ä¢ Rx options: warfarin (INR 2‚Äì3) S 68% T stroke (heparin S warfarin bridge if h/o stroke) 
ASA (81‚Äì325 mg/d): better than placebo (21% T stroke) but inferior to warfarin
ASAclopi inferior to warfarin but T stroke (& c bleed) c/w ASA alone (NEJM 2009;360:2066)
? dabigatran (oral direct thrombin inhib): 100 mg bid ‚âàefficacy & T bleeding and 150 mg
bid T stroke and ‚âàbleeding c/w warfarin (w/o need to ‚úìINR; RE-LY, NEJM 2009;361:1139) 
‚Ä¢ Whom to Rx: valvular AF, prior stroke/TIA, or 
2 risk factors S warfarin
1 risk factor S warfarin or ASA; 0 risk factors S ASA 
if not good candidate for warfarin (c risk of bleeding) S ASA  ? clopidogrel
if require ASAclopiwarfarin (eg,AF & s/p recent stenting): INR 2‚Äì2.5,ASA 75‚Äì81 mg/d 
AF
1-36
III
IC
IA

--- Fim da P√°gina 48 ---

SYNCOPE
1-37
SYNCOPE
Definition
‚Ä¢ Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion
‚Ä¢ If CPR or cardioversion required, then SCD and not syncope (different prognosis)
Etiologies (NEJM 2002;347:878; JACC 2006;47:473; Eur Heart J 2009;30:2631)
‚Ä¢ Neurocardiogenic (a.k.a. vasovagal, 20%; NEJM 2005;352:1004): c sympathetic tone S
vigorous contraction of LV S mechanoreceptors in LV trigger c vagal tone (hyperactive
Bezold-Jarisch reflex) S T HR (cardioinhibitory) and/or T BP (vasodepressor)
cough, deglutition, defecation & micturition S c vagal tone and thus can be precipitants
related disorder: carotid sinus hypersensitivity
‚Ä¢ Orthostatic hypotension (10%)
hypovolemia, diuretics, deconditioning
vasodilators (espec. if combined w/  chronotropes)
autonomic neuropathy (1  Parkinson‚Äôs, Shy-Drager, Lewy body dementia, POTS;
2  diabetes, EtOH, amyloidosis, renal failure) (NEJM 2008;358:615)
‚Ä¢ Cardiovascular
Arrhythmia (15%)
Bradyarrhythmias: SSS, high-grade AV block,  chronotropes, PPM malfunction
Tachyarrhythmias:VT, SVT (syncope rare unless structural heart disease or WPW)
Mechanical (5%)
Endocardial:AS, MS, PS, prosthetic valve thrombosis, myxoma
Myocardial: pump dysfxn from MI or outflow obstruction from HCMP (but usually VT)
Pericardial: tamponade
Vascular: PE, PHT, aortic dissection, ruptured AAA, subclavian steal
‚Ä¢ Neurologic (10%): seizure (technically not syncope),TIA/CVA, vertebrobasilar
insufficiency, dissection of cerebral arteries, migraine, narcolepsy
‚Ä¢ No cause identified in 40% of cases
‚Ä¢ Misc. causes of LOC (but not syncope): hypoglycemia, hypoxia, anemia, psychogenic
Workup (etiology cannot be determined in 40% of cases)
‚Ä¢ H&P incl. orthostatic VS have highest yield and most cost effective (Archives 2009;169:1299)
‚Ä¢ History (from Pt and witnesses if available)
activity and posture before the incident
precipitating factors: exertion (AS, HCMP, PHT), positional  (orthostatic hypotension),
stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing,
warm environment, N/V, cough/micturition/defecation/swallowing (neurocardiogenic),
head turning or shaving (carotid sinus hypersens.); arm exercise (subclavian steal)
prodrome (eg, diaphoresis, nausea, blurry vision): cardiac 5 sec, vasovagal 5 sec
associated sx: chest pain, palp., neurologic, post-ictal, bowel or bladder incontinence
(convulsive activity for 10 sec may occur with transient cerebral hypoperfusion)
‚Ä¢ PMH: prior syncope, previous cardiac or neurologic dis.; no CV disease at baseline S 5%
cardiac, 25% vasovagal; CV disease S 20% cardiac, 10% vasovagal (NEJM 2002;347:878)
‚Ä¢ Medications
vasodilators: -blockers, nitrates,ACEI/ARB, CCB, hydralazine, phenothiazines, antidep.
diuretics;  chronotropes (eg, -blockers and CCB)
proarrhythmic or QT prolonging: class IA, IC or III antiarrhythmics, et al. (see ‚ÄúECG‚Äù)
psychoactive drugs: antipsychotics,TCA, barbiturates, benzodiazepines, EtOH
‚Ä¢ Family history: CMP, SCD
‚Ä¢ Physical exam
VS including orthostatics ( if supine S standing results in 20 mmHg T SBP,
10 mmHg T DBP, or 10‚Äì20 bpm c HR), BP in both arms
cardiac: HF (c JVP, displ. PMI, S3), murmurs, LVH (S4, LV heave), PHT (RV heave, c P2)
vascular exam: ‚úìfor asymmetric pulses, carotid bruits, carotid sinus massage
neurologic exam: focal findings, evidence of tongue biting; fecal occult blood test
‚Ä¢ ECG (abnormal in 50%, definitively identifies cause of syncope in 10%)
sinus bradycardia, sinus pauses,AVB, BBB, SVT,VT
ischemic changes (new or old); atrial or ventricular hypertrophy
markers of arrhythmia: ectopy, c QT, preexcitation (WPW), Brugada,  wave (ARVC)
Other diagnostic studies (consider ordering based on results of H&P and ECG)
‚Ä¢ Ambulatory ECG monitoring: if suspect arrhythmogenic syncope
Holter monitoring (continuous ECG 24‚Äì48 h): useful if frequent events
arrhythmia  sx (4%); asx but signif. arrhythmia (13%); sx but no arrhythmia (17%)
Event recorder (activated by Pt to record rhythm strip): useful for infrequent events, but
problematic if no prodrome; yield 20‚Äì50% over 30‚Äì60 d of monitoring

--- Fim da P√°gina 49 ---

Loop recorders (continuously save rhythm strip and ‚à¥can be activated after an
event): useful for infrequent events including w/o prodrome (Mayo Clin Proc 2008;83:1280).
Implantable loop recorders (inserted SC; can record up to 3 y): useful for very
infrequent events; yield 90% after 1 y (AJC 2003;92:1231)
‚Ä¢ Echo: r/o structural heart disease (eg, CMP [incl HCMP & ARVD], valvular disease
[incl AS, MS, MVP], myxoma, amyloid, PHT, 	 anomalous coronaries)
‚Ä¢ ETT: esp. w/ exertional syncope; r/o ischemia- or catecholamine-induced arrhythmias
‚Ä¢ Cardiac catheterization: consider if noninvasive tests suggest ischemia
‚Ä¢ Electrophysiologic studies (EPS)
consider if arrhythmia detected, if structural heart disease, or if CAD (esp. with low EF)
50% abnl (inducible VT, conduction abnormalities) if heart disease, but ? significance
3‚Äì20% abnl if abnl ECG; 1% abnl if normal heart and normal ECG (Annals 1997;127:76)
‚Ä¢ Tilt table testing (provocative test for vasovagal syncope): r/o other causes first
 in 50% w/ recurrent unexplained syncope; Se 26‚Äì80%, Sp 90%; reprod. 80%
‚Ä¢ Cardiac MRI: helpful to dx ARVC if suggestive ECG, echo (RV dysfxn), or  FH of SCD
‚Ä¢ Neurologic studies (cerebrovascular studies, CT, MRI, EEG): if H&P suggestive; low yield
Figure 1-6 Approach to syncope
SYNCOPE
1-38
Syncope
Cardiac
Mechanical
History, Physical Exam (incl. orthostatics), 12-lead ECG
? Neuro-
cardiogenic
? Neurologic
? Arrhythmia
Orthostatic
hypotension
Arrhythmia
negative
abnl neuro
exam
situational or
   prodrome
diagnostic
suggestive
echo ¬± ETT
(¬± CTA to r/o
PE or AoD)
orthostatics
abnl rhythm
on ECG
? tilt table
if recurs
EEG, cerebrovasc,
CT/MRI
EP study
structurally abnl
heart or ischemia
ambul. ECG
if recurs
valve, tamp.,
PE,PHT
normal
abnl heart
or ECG,
exertional or
    prodrome
+
‚àí
+
(Adapted from JACC 2006;47:473)
High-risk features (usually warrant admission with telemetry & further testing)
‚Ä¢ Age 60 y, h/o CAD, CMP, valvular disease, congenital heart disease, arrhythmias
‚Ä¢ Syncope c/w cardiac cause (lack of prodrome, exertional, resultant trauma)
‚Ä¢ Recurrent syncope
‚Ä¢ Abnormal cardiac exam or ECG
Treatment
‚Ä¢ Arrhythmia, cardiac mechanical, or neurologic syncope: treat underlying disorder
‚Ä¢ Vasovagal syncope: ? midodrine, fludrocortisone, disopyramide, SSRI 
? 16 oz of H2O before at-risk situations (Circ 2003;108:2660)
no proven benefit w/ -blockers (Circ 2006;113:1164) or PPM (JAMA 2003;289:2224)
‚Ä¢ Orthostatic syncope: volume replete (eg, 500 mL PO q a.m.); if chronic S rise from supine
to standing slowly, compressive stockings, midodrine, fludrocortisone, high Na diet
Prognosis (Ann Emerg Med 1997;29:459; NEJM 2002;347:878)
‚Ä¢ 22% overall recurrence rate if idiopathic, else 3% recurrence
‚Ä¢ Cardiac syncope: 2-fold c in mort., 20‚Äì40% 1-y SCD rate, median survival 6 y
‚Ä¢ Unexplained syncope w/ 1.3-fold c in mort., but noncardiac or unexplained syncope w/ nl
ECG, no h/o VT, no HF, age 45 S low recurrence rate and 5% 1-y SCD rate
‚Ä¢ Vasovagal syncope: Pts not at increased risk for death, MI, or stroke
‚Ä¢ ‚úìstate driving laws and MD reporting requirements. Consider appropriateness of Pt
involvement in exercise/sport, operating machinery, high-risk occupation (eg, pilot).

--- Fim da P√°gina 50 ---

PPM/ICD
1-39
INTRACARDIAC DEVICES
Pacemaker Code
A, atrial;V, vent.;
1st letter
2nd letter
3rd letter
4th letter
I, inhibition; D, dual;
Chamber
Chamber
Response to
Program
R, rate-adaptive
paced
sensed
sensed beat
features
Common Pacing Modes
VVI
Ventricular pacing on demand w/ single lead in RV. Sensed ventricular
beat inhibits V pacing. Used in chronic AF with symptomatic bradycardia.
DDD
A & V sensing & pacing (RA & RV leads). Sensed A beat inhibits A pacing &
triggers V pacing S tracking of intrinsic atrial activity. Maintains AV synchrony.
Magnet
Pacing at fixed rate regardless of intrinsic activity. Use to ‚úìability to capture
(place over 
when output inhibited by intrinsic rhythm. Use if Pt hemodynamically 
generator)
unstable due to inappropriate PPM inhibition or PPM-induced tachycardia.
Indications for Pacing (Circ 2008;117:2820)
AV block
Symptomatic 3 or 2 AVB; ? asx 3 or type II 2 AVB
HR 40; pauses 3 sec while awake; alternating L and R BBB
Sinus node
SB or pauses a/w sxs or ? if sx w/o clear assoc. Chronotropic incompet.
Acute MI
See ‚ÄúSTEMI‚Äù
Tachy-
Sx recurrent SVT that can be term. by pacing after failing drugs & ablation
arrhythmia
Sustained pause-dependent VT; ? high-risk Pts w/ congenital long QT
Syncope
Carotid sinus hypersensitivity with asystole 3 sec
? Neurocardiogenic syncope w/ prominent cardioinhib. response
? Syncope with bi- or trifascicular block and not likely 2 to other causes
CMP
Sx DCMP (BiV pacing); ? refractory sx HCMP w/ signif outflow obstruction
Permanent Pacemaker (PPM) Complications
Issue
Manifestation
Description
Failure to
Bradycardia
Battery depletion, lead fracture/dislodgment,
pace
c pacing threshold due to local tissue rxn/injury, or
myopotential sensing S inappropriate inhibition
Failure to sense
Inapprop. pacing
Lead dislodgment or sensing threshold too high
PM-mediated
Tachycardia
Seen w/ DDD.V depol. S retrograde A activation S
tachycardia
sensed by A lead S triggers V pacing S etc.
PM syndrome
Palpit, HF
Seen w/ VVI. Due to loss of AV synchrony.
Cardiac Resynch Therapy (CRT) / Biventricular (BiV) Pacing (JACC 2008;51:2085)
‚Ä¢ 3-lead pacemaker (RA, RV, coronary sinus); R S in V1 suggests appropriate LV capture
‚Ä¢ Goal: enhance synch RV & LV fxn (c CO, T remodeling, even if nl EF, NEJM 2009;361:2123)
‚Ä¢ Pt selection: NYHA III/IV HF despite med Rx  LVEF 35%  QRS 120 ms;
no clear benefit if QRS 120 ms w/ echo dyssynchrony (NEJM 2007;357:2461);
? lesser benefit if chronic AF
‚Ä¢ Benefits: T HF sx, T HF hosp., c survival (NEJM 2004;350:2140 & 2005;352:1539); T HF events
compared w/ ICD alone in NYHA I/II & QRS 150 ms (MADIT-CRT, NEJM 2009;361:1329)
Implantable Cardiac Defibrillator (ICD) (NEJM 2003;349:1836; JACC 2006;48:1064)
‚Ä¢ RV lead capable of defibrillation & pacing ( 	 antitachycardia pacing,ATP); 	 RA lead
‚Ä¢ Goal: terminate VT/VF w/ shock or burst of pacing, prevent sudden cardiac death (SCD)
‚Ä¢ Patient selection (JACC 2008;51:2085)
2 prevention: survivors of VF arrest, unstable VT w/o reversible cause (NEJM
1997;337:1576); structural heart disease & spontaneous sustained VT (even if asx) 
1 prevention: life expectancy 1 y, LVEF 30% or LVEF 30‚Äì35% & NYHA II-III or
LVEF 35‚Äì40% & inducible VT/VF (wait 40 d if post-MI or 9 mos for non-
ischemic CMP; NEJM 2009;361:1427); for HCMP,ARVD, Brugada, sarcoid, LQTS,
Chagas, or congenital heart, ICD if risk factors for SCD
‚Ä¢ Benefits: T mortality from SCD c/w antiarrhythmics or placebo
‚Ä¢ ICD discharge: ‚úìdevice to see if appropriate; r/o ischemia; 6 mos driving ban; if recur-
rent VT, ? drug Rx (eg, amio  B, JAMA 2006;295:165) or VT ablation (NEJM 2007;357:2657).
Nb, ablation at time of ICD T risk of VT by 40% (Lancet 2010;375:31).
Device infection (Circ 2010;121:458)
‚Ä¢ Presents as pocket infection (warmth, erythema, tenderness) and/or sepsis w/ bacteremia
‚Ä¢ Infection in 1‚ÅÑ2 of Pts w/ S. aureus bacteremia (even w/o s/s and w/  TTE/TEE)
‚Ä¢ Treatment: abx and removal of system

--- Fim da P√°gina 51 ---

PREOP EVAL
1-40
CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY
Clinical Assessment
Active Cardiac Conditions
Clinical Risk Factors
‚Ä¢ MI w/in 30 d or current unstable or severe angina 
‚Ä¢ h/o CAD
‚Ä¢ Decompensated HF
‚Ä¢ h/o HF
‚Ä¢ Significant arrhythmia (eg, high-grade AVB, Mobitz II,
‚Ä¢ h/o Cerebrovascular dis.
3 AVB, new or sx VT, SVT w/ HR 100, sx brady)
‚Ä¢ Diabetes mellitus
‚Ä¢ Severe AS or sx MS
‚Ä¢ Renal insuffic. (Cr 2 mg/dL)
Surgery-Specific Risk
High (5% risk)
Intermediate (1‚Äì5%)
Low (1%)
‚Ä¢ Aortic or other major
‚Ä¢ Intrathoracic; intraperitoneal; 
‚Ä¢ Endoscopic
vascular
prostate
‚Ä¢ Breast; superficial
‚Ä¢ Peripheral vasc.
‚Ä¢ CEA; head & neck
‚Ä¢ Cataract; ambulatory
‚Ä¢ Orthopedic
Functional Capacity
1‚Äì4 METs
4‚Äì10 METs
10 METs
‚Ä¢ ADLs
‚Ä¢ Climb a flight of stairs/hill
‚Ä¢ Strenuous sports
‚Ä¢ Walk indoors
‚Ä¢ Walk briskly; heavy housework
‚Ä¢ Walk 1‚Äì2 level blocks
‚Ä¢ Golf, doubles tennis
Noninvasive Testing Result
High risk
Intermediate risk
Low risk
Ischemia at 4 METs manifested 
Ischemia at 4‚Äì6 METs
No ischemia or
by 1 of:
manifested by 1 of:
at 7 METs w/
‚Ä¢ Horiz/down ST T 1 mm or STE
‚Ä¢ Horiz/down ST T 1 mm
‚Ä¢ ST T 1 mm or
‚Ä¢ 5 abnl leads or 3 min after exert
‚Ä¢ 3‚Äì4 abnl leads
‚Ä¢ 1‚Äì2 abnl leads
‚Ä¢ SBP T 10 mmHg or typical angina
‚Ä¢ 1‚Äì3 min after exert
Preoperative evaluation
Figure 1-7 ACC/AHA approach to preoperative cardiovascular evaluation for non‚Äìcardiac surgery
Peri-op surveillance;
post-op risk stratification
& risk factor mgmt
Step 1
Need for emergency
non-cardiac surgery?
yes
no
Further evaluation
prior to OR;
Rx as indicated
Step 2
Active cardiac
conditions?
yes
no
Consider periop Œ≤B if CAD or
>1 clinical risk factors.
Step 4
Fxnal capacity
‚â•4 METs w/o sx?
yes
no or unknown
Consider periop Œ≤B.
? Non-inv test if will Œî mgmt.
intermed
risk surgery
high risk
surgery
Step 5
Presence of
clinical
risk
factors?
Consider non-inv
test if will Œî mgmt.
1‚Äì2
‚â•3
Operating
Room
Step 3
Low-risk surgery?
none
yes
no
Periop Œ≤B
if to OR
(Circ 2009;120:e169)

--- Fim da P√°gina 52 ---

PREOP EVAL
1-41
Pre-operative testing and therapy
‚Ä¢ ECG if 1 risk factor and planned vascular surgery, or if known vascular disease and
intermediate risk surgery. ? prior to any vascular surgery.
‚Ä¢ TTE if dyspnea of unknown origin or if HF w/ c dyspnea and no TTE in past 12 mo
‚Ä¢ Stress test if active cardiac issues (see above), or vascular surgery w/ 3 risk factors
& it will  mgmt. Overall low PPV to predict periop CV events.
‚Ä¢ Coronary revascularization should be based on standard indications (eg,ACS,
refractory sx, lg territory at risk). Has not been shown to  risk of death or
postop MI when done prior to elective vasc. surgery based on perceived cardiac
risk (NEJM 2004;351:2795) or documented extensive ischemia (AJC 2009;103:897), but sys-
tematic angiography T 2‚Äì5 y mortality in one vascular surgery trial (JACC 2009;54:989).
‚Ä¢ Given need for dual antiplatelet Rx after stenting, wait 4 wk after BMS and ideally
12 mo after DES before discontinuing ADP receptor blockade; continue ASA
‚Ä¢ If possible, wait 4‚Äì6 wk after MI (even if  ETT or  ETT & revascularized). If no
revasc, wait 6 mo before elective surgery.
‚Ä¢ Preop statins: T ischemia & CV events in Pts undergoing vascular surg (NEJM 2009;361:980)
Perioperative -blocker use (Circ 2009;120:2123; JAMA 2010;303:551)
‚Ä¢ Conflicting evidence regarding efficacy of B for T periop events. Some studies have
shown T cardiac death & MI (NEJM 1996;335:1713 & 1999;341:1789) whereas another T MI
but c death & stroke and c bradycardia/HoTN (Lancet 2008;371;1839).
‚Ä¢ Consider periop B if CAD,  stress test, or 1 cardiac risk factor, espec if vascular surgery  
‚Ä¢ Ideally initiate 1 wk prior to surgery and titrate during preop, intraop, and postop peri-
ods to achieve HR 55‚Äì65 bpm and BP control. Avoid bradycardia and hypotension.
Postoperative monitoring
‚Ä¢ ‚úìPostop ECG if known CAD or high-risk surgery. Consider if 1 risk factor for CAD.
‚Ä¢ ‚úìPostop troponin only if new ECG s or chest pain suggestive of ACS

--- Fim da P√°gina 53 ---

